PosterSessionOnline

EUROPEAN HEMATOLOGY ASSOCIATION

EHA2026

11-14 June 2026 Stockholm, Sweden

N. Poster

Poster title

Applicant name

Status


336-PF	CHRONOLOGICAL OUTCOME AND RISK FACTORS FOR CHILDREN AND YOUNG ADULTS DIAGNOSED WITH ACUTE LYMPHOBLASTIC LEUKAEMIA AND HIGH-RISK GENETICS.	Anthony Moorman	Received

337-PF	SINGLE-CELL SEQUENCING REVEALS PATHWAYS AND PERTURBATIONS PREDICTIVE OF CENTRAL NERVOUS SYSTEM DISSEMINATION IN B-LINEAGE ACUTE LYMPHOBLASTIC LEUKEMIA	Luca Vincenzo Cappelli	Received

342-PF	EXPLORING THE NON-CANONICAL FUNCTION OF EZH2 IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA	Stef Van den Bergh	Received

348-PF	CEBP AND ZEB2 ALTERATIONS DEFINE THREE DISTINCT SUBTYPES OF B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA	Rathana Kim	Received

349-PF	PRECLINICAL IN VIVO AND EX VIVO ACTIVITY OF DASATINIB IN ABL1-REARRANGED T-ACUTE LYMPHOBLASTIC LEUKEMIA PATIENT-DERIVED XENOGRAFT MODELS	Diego Barcenas Lopez	Received

350-PF	THERAPEUTIC EFFECT OF CX-4945 COMBINED WITH XPO1 INHIBITOR BY TARGETING AMINO ACID METABOLISM IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA	Zheng Ge	Received

353-PF	DYNAMIC BH3 PROFILING IMPROVES CLINICAL RESPONSE IN RELAPSED AND REFRACTORY PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS	Albert Manzano-Muñoz	Received

357-PF	THE CIRCULATING BLOOD PROTEOME OF CHILDHOOD ACUTE LEUKEMIA	Dea Gogishvili	Received

359-PF	PROK1 IS A SUSCEPTILITY LOCUS FOR ANTHRACYCLINE-RELATED CARDIOMYOPATHY IN LONG-TERM CHILDHOOD ACUTE LEUKEMIA SURVIVORS	Paul Saultier	Received

362-PF	CDK8 AT THE MITOTIC SPINDLE: A NOVEL VULNERABILITY IN LEUKEMIA	Elisabeth Gamper	Received

363-PF	INTEGRATIVE SINGLE-CELL AND EX VIVO PROFILING IDENTIFIES REGULATORY DRIVERS OF DRUG RESPONSES IN PEDIATRIC B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA	Arghavan Alizadeh Fekejvar	Received

364-PF	COMBINATION OF OPTICAL GENOME MAPPING (OGM) AND RNA SEQUENCING REFINES CLASSIFICATION OF ADULT T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (T-ALL)	Idoia Vázquez	Received

366-PF	CHARACTERISING THE MITOCHONDRIA OF B-ALL CELLS WITH DIFFERENT PRIMARY GENETIC TRANSLOCATIONS.	Jenny Chatzigerou	Received

367-PF	CHARACTERIZING AND TARGETING METABOLIC REWIRING IN PEDIATRIC PAX5-REARRANGED B-ALL PDX-DERIVED MODELS	Rebecca Rapisarda	Received

368-PF	FUNCTIONAL STUDY OF CIRCRNAS WITH ECTOPIC EXPRESSION IN T-ALL AND CIRCRNA-DRIVEN T-ALL SUBTYPE CLASSIFICATION	Stefania Bortoluzzi	Received

371-PF	DDX3X DOWNREGULATION BUFFERS JAK-STAT SIGNALING IN CRLF2 REARRANGED ACUTE LYMPHOBLASTIC LEUKEMIA	Lisa Russell	Received

373-PF	SPATIAL ANALYSIS OF MICRO-NICHES IN TDT+ ACUTE LEUKEMIA IDENTIFIES FEATURES ASSOCIATED WITH OVERALL SURVIVAL	Karin Huber	Received

376-PF	EARLY USE OF INOTUZUMAB OZOGAMICIN IN FIRST REMISSION ACHIEVES DEEP AND DURABLE MRD ERADICATION IN ADULTS WITH PHILADELPHIA CHROMOSOME-NEGATIVE B-ALL: A PROSPECTIVE PHASE II STUDY	Runxia Gu	Received

377-PF	A RISK-STRATIFIED TREATMENT STRATEGY COMBINING CHEMOTHERAPY AND CAR-T CELL THERAPY FOR PEDIATRIC RELAPSED/REFRACTORY T-LYMPHOBLASTIC LYMPHOMA	Ying Liu	Received

378-PF	GENOMIC ARCHITECTURE OVERRIDES SINGLE-LOCUS RISK SIGNALS IN T-ALL: PROGNOSTIC UTILITY OF A MULTI-GENE NGS CLASSIFIER INDEPENDENT OF MEASURABLE RESIDUAL DISEASE	Neha Singh	Received

379-PF	PREDICTING CNS RELAPSE IN CHILDREN AND YOUNG ADULTS DIAGNOSED WITH ACUTE LYMPHOBLASTIC LEUKAEMIA (ALL)	Anthony Moorman	Received

380-PF	EFFICACY AND GENETIC CORRELATES OF VENETOCLAX-BASED IMMUNOCHEMOTHERAPY IN OLDER/UNFIT B-ALL: A PHASE 2 STUDY IN THE ERA OF NOVEL COMBINATIONS: RESULTS A PHASE 2 MULTI-CENTER CLINICAL TRIAL	Runxia Gu	Received

381-PF	LINEAGE PLASTICITY–MEDIATED RESISTANCE TO CD7-DIRECTED CAR-T THERAPY IN RELAPSED/REFRACTORY T-ALL/LBL	Jiahua Niu	Received

382-PF	PRACTICAL RESULTS OF MRD DIRECTED BFM 2000 IN TYA IN COMPARISON TO NON MRD BASED MODIFIED BFM AND HCVAD- ACUTE LYMPHOBLASTIC. A COMPARATIVE ANALYSIS OF 279 PATIENTS WITH LEUKEMIA CONTEXT	Misbah Maktoob	Received

384-PF	ADDITION OF VENETOCLAX ENHANCES MINIMAL RESIDUAL DISEASE RESPONSE IN CRLF2-REARRANGED PHILADELPHIA-LIKE ALL	Ibrahim Aldoss	Received

385-PF	PREDICTING RELAPSE AFTER FRONTLINE BLINATUMOMAB IN CHILDREN AND YOUNG PEOPLE WITH B-ALL	Miguel Vieira Martins	Received

386-PF	VENETOCLAX, CLADRIBINE, AND LOW-DOSE CYTARABINE FOR THE TREATMENT OF PH- RELAPSE/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA: AN ANALYSIS OF A PHASE 2 TRIAL	Shengli Xue	Received

387-PF	PREGNANCY-ASSOCIATED ACUTE LYMPHOBLASTIC LEUKEMIA: A FRENCH NATIONWIDE MULTICENTER RETROSPECTIVE COHORT	Elise Bandet	Received

388-PF	TREATMENT RESPONSE, SURVIVAL AND PROGNOSTIC FACTORS IN ADULT PATIENTS WITH LYMPHOBLASTIC LYMPHOMA TREATED ACCORDING TO PETHEMA ALL PROTOCOLS IN SPAIN	Vitor Botafogo	Received

393-PF	UPDATED RESULTS FROM THE PHASE II STUDY OF DUAL EPIGENETIC TARGETING WITH CHIDAMIDE AND AZACITIDINE IN PATIENTS WITH HIGH-RISK ACUTE MYELOID LEUKEMIA AFTER ALLO-HSCT	Xiao-Hui Hu	Received

394-PF	OUTCOME OF SECOND-LINE THERAPY IN ADULT B-CELL PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA	Wei-Ying Jen	Received

395-PF	ADULT T-ALL OUTCOMES AND THE PROGNOSTIC IMPACT OF EARLY T-CELL PRECURSOR TREATED WITH PEDIATRIC-INSPIRED REGIMEN	Yael Morgenstern	Received

397-PF	DYNAMIC MEASURABLE RESIDUAL DISEASE KINETICS AND CONDITIONAL TRANSPLANTATION BENEFIT IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA: A GRELAL CHILE REAL-WORLD STUDY	Yorman Flores	Received

399-PF	INOTUZUMAB OZOGAMICIN AS SALVAGE AND BRIDGING THERAPY AFTER CAR-T FAILURE IN RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA	JIUJIANG HE	Received

402-PF	THE FIRST CZECH REAL-WORLD EVIDENCE OF BREXUCABTAGENE AUTOLEUCEL TREATMENT OUTCOMES AND TOXICITY IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA	Stepan Hrabovsky	Received

403-PF	PEGASPARGASE TOXICITY ACROSS DIFFERENT INDUCTION DOSING SCHEMES IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA: A COMPREHENSIVE RETROSPECTIVE ANALYSIS	Stepan Hrabovsky	Received

404-PF	ASCIMINIB EFFECTIVENESS IN PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ ALL) IN THE REAL WORLD: THE ASCERTAIN STUDY	Marlise Luskin	Received

405-PF	REAL-WORLD INCIDENCE AND MANAGEMENT OF CRS AND ICANS IN ADULTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME–POSITIVE B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA TREATED WITH FRONTLINE TKI PLUS BLINATUMOMAB	DZ DZ	Received

411-PF	RESNET TO THE RESCUE: AN AUTOMATED APPROACH FOR THE DETECTION OF MEASURABLE RESIDUAL DISEASE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA	Maximilian Roehnert	Received

416-PF	TNIK EXPANDS LEUKEMIC STEM CELLS BY ACTIVATING NF-?B SIGNALING AND REPRESENTS A NOVEL THERAPEUTIC TARGET IN ACUTE MYELOID LEUKEMIA	Luca Palombella	Received

417-PF	INTEGRATED MOLECULAR PROFILING REVEALS CRYPTIC FUSIONS AND BLAST-INDEPENDENT RISK STRATIFICATION IN DDX41-ASSOCIATED AML	Ira Kraft	Received

419-PF	BONE MARROW STROMAL CELLS IMPAIR NATURAL KILLER (NK) CELL ACTIVATION AND PROMOTE RESISTANCE OF ACUTE MYELOID LEUKEMIA CELLS TO NK CELL CYTOTOXICITY THROUGH CYTOKINE SIGNALLING	Salome Decombis	Received

421-PF	SINGLE-CELL TRANSCRIPTOMIC ANALYSIS UNCOVERS MOLECULAR MECHANISMS AND IDENTIFIES POTENTIAL THERAPEUTIC TARGETS IN REFRACTORY/RELAPSED IN ACUTE MYELOID LEUKEMIA	Jianbiao Zhou	Received

424-PF	COMBINED INHIBITION OF HSP90 AND CDK9 OVERCOMES VENETOCLAX-RESISTANCE IN AML	Marie Kemkes	Received

427-PF	ACU SMALL MOLECULE STING AGONISTS DEMONSTRATE TP53-INDEPENDENT ANTI-LEUKAEMIC ACTIVITY AND VENETOCLAX SYNERGY IN ACUTE MYELOID LEUKAEMIA	Yin Yuan	Received

428-PF	ZMYND8 READS H3K14AC TO ACTIVATE TFAM TRANSCRIPTION AND PROMOTES ACUTE MYELOID LEUKEMIA PROGRESSION BY SUSTAINING MITOCHONDRIAL OXIDATIVE PHOSPHORYLATION	hui feng	Received

429-PF	ACUTE MYELOID LEUKEMIA WITH ABERRANT MONOCYTES: IS IT A DISTINCT CLINICAL ENTITY AND WHAT IS THE RELEVANCE OF MEASURABLE RESIDUAL DISEASE?	Tom Reuvekamp	Received

430-PF	DEVELOPMENT OF A NOVEL T-CELL IMMUNOTHERAPY FOR NPM1-MUTATED AML	DZ DZ	Received

431-PF	METABOLIC REWIRING VIA METFORMIN RESTORES VENETOCLAX SENSITIVITY IN AML	Mai Fujita	Received

432-PF	SINGLE CELL CHARTING OF DNMT3A-MUTANT LEUKEMIC EVOLUTION	Sanne Massaar	Received

435-PF	GLOBAL ALTERATIONS IN 3D DNA ARCHITECTURE DRIVE UNIQUE LEUKEMOGENIC PROFILES IN IDH1- AND DNMT3A-MUTANT ACUTE MYELOID LEUKEMIA	Sophie Steinhäuser	Received

438-PF	MORIN OVERCOMES VENETOCLAX RESISTANCE IN AML BY MODULATING THE USP15/HSP70/BCL-2 AXIS	Zi-Yuan Nie	Received

439-PF	SINGLE-CELL SURFACE PROTEOMICS AND LONG-READ METHYLOMICS IDENTIFY DETERMINANTS OF HMA RESPONSE AND RESISTANCE IN RELAPSED AML	Aaron Viny	Received

440-PF	RUNX1 MUTATIONS ACTIVATING BCAT1 IDENTIFIED BY LENTIVIRAL LIBRARY AS A THERAPEUTIC VULNERABILITY IN AML	Siyang Wang	Received

442-PF	PIEZO1 AS A KEY REGULATOR OF HEMATOPOIETIC STEM CELL QUIESCENCE AND ACUTE MYELOID LEUKEMIA PROGRESSION	Lucia de la Mata	Received

443-PF	LOOKING BEYOND VARIANT ALLELE FREQUENCY (VAF) FOR THE MONOALLELIC/BIALLELIC DETERMINATION OF TP53 MUTATIONS (MUTS) IN ACUTE MYELOID LEUKEMIA (AML) AND ASSOCIATIONS WITH OTHER GENOMIC ABERRATIONS	Jonathan Gerber	Received

444-PF	VISTA SUPPORTS PROLIFERATION AND MAINTENANCE OF ACUTE MYELOID LEUKEMIA STEM CELLS IN A CELL-INTRINSIC MANNER	Lukas Bähler	Received

448-PF	HIGH DIMENSIONAL SPECTRAL IMMUNE PROFILING REVEALS PROGNOSTIC AML SUBGROUPS AND A METABOLICALLY ACTIVE CD56? MONOCYTE POPULATION LINKED TO POOR OUTCOME	Shanna Hogeling	Received

449-PF	IMPROVED SINGLE-CELL LONG-READ GENOTYPING DEFINES CLONAL ARCHITECTURES, LINEAGE COMMITMENT AND TRANSCRIPTIONAL PROGRAMS IN SRSF2MUT AML	Angelos Galanopoulos	Received

451-PF	LIPID METABOLIC REWIRING DRIVES VENETOCLAX RESISTANCE IN ACUTE MYELOID LEUKEMIABEYOND BCL2 DEPENDENCY	Giulia Ciotti	Received

455-PF	CD36 AS A POTENTIAL MARKER AND THERAPEUTIC TARGET OF LEUKEMIC STEM CELLS IN ACUTE MYELOID LEUKEMIA	Narges Aghaallaei	Received

456-PF	EZH2 MODULATES HELLS EXPRESSION THROUGH EPIGENETIC ENHANCER ACTIVATION IN ACUTE MYELOID LEUKEMIA	Zheng Ge	Received

458-PF	1Q AMPLIFICATION AS A NOVEL MECHANISM OF RESISTANCE TO VENETOCLAX IN AML PATIENTS	Laura Beckmann	Received

459-PF	THE PICALM::MLLT10 FUSION COOPERATES WITH MUTATIONS IN CBL AND LEADS TO LEUKEMIA IN A MURINE MODEL	Rhea Desai	Received

460-PF	UNFOLDED PROTEIN RESPONSE AND AUTOPHAGY FACILITATE SURVIVAL OF RESIDUAL SENESCENT-LIKE ACUTE MYELOID LEUKEMIA CELLS ARISING AFTER CHEMOTHERAPY	Anna Skwarska	Received

462-PF	PASSENGER VARIANTS AS PAN-CLONAL MARKERS OF PEDIATRIC AML: IMPLICATIONS FOR MOLECULAR MRD	Ruth Shiloh	Received

464-PF	THERAPEUTIC ROLE OF GLV8 BY TARGETING GPR84 IN VENETOCLAX-RESISTANT ACUTE MYELOID LEUKEMIA	Zheng Ge	Received

467-PF	MUTATION-SPECIFIC REMODELING OF THE BONE MARROW MICROENVIRONMENT IN HIGH-RISK AML	Manja Wobus	Received

468-PF	TARGETING MITOCHONDRIAL TRANSFER WITH LIMK INHIBITION AND METFORMIN OVERCOMES MACROPHAGE-DRIVEN THERAPY RESISTANCE IN ACUTE MYELOID LEUKAEMIA	Mark Williams	Received

469-PF	UNMASKING CRYPTIC GENOMIC ALTERATIONS IN THERAPY-RELATED MYELOID NEOPLASMS (T-MN) USING OPTICAL GENOME MAPPING (OGM)	Sara García Ávila	Received

471-PF	MAGNETIC-INDUCED CELL-PATIENT-DERIVED XENOGRAFT (MAGIC-PDX) MODEL AS PARALLEL STUDIES FOR PERSONALIZED TREATMENT IN HEMATOLOGICAL MALIGNANCIES	Qianli Jiang	Received

472-PF	RAPID PLASMA PROTEOMIC STRATIFICATION OF TP53 AND FLT3 POSITIVE ACUTE MYELOID LEUKEMIA	Albin Osterroos	Received

475-PF	NANOBODY-BASED CHIMERIC ANTIGEN RECEPTOR T CELLS TARGETING TYROBP IN PEDIATRIC ACUTE MYELOID LEUKEMIA	Laurens Van Camp	Received

476-PF	DIAGNOSTIC IMPACT OF OPTICAL GENOME MAPPING IN ACUTE MYELOID LEUKEMIA	Anna Beko	Received

479-PF	HIGH PTP4A3 EXPRESSION IS ASSOCIATED WITH ADVERSE PROGNOSIS AND PRO-LEUKEMOGENIC SIGNALING PATHWAYS IN ACUTE MYELOID LEUKEMIA	Juan Luiz Coelho-Silva	Received

480-PF	ZBTB16::RARA DISRUPTS ANTIOXIDANT HOMEOSTASIS AND CREATES AN EXPLOITABLE REDOX VULNERABILITY IN ACUTE PROMYELOCYTIC LEUKEMIA	Alessandra Zaza	Received

481-PF	DJ-1 REGULATES NECROPTOSIS THROUGH THE TNFAIP3–RIPK1 AXIS IN FLT3-ITD ACUTE MYELOID LEUKEMIA	shifeng lou	Received

482-PF	LACTATE REGULATORY GENE LSP1 LEADING TO BCL-2 INHIBITOR RESISTANCE THROUGH DUAL EFFECTS BY PROMOTING AML CELL INVASION AND IMMUNE ESCAPE	Zhibo Guo	Received

483-PF	LDLR AND KLF2 ARE CRITICAL MEDIATORS IN STATIN-INDUCED CELL DEATH IN AML	Yuta Fukui	Received

484-PF	COMPUTATIONAL ASSESSMENT OF CD34+CD38- ACUTE MYELOID LEUKEMIA STEM CELL FREQUENCY AT DIAGNOSIS	Felix Zwolle	Received

488-PF	CLINICAL FEATURES, TREATMENT PATTERNS AND OUTCOMES OF 4,351 ADULT PATIENTS WITH SECONDARY ACUTE LEUKEMIA: A PETHEMA STUDY	Pau Montesinos	Received

490-PF	CHIDAMIDE PLUS VENETOCLAX AND AZACITIDINE (VAC) VERSUS VA REGIMEN IN NEWLY DIAGNOSED IMMUNOPHENOTYPICALLY MATURE MONOCYTIC AML: AN UPDATED ANALYSIS FROM A MULTICENTER RANDOMIZED STUDY	Kaiwen Tan	Received

491-PF	NOVEL RANDOM SURVIVAL FOREST MODEL FOR PRECISION RISK STRATIFICATION IN NPM1-MUTATED ACUTE MYELOID LEUKEMIA	Yiyi Yao	Received

493-PF	CD7 CAR T-CELL THERAPY IN RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA	Zhao defeng	Received

496-PF	VENETOCLAX PLUS ´2 + 5´ MODIFIED INTENSIVE CHEMOTHERAPY WITH DAUNORUBICIN AND CYTARABINE IN FIT ELDERLY PATIENTS WITH UNTREATED DE NOVO ACUTE MYELOID LEUKEMIA: A MULTICENTER PROSPECTIVE ANALYSIS	Jiajia Pan	Received

497-PF	GENOMIC SIGNATURE AND CLINICAL FEATURES OF DHX15 MUTATED RUNX1::RUNX1T1 AML.	Eleonora Boscaro	Received

500-PF	THE EFFICACY OF PIVEKIMAB SUNIRINE (PVEK) IN PATIENTS (PTS) WITH BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM (BPDCN) WITH BASELINE SKIN INVOLVEMENT IN THE CADENZA STUDY	Scott Moran	Received

503-PF	LONG-TERM OUTCOMES WITH VENETOCLAX PLUS "7+3" (DAV) INDUCTION IN NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA	Huafeng Wang	Received

507-PF	RESULTS FROM THE PHASE 1 MONOTHERAPY DOSE ESCALATION OF APL-4098, AN ORAL GCN2 INHIBITOR, IN RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (R/R AML) AND MYELODYSPLASTIC SYNDROMES (MDS)/AML PATIENTS	Nadine Clemo	Received

510-PF	HYPOMETHYLATING AGENTS PLUS VENETOCLAX IN YOUNGER AML: META-ANALYSIS OF A SHIFTING TREATMENT PARADIGM	Matteo Molica	Received

511-PF	OUTCOMES AND RISK STRATIFICATION WITH HIGH-DOSE CYTARABINE, MITOXANTRONE, AND VENETOCLAX IN RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA	Andrew Berdel	Received

515-PF	OPTIMIZED CD33(FL33) CAR-T CELLS IN RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA: A PHASE 1/2CLINICAL TRIAL	Jing Pan	Received

516-PF	MEASURABLE RESIDUAL DISEASE MONITORING IN PATIENTS WITH ACUTE MYELOID LEUKEMIA PRE- AND POST-ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION TO ASSESS RISK OF RELAPSE USING 16 KEY AML-ASSOCIATED GENES	Sean Glenn	Received

522-PF	GEMTUZUMAB OZOGAMICIN (GO) IN COMBINATION WITH CYTARABINE (ARA-C) IN RELAPSED ACUTE MYELOID LEUKEMIA (R-AML)	Giulia Arrigo	Received

523-PF	OUTCOMES AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IN ACUTE MYELOID LEUKEMIA TREATED WITH INTENSIVE CHEMOTHERAPY WITH VENETOCLAX	Leticia Campoverde	Received

525-PF	POPULATION-BASED STUDY OF ACUTE PROMYELOCYTIC LEUKEMIA IN GERMANY: INCIDENCE AND SURVIVAL OUTCOMES	David Baden	Received

527-PF	FLAG-MITOXANTRONE-VENETOCLAX (7 DAYS) IS AN EFFICIENT SALVAGE THERAPY IN RELAPSED/REFRACTORY AML, WITH AN IMPACT OF NGS ON RESPONSE, AND AN EXCELLENT BRIDGE TO ALLOGENEIC STEM CELL TRANSPLANTATION	Ahmad Ibrahim	Received

529-PF	UPDATED FINDINGS FROM THE PHASE 2 RIVER-81 STUDY OF ROMACICLIB (RVU120) COMBINED WITH VENETOCLAX IN ACUTE MYELOID LEUKEMIA AFTER FIRST-LINE VENETOCLAX AND HYPOMETHYLATING AGENT FAILURE	Pau Montesinos	Received

530-PF	UPDATED RESULT OF SELINEXOR-BASED NON-INTENSIVE CHEMOTHERAPY REGIMENS ADJUSTED ACCORDING TO EARLY RESPONSES ACHIEVE HIGH EARLY REMISSION IN NEWLY DIAGNOSED AML OR MDS	Donghua Zhang	Received

532-PF	DECITABINE/CEDAZURIDINE WITH OR WITHOUT A SECOND TARGETED AGENT (VENETOCLAX, GILTERITINIB, ENASIDENIB, OR IVOSIDENIB) AS FULLY ORAL PERSONALIZED MAINTENANCE THERAPY IN ACUTE MYELOID LEUKEMIA	Alexandre Bazinet	Received

533-PF	AUTOMATIC AND EXPLAINABLE ANALYSIS OF BONE MARROW SMEARS USING MACHINE LEARNING METHODS : AN INNOVATIVE MODEL FOR THE DIAGNOSIS OF ACUTE MYELOID LEUKEMIA	Jules Morata	Received

534-PF	FEASIBILITY AND CLINICAL IMPACT OF CYTARABINE CONSOLIDATION FOR AML IN A FULL OUTPATIENT SETTING	Marina Vallvé i Oliva	Received

535-PF	DNMT3A R882 HOTSPOT MUTATION DEFINES A HIGH-RISK SUBGROUP IN TREATMENT-NAÏVE AML IRRESPECTIVE OF CO-MUTATION STATUS	Zheng Ge	Received

536-PF	REAL-WORLD MANAGEMENT PRACTICES WITH VENETOCLAX-BASED THERAPY FOR AML - RESULTS FROM THE PROSPECTIVE REVIVE STUDY	Yakir Moshe	Received

537-PF	EXPOSURE-RESPONSE ANALYSIS OF ZIFTOMENIB COMBINED WITH VENETOCLAX/AZACITIDINE OR CYTARABINE/DAUNORUBICIN IN NEWLY DIAGNOSED AND RELAPSED/REFRACTORY NPM1-M OR KMT2A-R ACUTE MYELOID LEUKEMIA	Amitava Mitra	Received

539-PF	DETERMINANTS OF SURVIVAL IN 356 PATIENTS FAILING FRONTLINE VENETOCLAX–HMA FOR NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA	Naseema Gangat	Received

540-PF	REAL-WORLD INSIGHTS INTO SALVAGE CHEMOTHERAPY FOR FIT FAVORABLE-RISK AML PATIENTS AT FIRST RELAPSE	Elisa Seubert	Received

541-PF	LOW-DOSE INDUCTION CHEMOTHERAPY IS ASSOCIATED WITH VERY LOW EARLY MORTALITY IN PEDIATRIC ACUTE MEGAKARYOBLASTIC LEUKEMIA: A PROSPECTIVE MULTICENTER STUDY	Shengqin Cheng	Received

544-PF	A LARGE MULTICENTER REAL-WORLD STUDY DEMONSTRATES SUPERIOR OUTCOMES WITH VENETOCLAX-BASED REGIMENS IN ACUTE MYELOID LEUKEMIA HARBORING EZH2 MUTATIONS	Xiangli Chen	Received

545-PF	PROOF-OF-CONCEPT: DEEP LEARNING-BASED PREDICTION OF MEASURABLE RESIDUAL DISEASE IN ACUTE MYELOID LEUKEMIA WITHOUT REFERENCE VALUES	Maximilian Roehnert	Received

546-PF	FLAG-MITOXANTRONE WITH 7 DAYS VENETOCLAX IS A HIGHLY EFFICIENT REGIMEN IN NEWLY DIAGNOSED ACUTE MYELOBLASTIC LEUKEMIA AND AN EFFECTIVE BRIDGE TO ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION	Ahmad Ibrahim	Received

549-PF	CLADRIBINE COMBINED WITH LOW-DOSE CYTARABINE AND G-CSF IN UNFIT REFRACTORY/RELAPSED ACUTE MYELOID LEUKEMIA	Qiaoyi Zhou	Received

550-PF	A PHASE I/II STUDY OF GILTERITINIB AND MOMELOTINIB IN ADULTS WITH RELAPSED OR REFRACTORY FLT3-MUTATED ACUTE MYELOID LEUKEMIA	Nicholas Short	Received

551-PF	IMPACT OF TIME TO TREATMENT ON OUTCOMES IN HYPERPROLIFERATIVE ACUTE MYELOID LEUKEMIA	Benjamin Mccormick	Received

554-PF	ABSOLUTE LYMPHOCYTE COUNT AFTER INDUCTION CHEMOTHERAPY IS A PREDICTIVE BIOMARKER IN ACUTE MYELOID LEUKEMIA PATIENTS AND RELATES WITH POST-THERAPY CHANGES IN IMMUNE TRANSCRIPTOMIC BONE MARROW PROFILE.	Federico Zingarelli	Received

557-PF	SAFETY RUN-IN RESULTS OF THE CHIP-AML22 PHASE II TRIAL EVALUATING QUIZARTINIB COMBINED WITH CHEMOTHERAPY IN PEDIATRIC PATIENTS WITH NEWLY DIAGNOSED FLT3-ITD–POSITIVE, NPM1–WILD-TYPE AML	Gertjan Kaspers	Received

559-PF	SHORTER TREATMENT, FASTER DISCHARGE. THE IMPACT OF DAY 14 ASSESSMENT IN AML PATIENTS ON AZA-VEN: A SINGLE CENTER EXPERIENCE.	Felix Klingler	Received

560-PF	NEWER AML RISK SCORES IMPROVE RISK STRATIFICATION IN CPX-351 TREATED S-AML PATIENTS COMPARED TO ELN2022, BUT A TAILORED PROGNOSTIC MODEL IS STILL NEEDED	Carola Riva	Received

562-PF	REAL-WORLD EFFICACY AND SAFETY OF LISAFTOCLAX IN MYELOID NEOPLASMS: A MULTICENTER STUDY	Chen Cao	Received

565-PF	GILTERITINIB OR IVOSIDENIB IN COMBINATION WITH VENETOCLAX-BASED THERAPIES FOR FLT3- OR IDH1-MUTATED ACUTE MYELOID LEUKEMIA	Andrius Žucenka	Received

567-PF	ORAL AZACITIDINE MAINTENANCE IN FAVORABLE-RISK AML: ON BEHALF OF THE ISRAEL ACUTE LEUKEMIA GROUP (IALG)	Noa Hurvitz	Received

568-PF	PTPN11 MUTATED ACUTE MYELOID LEUKEMIA: EVALUATION OF DOMAIN-SPECIFIC MUTATIONS AND THEIR POTENTIAL IMPACT ON CO-MUTATIONAL PROFILES AND CLINICAL OUTCOMES	Francesca Crupi	Received

571-PF	MYC OVEREXPRESSION DRIVES POOR PROGNOSIS AND DIFFERENTIAL SENSITIVITY TO TREATMENTS ACCORDING TO TP53 STATUS IN CHRONIC LYMPHOCYTIC LEUKEMIA	Alba Garrote-de-Barros	Received

576-PF	REVISITING COMPLEX KARYOTYPE IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS TREATED WITH CONTINUOUS BTK INHIBITION: A MULTICENTER ERIC STUDY	Anna Puiggros	Received

577-PF	MCL1 COPY NUMBER GAIN IS A RECURRENT MARK OF VENETOCLAX RESISTANCE IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA	Carolyne Croizier	Received

578-PF	FERROPTOSIS AS A THERAPEUTIC TARGET IN CHRONIC LYMPHOCYTIC LEUKEMIA	Martin Boettcher	Received

583-PF	DISSECTION OF BIALLELIC NOTCH1 DISRUPTION IN CHRONIC LYMPHOCYTIC LEUKEMIA REVEALS CHROMOSOME 9 COPY NEUTRAL-LOSS OF HETEROZYGOSITY	Giulia Ianna	Received

584-PF	PTPN2 INHIBITION RESTORES T-CELL FUNCTION AND POTENTIATES T-CELL ENGAGER ACTIVITY IN CHRONIC LYMPHOCYTIC LEUKEMIA	Yair Herishanu	Received

585-PF	MULTI-OMIC INTEGRATION OF WGS, WTS, AND MIRNA PROFILES ELUCIDATES THE MOLECULAR BASIS OF CLL HETEROGENEITY	Wencke Walter	Received

590-PF	OUTCOMES AFTER 1L TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA BELONGING TO STEREOTYPED SUBSET #2, AN INTERNATIONAL MULTICENTER STUDY CONDUCTED BY ERIC.	Thomas Chatzikonstantinou	Received

597-PF	DUAL MAPK PATHWAY INHIBITION, ALONE OR COMPLEMENTED BY ANTI-CD20 IMMUNOTHERAPY, IN PREVIOUSLY TREATED HAIRY CELL LEUKEMIA/HCL: A HIGHLY ACTIVE TARGETED STRATEGY OF FIXED AND SHORT DURATION	Alessandro Mancini	Received

598-PF	FINAL RESULTS FROM ASSURE: A PHASE 3B STUDY OF THE SAFETY AND EFFICACY OF ACALABRUTINIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA	Stephen Opat	Received

604-PF	LONG-TERM FOLLOW-UP RESULTS OF A PHASE 2 STUDY OF VENETOCLAX ADDED TO IBRUTINIB TO ELIMINATE RESISTANCE MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)	Kerry Rogers	Received

609-PF	REAL-LIFE DATA ON FIRST LINE AND RELAPSED/REFRACTORY CLL ACALABRUTINIB TREATMENT: UPDATED 3Y RESULTS OF THE LARGE NAOS OBSERVATIONAL STUDY IN FRANCE, INCLUDING HIGH-RISK AND IBRUTINIB-EXPOSED PATIENTS	Anne Quinquenel	Received

610-PF	ORELABRUTINIB FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA: SAFETY AND EFFICACY RESULTS FROM A GLOBAL PHASE 1/2 STUDY	Yucai Wang	Received

612-PF	DURABLE RESPONSES AFTER TIME-LIMITED THERAPY WITH ZANUBRUTINIB PLUS RITUXIMAB IN PATIENTS WITH TREATMENT-NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA	Jan Burger	Received

614-PF	SAFETY OF FIXED-DURATION (FD) ACALABRUTINIB-VENETOCLAX COMBINATIONS IN PATIENTS (PTS) WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) STRATIFIED BY AGE: POST HOC ANALYSIS OF THE PHASE 3 AMPLIFY TRIAL	John F. Seymour	Received

616-PF	IMPACT OF IGHV MUTATIONAL STATUS ON OUTCOME IN CHRONIC LYMPHOCYTIC LEUKEMIA	Christof Schneider	Received

617-PF	FIXED-DURATION IBRUTINIB PLUS VENETOCLAX IN FRONTLINE CLL/SLL: UPDATED REAL-WORLD OUTCOMES FROM THE SPANISH LI+VE STUDY	DZ dz	Received

619-PF	AUTOIMMUNE COMPLICATIONS IN CHRONIC LYMPHOCYTIC LEUKAEMIA – A SINGLE INSTITUTION STUDY OVER 30 YEARS	Stephen Mulligan	Received

624-PF	PERIPHERAL BLOOD NEUTROPHIL QUANTITY AND MATURATION PREDICT TREATMENT-FREE REMISSION IN CHRONIC MYELOID LEUKEMIA	Tatsuya Mihashi	Received

626-PF	GENOMIC AND TRANSCRIPTOMIC FEATURES OF TRANSFORMED CHRONIC MYELOID LEUKEMIA IN BLAST PHASE	Mei Bao	Received

627-PF	PROGNOSTIC IMPACT OF ADDITIONAL SOMATIC MUTATIONS ON TKD DEVELOPMENT, MOLECULAR RESPONSE AND SURVIVAL IN CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH TYROSINE KINASE INHIBITORS	Ruth Stuckey	Received

629-PF	LONG-TERM OUTCOMES OF VERY LOW-DOSE DASATINIB IN OLDER PATIENTS WITH NEWLY DIAGNOSED CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA: EXTENDED FOLLOW-UP OF THE DAVLEC PHASE 2 TRIAL	Kazunori Murai	Received

632-PF	ASCIMINIB VERSUS SECOND-GENERATION TKIS IN CHRONIC-PHASE CML AFTER =2 PRIOR TKIS: A PROPENSITY SCORE-MATCHED ANALYSIS	Noora Obaidallah	Received

634-PF	HIGHER FIRST LINE TKI RESISTANCE IN ADOLESCENTS AND YOUNG ADULTS (AYA) WITH CHRONIC MYELOID LEUKEMIA. EVIDENCE FROM A POPULATION-BASED REGISTRY.	Maria Jose Herranz Marti	Received

636-PF	TYROSINE KINASE INHIBITOR USE AND THE RISK OF NEURODEGENERATIVE DISEASE: A SWEDISH POPULATION-BASED COHORT STUDY	Felix Wittström	Received

637-PF	IMPACT OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION ON CLINICAL OUTCOMES IN CHRONIC MYELOID LEUKEMIA IN BLAST PHASE	DZ DZ	Received

639-PF	EFFICACY AND SAFETY OF REDUCED-DOSE DASATINIB (50 MG/DAY) AS FIRST-LINE THERAPY IN CHRONIC MYELOID LEUKEMIA: RESULTS FROM A MULTICENTER REAL-WORLD STUDY BY THE SPANISH CML GROUP	Gonzalo Maortua Langdon	Received

640-PF	LOSS OF HNRNPK DRIVES CMML THROUGH ABERRANT NF1 SPLICING AND RAS ACTIVATION	Miguel Angel Marugal	Received

643-PF	REFINING MDS CLASSIFICATION: CHARACTERIZATION OF NOVEL STAG2, EZH2, -7, AND TET2 BI-ALLELIC ENTITIES AND THEIR IMPACT ON RISK STRATIFICATION	Carlos Ruiz Arenas	Received

644-PF	RETROTRANSPOSABLE ELEMENT DEREPRESSION DISTINGUISHES DNMT3A- FROM TET2-MUTANT CLONAL HEMATOPOIESIS	Mohammad M Karimi	Received

647-PF	YOUNG AGE AT DIAGNOSIS OF A MYELOID NEOPLASIA AS A STANDALONE CRITERION FOR GERMLINE INVESTIGATION: RESULTS FROM A PROSPECTIVE COHORT STUDY	Panagiotis Baliakas	Received

651-PF	CLK INHIBITOR CTX-712 POTENTIATES THE ACTIVITY OF ABT-199 AND AZACYTIDINE IN MYELOID LEUKEMIA	Guillermo Garcia-Manero	Received

654-PF	INCREASED MITOCHONDRIAL ACTIVITY IN HSPCS AND MONOCYTES/MACROPHAGES COMPARTMENT REVEALS METABOLIC VULNERABILITIES IN MYELODYSPLASTIC SYNDROMES	Manuela Albuquerque de Melo	Received

656-PF	WHOLE GENOME SEQUENCING REVEALS NOVEL, CLINICALLY RELEVANT BIOMARKER MISSED BY STANDARD OF CARE FOR PATIENTS WITHIN MYELODYSPLASTIC SYNDROME	Alex Bataller	Received

658-PF	IMMUNE AND NICHE-ASSOCIATED TRANSCRIPTIONAL REMODELING ACROSS MDS AND AML AND ITS RELATIONSHIP TO RECURRENT GENETIC ALTERATIONS	Seon Young Kim	Received

659-PF	UPDATED OVERALL SURVIVAL AND LONG-TERM TRANSFUSION INDEPENDENCE IN ESA-NAIVE PATIENTS WITH LOWER-RISK MDS: RESULTS FROM THE PHASE 3 COMMANDS TRIAL	Valeria Santini	Received

666-PF	IMPACT OF U2AF1 PATHOGENIC VARIANTS ON PROGNOSIS OF MYELODYSPLASTIC NEOPLASMS WITH RUNX1 MUTATION	Linlin Liu	Received

668-PF	ROXADUSTAT IMPROVES TRANSFUSION INDEPENDENCE IN LR-MDS PATIENTS WITH ANEMIA AND HIGH TRANSFUSION BURDEN AND IN RING SIDEROBLAST POSITIVE AND NEGATIVE DISEASE: POST-HOC ANALYSIS OF MATTERHORN STUDY	Amer M. Zeidan	Received

669-PF	OUTCOMES AND CHARACTERISTICS OF LOWER-RISK MDS PATIENTS WITH ELEVATED SERUM ERYTHROPOIETIN LEVELS (=500 IU/L): A MULTICENTER STUDY BY THE POLISH ADULT LEUKEMIA GROUP (PALG)	Piotr Stompór	Received

670-PF	REAL-WORLD OUTCOMES OF IMETELSTAT: INTERROGATING SAFETY, EFFICACY AND PREDICTORS OF RESPONSE IN HEAVILY PRETREATED LOWER-RISK MDS PATIENTS	Rami S. Komrokji	Received

672-PF	PHASE I STUDY OF OP-2100, AN ORALLY BIOAVAILABLE PRODRUG OF DECITABINE, FOR PATIENTS WITH RELAPSED OR REFRACTORY HIGH-RISK MYELODYSPLASTIC SYNDROME AND CHRONIC MYELOMONOCYTIC LEUKEMIA	Senji Kasahara	Received

673-PF	A NEW ORAL DOSAGE FORM OF DECITABINE/CEDAZURIDINE DEMONSTRATED CONSISTENT EFFICACY AND FAVORABLE SAFETY PROFILE IN MYELODYSPLASTIC SYNDROMES PATIENTS IN CHINA: FIRST RESULTS FROM A PIVOTAL TRIAL	Xinping Zhou	Received

674-PF	BEYOND STATIC BASELINES: PREDICTIVE VALUE OF DYNAMIC KARYOTYPE EVOLUTION FOR DISEASE PROGRESSION AND LEUKEMIC TRANSFORMATION IN MYELODYSPLASTIC NEOPLASMS	Zheng Ge	Received

677-PF	BLAST DEMONSTRATES HIGHER PROGNOSTIC ACCURACY FOR SURVIVAL THAN CPSS IN CHINESE PATIENTS WITH CHRONIC MYELOMONOCYTIC LEUKEMIA	Zheng Ge	Received

679-PF	TARGETING ASH1L-STING AXIS RESTORES NK CELL FUNCTION AND AMELIORATES IMMUNE-MEDIATED BONE MARROW FAILURE DISEASES	Nan Song	Received

680-PF	MODELING PNH EVOLUTION: GENETIC DRIFT AND CLINICAL DETERMINANTS	Ramkarthic Ramanathan	Received

684-PF	PREVALENCE AND CLINICAL IMPACT OF CLONAL HEMATOPOIESIS IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: A MULTICENTER STUDY.	Nicole Galli	Received

685-PF	RESTORATION OF RPS19 EXPRESSION IN HUMAN CELLULAR MODELS OF DIAMOND-BLACKFAN ANAEMIA SYNDROME	Joan Case	Received

690-PF	SOVLEPLENIB AMELIORATES APLASTIC ANEMIA THROUGH THE MODULATION OF CGAS-STING-NF-?B PATHWAY	Hong Liu	Received

691-PF	LONG-TERM MUTATIONAL ANALYSIS, CLONAL METRICS AND DYNAMICS IN PATIENTS WITH CHRONIC IDIOPATHIC NEUTROPENIA HIGHLIGHT THE IMPORTANCE OF MOLECULAR MONITORING	Helen Papadaki	Received

693-PF	LONG-TERM SAFETY WITH IPTACOPAN TREATMENT IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH): POOLED ANALYSIS OF DATA FROM PHASE 2 AND 3 STUDIES AND THE ROLL-OVER EXTENSION PROGRAM	Alexander Röth	Received

694-PF	PLATELET PNH CLONE ASSESSMENT BY FLOW CYTOMETRY ISFEASIBLE AND PROVIDES A RELIABLE ESTIMATE OF CLONE SIZE AND PLATELET ACTIVATION IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA	Lucas Sales	Received

707-PF	DANICOPAN ADD-ON THERAPY IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: UK EXPERIENCE	Morag Griffin	Received

710-PF	EFFECTIVENESS AND SAFETY OF IPTACOPAN IN CHINESE PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: FIRST REPORT FROM A MULTICENTER AMBISPECTIVE REAL-WORLD COHORT STUDY (IMPACT-PNH CHINA)	Hui Liu	Received

711-PF	CLINICAL SPECTRUM AND MUTATIONAL BURDEN OF PIGA VARIANTS DETECTED BY BONE MARROW NGS: REAL-WORLD DIAGNOSTIC IMPLICATIONS AND CORRELATION WITH PNH CLONE SIZE	Min Wu	Received

713-PF	IMPACT OF IPTACOPAN, A COMPLEMENT INHIBITOR, ON CHINESE PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: A MULTICENTER RETROSPECTIVE COHORT STUDY	Shuqian Xu	Received

716-PF	REPROGRAMMING BCMA-TARGETED CAR-T CELLS THROUGH GAMMA-SECRETASE MODULATION BLOCKS ANTIGEN SHEDDING AND EXTENDS CAR-T LONGEVITY	sheetal Sharma	Received

717-PF	GENETIC SUSCEPTIBILITY TO ARTERIAL THROMBOEMBOLISM IN NEWLY DIAGNOSED MULTIPLE MYELOMA IN THE UK NCRI MYELOMA XI TRIAL.	Sina Beer	Received

719-PF	T(8;14) IMPROVES THE IMS/IMWG CONSENSUS GENOMIC STAGING FOR DEFINING HIGH-RISK MULTIPLE MYELOMA PATIENTS	Anaïs Schavgoulidze	Received

720-PF	TARGETING GLUTAMINE METABOLISM AS A NEW STRATEGY TO IMPROVE ANTI-BCMA T CELL ENGAGER ACTIVITY IN MYELOMA CELLS.	Nicola Giuliani	Received

723-PF	RAS–MAPK MUTATIONAL PROFILE IS ASSOCIATED WITH MULTI-PATHWAY GENOMIC ALTERATIONSAND A DISTINCT TERMINALLY DIFFERENTIATED/EXHAUSTED T-CELL SIGNATURE IN NEWLY DIAGNOSEDMULTIPLE MYELOMA	Paula Piñero	Received

725-PF	ABS CATA-001: A NOVEL CD38/AL BISPECIFIC FOR TREATING MULTIPLE MYELOMA	Chengcheng Fu	Received

726-PF	FUNCTIONAL CONSEQUENCES OF TP53 LOSS ACROSS MAJOR IGH TRANSLOCATION SUBTYPES IN MULTIPLE MYELOMA	Sara Cristóbal Vargas	Received

729-PF	COEVOLUTION OF NK AND TUMOR CELL STATES ALONG MULTIPLE MYELOMA PROGRESSION FROM PRECURSOR CONDITIONS	Cristina Aquilina	Received

730-PF	A MYELOID-DORMANT METABOLIC TRANSCRIPTOME IDENTIFIES A POOR-PROGNOSIS SUBGROUP IN HYPERDIPLOID MULTIPLE MYELOMA WITH TARGETABLE VULNERABILITIES	Naroa Barrena	Received

731-PF	CONCURRENT RAS/RAF MUTATIONS DEFINE AN ULTRA-HIGH-RISK SUBGROUP IN MULTIPLE MYELOMA WITH GAIN OF CHROMOSOME 1Q	Xueshi YE	Received

733-PF	A NOVEL CDK9 INHIBITOR, GT-02897, SELECTIVELY INDUCES CYTOTOXIC EFFECTS AND EXHIBITS PRECLINICAL SYNERGISTIC ACTIVITY IN MYELOMA	Osman Aksoy	Received

734-PF	SINGLE CELL RNA SEQUENCING REVEALS IMMUNE MICROENVIRONMENT REMODELING IN PRIMARY PLASMA CELL LEUKEMIA: REAL-WORLD EVIDENCE FROM THE KMMWP-2204 STUDY	Sung-Hoon Jung	Received

737-PF	CRBN-INDEPENDENT IKZF1 DEGRADATION VIA TRIM21 BY DNA DEMETHYLATING AGENTS AS A NOVEL THERAPEUTIC MECHANISM FOR MULTIPLE MYELOMA	Yuta Yamamoto	Received

739-PF	GENOMIC LANDSCAPE AND CHARACTERIZATION OF END STAGE MULTIPLE MYELOMA	Julia Wiedmeier-Nutor	Received

740-PF	ANSELAMIMAB TARGETS BOTH CYTOTOXIC SOLUBLE PREFIBRILLAR SPECIES AND INSOLUBLE FIBRILS OF LIGHT CHAIN AMYLOIDOSIS	Daniel Zaldumbide	Received

741-PF	TRAF2 AND NCK INTERACTING KINASE SIGNALING DRIVES MULTIPLE MYELOMA DEVELOPMENT AND PROGRESSION	Adrian Wegmüller	Received

742-PF	MAGNETICALLY INDUCED CELL-PATIENT OR CELL LINE DERIVED XENOGRAFT (MAGIC-PDX/CDX) MODELS FOR THE RAPID ESTABLISHMENT OF MULTIPLE MYELOMA AND DRUG SCREENING	Qianli Jiang	Received

744-PF	ROLE AND MECHANISM OF PIM-2 KINASE INHIBITOR-INDUCED IMMUNOGENIC CELL DEATH IN MULTIPLE MYELOMA	Rong Fu	Received

745-PF	PHF19 DRIVES LENALIDOMIDE RESISTANCE BY EPIGENETICALLY REPROGRAMMING THE IRF4/MYC AXIS IN MULTIPLE MYELOMA	Xiyue Sun	Received

746-PF	A NOVEL CIRCULAR RNA PRODUCED BY THE "NUCLEAR FACTOR OF ACTIVATED T-CELLS, CYTOPLASMIC 3" GENE (CIRCNFATC3), DISCOVERED BY NANOPORE SEQUENCING, HOLDS SIGNIFICANT PROGNOSTIC VALUE IN MULTIPLE MYELOMA	Evangelos Terpos	Received

747-PF	A SYSTEMIC LIPID SIGNATURE DISTINGUISHES AL AMYLOIDOSIS AND SUGGESTS METABOLIC CROSSTALK ACROSS BONE MARROW, CIRCULATION, AND PERIPHERAL TISSUES	Oshrat Hershkovitz-Rokah	Received

749-PF	CHARACTERIZATION OF THE LONG NON-CODING RNA LANDSCAPE IN MULTIPLE MYELOMA REVEALS NOVEL PUTATIVE DRIVER GENES ASSOCIATED WITH POOR OVERALL SURVIVAL	Silke Nielsen	Received

752-PF	PROGNOSTIC BIOMARKERS BEYOND BONE DISEASE IN NEWLY DIAGNOSED MULTIPLE MYELOMA: INTEGRATING PROTEOMIC, GENOMIC, AND BONE METABOLISM SIGNATURES	Ioannis Ntanasis-Stathopoulos	Received

753-PF	A COMMON GENE EXPRESSION SIGNATURE ACROSS MULTIPLE MYELOMA DISEASE STAGES IDENTIFIES HIGH-RISK OF DISEASE PROGRESSION	Claudio Cerchione	Received

756-PF	LIQUID BIOPSY–BASED THREE-DIMENSIONAL TELOMERE PROFILING DISTINGUISHES AL AMYLOIDOSIS FROM MULTIPLE MYELOMA AT DIAGNOSIS	Sabine Mai	Received

758-PF	LNCRNA NEAT1 ORCHESTRATES A CERNA NETWORK GOVERNING CORE PATHWAYS OF PROLIFERATION AND CELLULAR DYNAMICS IN MULTIPLE MYELOMA	Niccolò Bolli	Received

760-PF	CXCR4 REWIRES MITOCHONDRIAL FUNCTION TO SUSTAIN METABOLIC PLASTICITY AND SURVIVAL IN MULTIPLE MYELOMA	Katia Beider	Received

761-PF	PHARMACOLOGIC BCMA UPREGULATION WITH ATRA ENHANCES BELANTAMAB MAFODOTIN ACTIVITY IN MULTIPLE MYELOMA	Amaya Llorente	Received

762-PF	DREAMM-9 FINAL ANALYSIS: BELANTAMAB MAFODOTIN (BELAMAF), BORTEZOMIB, LENALIDOMIDE, AND DEXAMETHASONE (BVRD) FOR TRANSPLANT-INELIGIBLE (TI) NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM)	Enrique M. Ocio	Received

763-PF	UPDATED RESULTS OF A PHASE 1 FIRST-IN-HUMAN STUDY OF CEMSIDOMIDE, A NOVEL MONODAC® DEGRADER, WITH DEXAMETHASONE (DEX) IN PATIENTS WITH (RRMM)	Sagar Lonial	Received

764-PF	DURABLE CLINICAL BENEFIT WITH B-CELL MATURATION ANTIGEN THERAPY, BELANTAMAB MAFODOTIN, POMALIDOMIDE, AND DEXAMETHASONE, IN RELAPSED/?REFRACTORY MULTIPLE MYELOMA: DREAMM-8 LONG-TERM RESPONDER ANALYSIS	Meletios A. Dimopoulos	Received

765-PF	IMPACT OF SUSTAINED MRD NEGATIVITY ON LONG-TERM OUTCOME OF TRANSPLANT ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS ENROLLED IN THE RANDOMIZED PHASE 2 FORTE TRIAL	Giuseppe Bertuglia	Received

766-PF	ISATUXIMAB–RD INDUCTION FOLLOWED BY ISA-R MAINTENANCE COMPARED TO RD INDUCTION FOLLOWED BY R MAINTENANCE IN ELDERLY PTS WITH NDMM WITH EMPHASIS ON FRAIL AND NON-FRAIL PTS (AGMT MM04 TRIAL)	Heinz Ludwig	Received

768-PF	VALIDATION OF A MYELOMA ELDERLY PROGNOSTIC SCORE (MEPS) BASED ON FRAILTY AND HIGH-RISK CYTOGENETICS IN TRANSPLANT INELIGIBLE PATIENTS: A COLLABORATION OF THE GREEK AND PORTUGUESE MYELOMA STUDY GROUPS	Eirini Katodritou	Received

773-PF	PROMISING PERFORMANCE OF PET/CT USING [68GA]GA-PENTIXAFOR FOR INITIAL STAGING AND THERAPEUTIC EVALUATION OF MULTIPLE MYELOMA PATIENTS IN FIRST LINE TREATMENT OR RELAPSE: INTERIM ANALYSIS.	Caroline Milin	Received

776-PF	PFS2 OUTCOMES BY PRIOR THERAPY FROM DREAMM-8: BELANTAMAB MAFODOTIN, POMALIDOMIDE, AND DEXAMETHASONE VS POMALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA	Güldane Cengiz Seval	Received

778-PF	UNRAVELING 1Q?/T(4;14) DOUBLE-HIT MYELOMA: CLINICAL AGGRESSIVENESS, EXTRAMEDULLARY RELAPSE, AND MOLECULAR TARGETS FROM A MULTICENTER AND MULTI-OMIC STUDY	Yi Tao	Received

779-PF	DARATUMUMAB RETREATMENT AFTER CONTINUOUS FRONTLINE DARA-VCD WITH BACKBONE SWITCH IN TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: RESULTS FROM THE MULTICENTER GMMG-DADA STUDY	Tim Richardson	Received

780-PF	A PRELIMINARY STUDY ON THE SAFETY AND EFFICACY OF INTRATHECAL COMBINED WITH INTRAVENOUS CAR-T CELL THERAPY FOR B-CELL MALIGNANCIES WITH CENTRAL NERVOUS SYSTEM INVOLVEMENT	Yanli Feng	Received

781-PF	FUNCTIONAL CURE IN WALDENSTROM´S MACROGLOBULINEMIA: DETERMINANTS OF 10-YEAR PROGRESSION-FREE SURVIVAL	Maria Gavriatopoulou	Received

783-PF	IMPACT OF AUTOLOGOUS STEM CELL TRANSPLANTATION FOLLOWING QUADRUPLET THERAPY (DARA-VRD) ON SURVIVAL OUTCOMES IN MULTIPLE MYELOMA: A REAL-WORLD DATA ANALYSIS	Lanzhu Yue	Received

785-PF	MAGNAZ-TRIAL: A MULTICENTER PHASE II STUDY OF ZANUBRUTINIB TREATMENT IN ANTI-MAG POLYNEUROPATHY	Monique Minnema	Received

786-PF	PERIPHERAL BLOOD MASS SPECTROMETRY REVEALS EARLY RELAPSE DYNAMICS AFTER MAINTENANCE DISCONTINUATION IN MULTIPLE MYELOMA	Anna Pula	Received

787-PF	WHOLE GENOME SEQUENCING OF MULTIPLE MYELOMA CELLS WITH A NOVEL CLINICAL ASSAY UNCOVERS DIVERSITY OF GENETIC ALTERATIONS UNDERLYING IMMUNOTHERAPY RESISTANCE	Bruno Paiva	Received

789-PF	EXTRAPOLATED PROGRESSION-FREE SURVIVAL WITH BELANTAMAB MAFODOTIN/LENALIDOMIDE/DEXAMETHASONE EXCEEDS 7 YEARS IN INTERMEDIATE-FIT AND FRAIL, TRANSPLANT-INELIGIBLE, NEWLY DIAGNOSED MULTIPLE MYELOMA	Evangelos Terpos	Received

792-PF	LONG-TERM OUTCOMES WITH SUSTAINED MINIMAL RESIDUAL DISEASE NEGATIVITY IN BELANTAMAB MAFODOTIN–TREATED PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: AN UPDATE FROM DREAMM-8	Meletios A. Dimopoulos	Received

794-PF	PLASMACYTOMA REDUCED QUICKLY IN PATIENTS(PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA BY APONERMIN +KT-DECP REGIMEN	Aijun Liu	Received

795-PF	BONE MARROW QUALITY INDEX (BMQI) AS A MARKER OF SAMPLE QUALITY IN POST-TREATMENT MRD ASSESSMENT: DATA FROM THE REMNANT TRIAL	Jón Þórir Óskarsson	Received

797-PF	CIBMTR REAL-WORLD OUTCOMES OF OLDER PATIENTS TREATED WITH IDECABTAGENE VICLEUCEL	Doris Hansen	Received

802-PF	MORTALITY AND CLINICAL RISK FACTORS IN PATIENTS WITH MULTIPLE MYELOMA.	Maria Ordoñez Garcia	Received

803-PF	DEEP PERIPHERAL IMMUNE PHENOTYPING REVEALS PROFOUND T-CELL SENESCENCE, NK-CELL DYSREGULATION, AND MONOCYTE SKEWING IN RELAPSED/REFRACTORY MULTIPLE MYELOMA	Yajing Zhang	Received

812-PF	MIF/MTOR PATHWAY DRIVES INFLAMMATION IN IMCD WITH ANA POSITIVITY PRONE TO SEVERE DISEASE AND WORSE PROGNOSIS	Shengnan Ding	Received

814-PF	IMPACT OF BRIDGING THERAPY AND DISEASE RESPONSE ON OUTCOMES AFTER ARI0002H BCMA CAR-T IN RELAPSED/REFRACTORY MULTIPLE MYELOMA	Anna de Daniel	Received

816-PF	COMPLETE CARDIAC RESPONSE IMPROVES THE SURVIVAL OF PATIENTS WITH AL AMYLOIDOSIS AND IMPAIRED GLOBAL LONGITUDINAL STRAIN	Foteini Theodorakakou	Received

819-PF	INFLAMMATORY MIMICS: MASS SPECTROMETRY RESOLVES FALSE-POSITIVE PARAPROTEINS ON SERUM IMMUNOFIXATION	Neela Easton	Received

820-PF	IMPACT OF SPECIFIC CYTOGENETIC ABNORMALITIES ON MRD KINETICS AND PROGNOSTIC VALUE IN MULTIPLE MYELOMA	Alberto Blanco Sánchez	Received

826-PF	CLONAL PLASMA CELL S-PHASE AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION PREDICTS SURVIVAL OUTCOMES IN MULTIPLE MYELOMA	Maximilian Steinhardt	Received

827-PF	PROGNOSTIC VALUE OF SERUM FERRITIN KINETICS IN ANTI-BCMA CAR-T THERAPY FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA	James Di Palma-Grisi	Received

828-PF	BCMA CAR-T THERAPY WITH RADIOTHERAPY BRIDGING AND MAINTENANCE ACHIEVES UNPRECEDENTED DURABLE RESPONSE IN EXTRAMEDULLARY MYELOMA	lili Zhou	Received

829-PF	MOLECULAR MARKERS AS A POSSIBLE FACTOR IN PROGRESSION IN MULTIPLE MYELOMA	Zhanna Kozich	Received

830-PF	COMPARATIVE EFFICACY OF LINVOSELTAMAB VERSUS TECLISTAMAB IN TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA: UPDATED MATCHING-ADJUSTED INDIRECT COMPARISON WITH LONGER FOLLOW-UP	Hans C. Lee	Received

831-PF	PROGNOSTIC VALUE OF TIME-TO-TREATMENT AND REGIMENS IN WALDENSTRÖM MACROGLOBULINEMIA: A REAL-WORLD MULTICENTER STUDY	Kyungju Kim	Received

832-PF	MATCHING-ADJUSTED INDIRECT COMPARISON FOR BELANTAMAB MAFODOTIN WITH POMALIDOMIDE AND DEXAMETHASONE VS DARATUMUMAB WITH POMALIDOMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA	Meral Beksaç	Received

834-PF	FRAILTY AND QUALITY OF LIFE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS	Klara Frederikke Koue Rydahl	Received

835-PF	ANTIDIABETIC MEDICATION USE AND MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE: ASSOCIATIONS WITH PREVALENCE AND M-PROTEIN TRAJECTORIES IN THE ISTOPMM STUDY	Kirstine Ostenfeld Larsen	Received

837-PF	OUTCOMES AFTER FRONTLINE QUADRUPLET FAILURE IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA	Luis Gerardo Rodriguez-Lobato	Received

839-PF	REAL-WORLD OUTCOMES AND SUBSEQUENT TREATMENT UTILIZATION FOLLOWING ANTI-B-CELL MATURATION ANTIGEN ANTIBODY-DRUG CONJUGATE EXPOSURE IN PATIENTS WITH MULTIPLE MYELOMA	Meletios A. Dimopoulos	Received

841-PF	MINIMAL RESIDUAL DISEASE TRAJECTORIES IN NEWLY DIAGNOSED MULTIPLE MYELOMA AND SURVIVAL OUTCOMES; A RETROSPECTIVE COHORT STUDY	Panagiotis Malandrakis	Received

842-PF	THE HIDDEN COST OF INFECTION, SEPTIC SHOCK AND SURVIVAL IN WALDENSTRÖM MACROGLOBULINEMIA	Abdulhaq Al Jafari	Received

844-PF	NORMAL PLASMA CELLS AS A PROGNOSTIC BIOMARKER AND PREDICTOR OF EARLY SEVERE INFECTION IN NEWLY DIAGNOSED MULTIPLE MYELOMA	Qun Li	Received

847-PF	MULTI-OMICS PROFILING AND MEASURABLE RESIDUAL DISEASE ANALYSIS USING LIQUID BIOPSIES FROM MULTIPLE MYELOMA PATIENTS IN CLINICAL ROUTINE – A TRANSLATIONAL STUDY	Jan Vorwerk	Received

848-PF	FACTORS INFLUENCING LONG PROGRESSION-FREE SURVIVAL IN MULTIPLE MYELOMA PATIENTS RECEIVING IXAZOMIB-BASED ALL-ORAL REGIMENS	Yanjuan He	Received

850-PF	FIRST-LINE USE OF CARFILZOMIB-BASED REGIMENS IMPROVES SURVIVAL OF NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS WITH EXTRAMEDULLARY PLASMACYTOMAS: A REAL-WORLD RETROSPECTIVE STUDY	Zheng Ge	Received

855-PF	GALECTIN-1 AS A MEDIATOR OF THROMBOTIC RISK IN MYELOPROLIFERATIVE NEOPLASMS?	Natalie J Jooss	Received

860-PF	BLOOD-BASED SINGLE-CELL PROFILING OF CIRCULATING PROGENITORS RESOLVES DISEASE STATE, PROGRESSION RISK, AND CLONAL IDENTITY ACROSS MYELOPROLIFERATIVE NEOPLASMS	Gal Dadi	Received

862-PF	MICE EXPRESSING KITD814V IN THE MAST CELL LINEAGE SHOW A SYSTEMIC MASTOCYTOSIS PHENOTYPE WITH SKIN LESIONS THAT CAN BE REVERSED BY TREATMENT WITH SPECIFIC TYROSINE KINASE INHIBITORS	Simona Stivala	Received

866-PF	JAK2V617F-POSITIVE MPN MICROENVIRONMENT DRIVES T LYMPHOCYTE EXHAUSTION	Lorena Pontes	Received

867-PF	PRECLINICAL EVIDENCE OF TARGETING ACVR1/HEPCIDIN BY NUVISERTIB, AN ORAL INVESTIGATIONAL PIM1 KINASE INHIBITOR, SUGGESTS POTENTIAL MECHANISTIC BASIS FOR HEMOGLOBIN BENEFIT IN MYELOFIBROSIS	Joseph M Scandura	Received

868-PF	FROM CLONAL HEMATOPOIESIS TO MYELOPROLIFERATIVE NEOPLASMS: A THROMBOINFLAMMATORY PERSPECTIVE ON JAK2V617F	Lea Löffler	Received

869-PF	AN INDUCIBLE TRANSGENIC SCL-CRE;KITD814V MOUSE MODEL RECAPITULATES ADVANCED SYSTEMIC MASTOCYTOSIS WITH SM-AHN AND VALIDATES AVAPRITINIB RESPONSE	Martina Konantz	Received

871-PF	LOSS OF CBP DRIVES MYELOID-DERIVED SUPPRESSOR CELL EXPANSION AND PREDICTS POOR PROGNOSIS VIA METTL14-DEPENDENT M6A MODIFICATION IN MYELOPROLIFERATIVE NEOPLASMS	Jian Huang	Received

872-PF	INCB160058 SELECTIVELY TARGETS JAK2V617F-DRIVEN HEMATOPOIESIS IN DIVERSE AND DRUG-RESISTANT MODELS OF MYELOPROLIFERATIVE NEOPLASMS (MPNS)	Hamza Celik	Received

876-PF	DISTINCT CYTOKINE EXPRESSION SIGNATURES IN ADOLESCENT AND YOUNG ADULTS (AYA) AND NON-AYA PATIENTS WITH BCR::ABL NEGATIVE MYELOPROLIFERATIVE NEOPLASM (MPN)	Alice Diepers	Received

878-PF	DNA METHYLATION PROFILING IDENTIFIES MYC AND MAPK PATHWAY DEREGULATION IN TRIPLE NEGATIVE MDS/MPN WITH SF3B1 MUTATION AND THROMBOCYTOSIS	Julien Broseus	Received

880-PF	DECIPHERING THE IMPACT OF CBL DOUBLE-HIT ALTERATIONS ACROSS MYELOID MALIGNANCIES	Anna Stengel	Received

887-PF	A NOVEL MACHINE LEARNING-BASED APPROACH IN 1206 PATIENTS RELIABLY DIFFERENTIATES CLONAL FROM NON-CLONAL EOSINOPHILIA: THE EOSINOPHILIA DIFFERENTIATION SCORE (EDS)	Johannes Lübke	Received

889-PF	TREATMENT STRATEGIES AND LIVE BIRTH RATES IN MPN PREGNANCIES: A SINGLE-CENTER ANALYSIS OF 165 PREGNANCIES	Kristine Poghosyan	Received

893-PF	LONG-TERM EFFICACY OF GECACITINIB ON MYELOFIBROSIS GRADE AND GENE MUTATION LEVEL: A PHASE IIIB EXTENSION STUDY IN PREVIOUSLY ENROLLED PATIENTS	Yi Zhang	Received

895-PF	BIOMETRIC DATA SHOWS GREATER ALIGNMENT WITH HAEMATOLOGIC RESULTS THAN SYMPTOM BURDEN IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS – UPDATES FROM THE MYMPNVOICE PATIENT APP	Patrick Harrington	Received

900-PF	MODEST INCREASES IN JAK2V617F AND CALR MUTATION ALLELE BURDEN PREDICT ADVERSE OUTCOMES AND ARE ASSOCIATED WITH ANAGRELIDE IN MYELOPROLIFERATIVE NEOPLASMS	Jennifer OSullivan	Received

901-PF	EFFICACY AND SAFETY OF ROPEGINTERFERON ALFA-2B IN JAPANESE PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA: SUBGROUP ANALYSIS OF THE SURPASS ET TRIAL	Yuka Sugimoto	Received

903-PF	EARLY-ONSET PHILADELPHIA-NEGATIVE MPN: AGE-DEPENDENT MUTATION DISTRIBUTION AND AGE-INDEPENDENT THROMBOTIC RISK	Olga Demska	Received

905-PF	TREATMENT PATTERNS AND COMPLICATIONS IN ESSENTIAL THROMBOCYTHEMIA – A POPULATION-BASED STUDY OF 3,234 PATIENTS IN SWEDEN	Anna Ravn Landtblom	Received

906-PF	NEUTROPHIL-LYMPHOCYTE RATIO AND JAK2 V617F ALLELE BURDEN AS PROGNOSTIC INDICATORS OF BIOLOGICAL ACTIVITY AND THROMBOTIC RISK IN POLYCYTHEMIA VERA.	Andrea Bender	Received

907-PF	MULTIPLE TET2 MUTATIONS CONFER INCREASED RISK OF LEUKEMIC TRANSFORMATION IN PATIENTS WITH MYELOFIBROSIS	Jian Huang	Received

908-PF	A PHASE IB STUDY OF 9MW3011, A FIRST-IN-CLASS ANTI-TMPRSS6 ANTIBODY, IN RELAPSED/REFRACTORY PATIENTS WITH POLYCYTHEMIA VERA	Bing Li	Received

910-PF	LONGITUDINAL ANALYSIS OF IRON DEFICIENCY MARKERS IN PATIENTS WITH POLYCYTHEMIA VERA ENROLLED IN THE PROSPECTIVE OBSERVATIONAL REVEAL STUDY	Jamile Shammo	Received

911-PF	AGE AS A CORE DISEASE MODIFIER: DISTINCT CLINICAL, MOLECULAR, AND PROGNOSTIC LANDSCAPES OF ESSENTIAL THROMBOCYTHEMIA IN ADOLESCENTS AND YOUNG ADULTS	Jian Huang	Received

913-PF	MEASURABLE RESIDUAL DISEASE IN MYELOFIBROSIS: CLONAL CORRELATES FROM A PROSPECTIVE PHASE II STUDY	Nico Gagelmann	Received

914-PF	RISK FACTORS FOR PROGRESSIVE KIDNEY IMPAIRMENT AMONG PATIENTS WITH POLYCYTHEMIA VERA (PV) ARE RECAPITULATED AND TREATABLE IN MOUSE MODELS OF PV	Brandi Reeves	Received

915-PF	A PHASE 1 STUDY OF THE PRMT5 INHIBITOR AZD3470 IN PATIENTS WITH RELAPSED/REFRACTORY CLASSIC HODGKIN LYMPHOMA (PRIMAVERA)	Pier Luigi Zinzani	Received

916-PF	PEMBROLIZUMAB IN CHILDREN AND YOUNG ADULTS WITH LOW-RISK CLASSIC HODGKIN LYMPHOMA WITH SLOW EARLY RESPONSE TO FRONT-LINE CHEMOTHERAPY: UPDATED RESULTS FROM KEYNOTE-667	Jennifer Adam	Received

917-PF	VALIDATION OF THE ADVANCED-STAGE HODGKIN LYMPHOMA INTERNATIONAL PROGNOSTIC INDEX (A-HIPI) IN THE GHSG HD21 TRIAL	Hishan Tharmaseelan	Received

918-PF	CHOP/MINICHOP AND TISLELIZUMAB IN ELDERLY PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA (CHL). FIRST REPORT OF THE PHASE II CATER-HL TRIAL (HD12) FROM THE AUSTRALASIAN LYMPHOMA AND LEUKAEMIA GROUP (ALLG).	Tara Cochrane	Received

919-PF	SEX-SPECIFIC CHARACTERISTICS AND OUTCOMES IN NODULAR LYMPHOCYTE-PREDOMINANT HODGKIN LYMPHOMA: AN ANALYSIS FROM THE GERMAN HODGKIN STUDY GROUP	Dennis A. Eichenauer	Received

921-PF	A GERIATRIC RISK SCORE INTEGRATING METABOLIC TUMOR BURDEN AND HOST VULNERABILITY OUTPERFORMS CONVENTIONAL TOOLS AND GUIDES TREATMENT INTENSIFICATION IN OLDER HODGKIN LYMPHOMA PATIENTS	Peiqi Zhao	Received

922-PF	REAL WORLD EFFICACY AND SAFETY COMPARISON OF SALVAGE REGIMENS COMBINING BRENTUXIMAB VEDOTIN AND CHEMOTHERAPY IN SECOND-LINE HODGKIN LYMPHOMA: A LYSA MULTICENTER RETROSPECTIVE STUDY.	Juliette Wencel	Received

923-PF	DURABLE COMPLETE RESPONSES AFTER NIVOLUMAB DISCONTINUATION IN RELAPSED/REFRACTORY CLASSIC HODGKIN LYMPHOMA: SEVEN-YEAR FOLLOW-UP AND RETREATMENT OUTCOMES	Liudmila Fedorova	Received

924-PF	INTERIM RESULTS OF A PET-GUIDED IMMUNE CHECKPOINT INHIBITOR–BASED FIRST-LINE STRATEGY IN ADVANCED-STAGE CLASSICAL HODGKIN LYMPHOMA	Anna Kravtsova	Received

925-PF	PROGNOSTIC VALUE OF PET METRICS IN CHILDREN AND YOUNG ADULTS WITH RELAPSED/REFRACTORY CLASSIC HODGKIN LYMPHOMA TREATED WITH NIVOLUMAB AND BRENTUXIMAB VEDOTIN ON CHECKMATE 744	Sarah Milgrom	Received

926-PF	PEMBROLIZUMAB (PEMBRO) IN PEDIATRIC PARTICIPANTS WITH HIGH-RISK CLASSIC HODGKIN LYMPHOMA (CHL): AN EXPLORATORY ANALYSIS OF CIRCULATING TUMOR DNA (CTDNA) FROM THE PHASE 2 KEYNOTE-667 STUDY	Jennifer Adam	Received

927-PF	REAL-WORLD OUTCOMES OF PEMBROLIZUMAB PLUS GVD AS SALVAGE THERAPY AND BRIDGE TO AUTOLOGOUS STEM CELL TRANSPLANTATION IN RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA: A MULTICENTER GATLA STUDY	Astrid Pavlovsky	Received

929-PF	SUPERIOR EFFICACY OF BRECADD VS PET-GUIDED ABVD AND BEACOPP IN ADVANCED-STAGE FRONTLINE HODGKIN LYMPHOMA: A MATCHING-ADJUSTED INDIRECT TREATMENT COMPARISON OF LONG-TERM FOLLOW-UP DATA OF HD21 STUDY	Fjoralba Kristo	Received

930-PF	ASSOCIATION OF CIRCULATING TUMOUR DNA AND EBV DNA CHARACTERISTICS WITH SURVIVAL OUTCOMES OF CHILDREN AND YOUNG ADULTS WITH HODGKIN LYMPHOMA IN EAST AFRICA	clara chamba	Received

935-PF	OUTCOMES OF LISOCABTAGENE MARALEUCEL (LISO-CEL) IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) MANTLE CELL LYMPHOMA (MCL): FIRST REAL-WORLD DATA FROM THE CIBMTR	Jennifer Huang	Received

936-PF	PROGNOSTIC IMPACT OF FDG-PET–BASED BONE MARROW ASSESSMENT COMPARED WITH CONVENTIONAL HISTOLOGY IN FOLLICULAR LYMPHOMA: A SUBANALYSIS OF THE FIL FOLL12 TRIAL	Giovanni Manfredi Assanto	Received

937-PF	RITUXIMAB (R), GOLCADOMIDE (GOLCA) +/- NIVOLUMAB (N) IN TREATMENT-NAIVE FOLLICULAR LYMPHOMA (FL). PRIMARY RESULTS OF THE INVESTIGATOR-LED RANDOMISED PHASE II TOP-FLOR STUDY.	Eliza Hawkes	Received

938-PF	EO2463 (EO) AN OFF-THE-SHELF MULTI-TARGET PEPTIDE IMMUNOTHERAPY: IN VIVO CD8 T CELL EXPANSION KINETICS CORRELATES WITH EFFICACY IN PATIENTS (PTS) WITH FOLLICULAR (FL) AND MARGINAL ZONE (MZL) LYMPHOMA	Jose C. Villasboas	Received

940-PF	CLONAL FEATURES AND MOLECULAR PREDICTORS OF MRD NEGATIVITY ATTAINMENT IN WALDENSTROM´S MACROGLOBULINEMIA: CLINICAL IMPLICATIONS FOR THERAPEUTIC DE-ESCALATION	Anastasia Vinnikova	Received

941-PF	IMPROVED CAUSE-SPECIFIC SURVIVAL FOR WALDENSTROM MACROGLOBULINEMIA IN THE ERA OF NOVEL THERAPIES	DZ DZ	Received

942-PF	FLP-R PROGNOSTIC INDEX IN RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA: A COMPARATIVE ANALYSIS WITH MZL-IPI, MALT-IPI AND POD24	Prokop Vodicka	Received

943-PF	PROGNOSTIC VALUE OF PET PARAMETERS IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL) TREATED WITH LISOCABTAGENE MARALEUCEL (LISO-CEL): RESULTS FROM THE TRANSCEND FL TRIAL	Anne-Segolene Cottereau	Received

944-PF	THE ZAP TRIAL: FIRST PROSPECTIVE VALIDATION OF AN MRD-ADAPTED, CHEMOTHERAPY-SPARING REGIMEN WITH ZANUBRUTINIB PLUS G-CHOP IN HIGH-RISK FOLLICULAR LYMPHOMA	Peiqi Zhao	Received

945-PF	UPDATED EFFICACY AND SAFETY RESULTS OF ROCBRUTINIB FROM THE PHASE 2 ROCK-1 STUDY IN PATIENTS WITH RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA AND PREVIOUSLY TREATED WITH BTK INHIBITOR	Yuqin Song	Received

946-PF	THE EFFICACY AND SAFETY OF OBINUTUZUMAB WITH ZANUBRUTINIB AS FIRST-LINE TREATMENT IN OLDER PATIENTS WITH MANTLE CELL LYMPHOMA	Yanan Zhu	Received

948-PF	PHASE 3 INMIND STUDY OF TAFASITAMAB PLUS LENALIDOMIDE AND RITUXIMAB FOR RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: CLINICAL CHARACTERISTICS AND OUTCOMES OF PATIENTS RECEIVING SECOND-LINE TREATMENT	Stefano Luminari	Received

949-PF	LONG-TERM FOLLOW-UP OF ORELABRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY MARGINAL ZONE LYMPHOMA	Lijuan Deng	Received

950-PF	IMPACT OF HIV STATUS ON CLINICAL FEATURES AND OUTCOMES OF HHV8-ASSOCIATED MULTICENTRIC CASTLEMAN DISEASE: INSIGHTS FROM A NATIONWIDE GELTAMO STUDY	Gianfranco Lapietra	Received

952-PF	INCIDENCE OF INFECTIONS IN PATIENTS TREATED WITH RITUXIMAB-BENDAMUSTINE WITH OR WITHOUT ACALABRUTINIB FOR UNTREATED MANTLE CELL LYMPHOMA: ANALYSIS OF THE PHASE 3 ECHO TRIAL	Martin Dreyling	Received

955-PF	LTB-TREAT: A VALIDATED INTERNATIONAL PROGNOSTIC MODEL FOR TIME TO TREATMENT IN LOW TUMOUR BURDEN FL.	Greg Hapgood	Received

957-PF	PREDICTIVE ROLE OF POSITRON EMISSION TOMOGRAPHY – COMPUTED TOMOGRAPHY (PET-CT) IN TREATMENT OF MANTLE CELL LYMPHOMA (MCL) WITH CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELLS	Vladan Vucinic	Received

959-PF	ORELABRUTINIB COMBINED WITH BENDAMUSTINE-RITUXIMAB OR OBINUTUZUMAB FOLLOWED BY ORELABRUTINIB MAINTENANCE IN UNTREATED MARGINAL ZONE LYMPHOMA (OPTIMIZE): A MULTICENTER, SINGLE-ARM, PHASE II STUDY	Xuewu Zhang	Received

964-PF	ZANUBRUTINIB PLUS R-CHOP AS FRONTLINE THERAPY FOR MYD88(L265P)/CD79B-MUTATED (MCD) DIFFUSE LARGE B-CELL LYMPHOMA: A PHASE II STUDY.	Chunmei Yang	Received

969-PF	TIME-DEFINED PD-1 BLOCKADE DURING EARLY CAR-T CONTRACTION OF IL-7/CCL19–ARMORED CAR-T CELLS IS ASSOCIATED WITH RESPONSE DEEPENING IN HIGH-RISK RELAPSED/REFRACTORY LBCL LOGO	Lixia Sheng	Received

970-PF	MINIMAL HINGE OPTIMIZATION MARKEDLY ENHANCES DUAL CD19/CD20 CAR T-CELL POTENCY AND YIELDS DURABLE 3-YEAR SURVIVAL IN RELAPSED/REFRACTORY B-CELL LYMPHOMA	Zekai Mao	Received

971-PF	FIRST-LINE ODRONEXTAMAB PLUS CHOP IN DIFFUSE LARGE B-CELL LYMPHOMA: OLYMPIA-3 PART 1B RESULTS	Bastian von Tresckow	Received

972-PF	PHASE I/II STUDY OF ZANUBRUTINIB IN COMBINATION WITH RITUXIMAB, IFOSFAMIDE, CARBOPLATIN, AND ETOPOSIDE IN RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: INTERIM RESULTS OF THE PHASE II PART	Hyungwoo Cho	Received

973-PF	BIRELENTINIB DEMONSTRATES MANAGEABLE SAFETY PROFILE AND UNIVERSAL ANTITUMOR ACTIVITY ACROSS MOLECULAR SUBTYPES IN DIFFUSE LARGE B-CELL LYMPHOMA	lugui qiu	Received

978-PF	DEVELOPMENT AND VALIDATION OF CAR-IPI, A MACHINE LEARNING–DERIVED PROGNOSTIC SCORE FOR RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA TREATED WITH ANTI-CD19 CAR T CELLS	Emmanuel Bachy	Received

980-PF	LOW EXPRESSION OF ZFP36L1 PREDICTS POOR OUTCOMES AND ASSOCIATES WITH MITOCHONDRIAL TRANSLATION PROGRAMS IN DLBCL	Yingyu Dong	Received

982-PF	PRELIMINARY RESULTS FROM SHORTEN-CTDNA: MEASURABLE RESIDUAL DISEASE-ADAPTED DE-ESCALATION OF FRONTLINE THERAPY FOR DIFFUSE LARGE B-CELL LYMPHOMA	DZ DZ	Received

983-PF	POST–CAR-T RELAPSE IN CNS-INVOLVED LYMPHOMA: TREATMENT PATTERNS AND CLINICAL OUTCOMES WITH A FOCUS ON SECOND CAR-T THERAPY	Fan Yang	Received

985-PF	REAL-WORLD COMPARATIVE STUDY OF THE EFFECTIVENESS, SAFETY, AND HEALTH CARE RESOURCE UTILIZATION (HCRU) OF LISOCABTAGENE MARALEUCEL AND BISPECIFICS IN THIRD-LINE OR LATER LARGE B-CELL LYMPHOMA (LBCL)	Narendranath Epperla	Received

986-PF	ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT AS CONSOLIDATION AFTER CD3XCD20 BISPECIFIC ANTIBODIES IN RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMAS: AN LWP-CTIWP STUDY ON 52 CASES FROM THE EBMT REGISTRY	Federico Erbella	Received

989-PF	A FULLY OBJECTIVE 3-VARIABLE PROGNOSTIC SCORE FOR DIFFUSE LARGE B-CELL LYMPHOMA: DEVELOPMENT AND EXTERNAL VALIDATION IN TWO INDEPENDENT COHORTS TOTALING 776 PATIENTS	Yoshimasa Kamoda	Received

990-PF	INTRODUCTION OF CAR-T CELL THERAPY DRAMATICALLY IMPROVED OUTCOMES OF PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA RECEIVING SECOND-LINE TREATMENT AT A POPULATION LEVEL	Prokop Vodicka	Received

992-PF	RE-EVALUATING THE ROLE OF AUTOLOGOUS STEM CELL TRANSPLANTATION IN PRIMARY CNS DIFFUSE LARGE B-CELL LYMPHOMA IN THE TARGETED-THERAPY ERA: A PROPENSITY SCORE–MATCHED MULTICENTER REAL-WORLD STUDY	Mengyuan Liu	Received

995-PF	COMPARATIVE REAL-WORLD OVERALL SURVIVAL IN DIFFUSE LARGE B-CELL LYMPHOMA: CAR T-CELL THERAPIES VERSUS BISPECIFIC ANTIBODIES	Vladimir Otasevic	Received

996-PF	FEASIBILITY AND SAFETY OF RAPID GLOFITAMAB RAMP-UP FOR THE TREATMENT OF RELAPSED AND REFRACTORY LARGE B-CELL LYMPHOMA	Celine Liem	Received

997-PF	OUTCOME OF NEWLY DIAGNOSED AGGRESSIVE B-CELL LYMPHOMA WITH CONCURRENT INDOLENT LYMPHOMA: A POOLED POST-HOC ANALYSIS OF FOUR PROSPECTIVE PHASE III DSHNHL/GLA TRIALS	Konstantinos Christofyllakis	Received

1001-PF	REAL-WORLD EFFICACY AND SAFETY OF THE MEDZ-R REGIMEN AS INDUCTION THERAPY IN NEWLY DIAGNOSED PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA	Ming Jiang	Received

1003-PF	TEMPORAL TRENDS IN HEPATITIS B RISK FOLLOWING LYMPHOMA: A POPULATION-BASED ANALYSIS USING SWEDISH LYMPHOMA REGISTRY DATA (2002–2024)	Torsten Dahlén	Received

1004-PF	REAL-WORLD ASIAN MULTI-CENTRE COHORT STUDY ON OUTCOMES OF POLA-R-CHP IN UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA	Nicole-Ann Lim	Received

1005-PF	PROSPECTIVE VALIDATION OF A WEIGHTED GAH SCORE IN PATIENTS =65 YEARS WITH LYMPHOPROLIFERATIVE NEOPLASMS: TOXICITY PREDICTION AND PROGNOSTIC IMPACT	Josefa Marco Buades	Received

1008-PF	ADDITION OF HIGH-DOSE METHOTREXATE TO STANDARD FIRST-LINE IMMUNOCHEMOTHERAPY IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA IS ASSOCIATED WITH ACUTE BUT NOT CHRONIC KIDNEY DISEASE	Silje Post Strøm	Received

1009-PF	NOVA-BCL6-1: A FIRST-IN-HUMAN PHASE 1 TRIAL OF LY4584180, A NOVEL BCL6 MOLECULAR GLUE, IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL MALIGNANCIES (TRIAL IN PROGRESS)	Yair Levy	Received

1012-PF	EXTRANODAL METABOLIC TUMOR VOLUME IDENTIFIES LARGE B-CELL LYMPHOMA SUBGROUPS THAT BENEFIT FROM POLA-R-CHP	Hajime Sakuma	Received

1013-PF	DEVELOPMENT OF A PROGNOSTIC MODEL INCORPORATING PLASMA EBV-DNA LEVEL FOR EBV-POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA: A RETROSPECTIVE, SINGLE-CENTER STUDY	Xinzhu Tang	Received

1015-PF	RECEIPT OF HOLDING THERAPY IS ASSOCIATED WITH INFERIOR OUTCOMES ACROSS THE CAR T TREATMENT PATHWAY IN RELAPSED/REFRACTORY LARGE B CELL LYMPHOMA	Inna Gong	Received

1016-PF	THE CLINICAL SIGNIFICANCE OF MYC::BCL6 FUSION IN MYC/BCL6 DOUBLE HIT LYMPHOMA PATIENTS	Shaoying Li	Received

1019-PF	IMMUNE DEFICIENCY AND INFECTION RISK FOLLOWING SECOND LINE CAR-T CELLS THERAPY IN RELAPSED REFRACTORY LARGE B CELLS LYMPHOMA	Mohamad Sabbah	Received

1022-PF	POLA-RCHP FOR DLBCL PATIENTS WITH EXTRANODAL INVOLVEMENT: REAL-WORLD EVIDENCE IN AN UNDERREPRESENTED POPULATION	Xi Chen	Received

1024-PF	LARGE B-CELL LYMPHOMA TREATMENT WITH LONCASTUXIMAB TESIRINE IN AN ITALIAN REAL-LIFE EXPERIENCE	Alessandro Broccoli	Received

1026-PF	EARLY TOXICITY OF AXICABTAGENE CILOLEUCEL BY LINE OF THERAPY IN DLBCL: A REAL-WORLD COMPARISON OF 2L VS =3L TREATMENT	Rebeca Bailen	Received

1027-PF	ZANUBRUTINIB PLUS R-CHOP (ZR-CHOP) IN NON-GERMINAL CENTER B-CELL-LIKE (NON-GCB) DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS WHO WERE POSITRON EMISSION TOMOGRAPHY-POSITIVE AFTER TWO CYCLES OF R-CHOP	Jie Wang	Received

1028-PF	EFFICACY OF CAR-T CELL THERAPY IN DOUBLE-EXPRESSOR TP53-POSITIVE RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: A MULTICENTER REAL-WORLD STUDY	Shihui Ren	Received

1033-PF	FIRST REPORT OF ROCBRUTINIB FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA	Yuqin Song	Received

1034-PF	REAL-WORLD MANAGEMENT AND OUTCOMES OF PTS WITH PRIMARY MEDIASTINAL B-CELL LYMPHOMA: INSIGHTS FROM THE FRENCH REALYSA COHORT.	Loic Renaud	Received

1035-PF	THE REAL-WORLD EFFICACY OF BRUTON´S TYROSINE KINASE INHIBITORS PLUS HIGH-DOSE METHOTREXATE BASED INDUTION TREATMENT FOR UNTREATED PRIMARY CNS LYMPHOMA: A SINGLE-CENTER RETROSPECTIVE ANALYSIS.	He Huang	Received

1036-PF	CHIDAMIDE IN COMBINATION WITH CHOP IN PREVIOUSLY UNTREATED PERIPHERAL T-CELL LYMPHOMA WITH T FOLLICULAR HELPER PHENOTYPE–RESULTS OF PHASE II SWIFT TRIAL	Qingqing Cai	Received

1038-PF	BLOOD CANCER ASSOCIATED HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS IS MORE LIKELY IN YOUNGER PATIENTS, AND ONLY AGE AND T-, NKT- AND NK-CELL LYMPHOMA DIAGNOSIS IMPACT SURVIVAL.	Mark Bishton	Received

1039-PF	COMPARABLE EFFICACY AND SAFETY OF BRENTUXIMAB VEDOTIN -BASED THERAPY TO THE ECHELON TRIALS: REAL-WORLD EVIDENCE FROM THE BRAVE STUDY	Mingci Cai	Received

1040-PF	MANAGEMENT AND OUTCOME OF SECONDARY CENTRAL NERVOUS SYSTEM (CNS) INVOLVEMENT IN AN INTERNATIONAL COHORT OF 62 PATIENTS WITH PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMLBCL)	Andrés José María Ferreri	Received

1042-PF	MITOXANTRONE HYDROCHLORIDE LIPOSOME-BASED CMOP±R REGIMEN FOR PREVIOUSLY UNTREATED NON-HODGKIN LYMPHOMA: RESULTS FROM A PHASE 3 MULTICENTER STUDY	Haiwen Huang	Received

1045-PF	AN OPEN LABEL, PHASE 2 TRIAL EVALUATING DARATUMUMAB-BORTEZOMIB-DEXAMETHASONE COMBINATION IN RELAPSED OR REFRACTORY PLASMABLASTIC LYMPHOMA: THE DALYA TRIAL ON BEHALF OF THE FONDAZIONE ITALIANA LINFOMI	Andrés José María Ferreri	Received

1047-PF	FACILITY-LEVEL DIFFERENCES TRANSLATE INTO LIVES LOST: ELDERLY PRIMARY CNS LYMPHOMA IN THE NATIONAL CANCER DATABASE	Rosa Rios	Received

1048-PF	AMPLIFICATION OF STAT3 AND TP53 MAY CONFER POOR PROGNOSIS IN PERIPHERAL T-CELL LYMPHOMA: ANALYSIS OF A SINGLE-CENTER COHORT	Alessandro Putelli	Received

1050-PF	PROPOSED DEFINITION FOR ´PRIMARY REFRACTORY´ DISEASE IN NODAL PERIPHERAL T-CELL LYMPHOMA: AN AUSTRALASIAN-CANADIAN COLLABORATIVE STUDY	Chathuri Abeyakoon	Received

1051-PF	BRENTUXIMAB VEDOTIN PLUS CHP-LIKE VERSUS CHOEP REGIMEN FOR THE FIRST-LINE TREATMENT OF PTCL PATIENTS: A MULTI-CENTER PROPENSITY-MATCHED POPULATION-BASED STUDY	Jun Fang	Received

1057-PF	PHASE IB STUDY OF SHR0302 PLUS SHR2554 IN RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA: SAFETY RUN-IN AND INITIAL EFFICACY	Rong Tao	Received

1060-PF	MENDELIAN RANDOMIZATION REVEALS THE CAUSATIVE ROLE OF GENETICALLY PREDICTED VIRAL INFECTION IN PAN-LYMPHOMA RISK	Haiwen Huang	Received

1063-PF	EARLY OUTCOME PREDICTION OF DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS USING ON-TREATMENT OMICS DATA	Tom van den Bosch	Received

1068-PF	INTEGRATION OF END-OF-TREATMENT CIRCULATING TUMOR DNA WITH PET-CT IMPROVES RESPONSE ASSESSMENT IN CLASSICAL HODGKIN LYMPHOMA	Vincent Camus	Received

1071-PF	CHROMOSOME 8Q COPY NUMBER GAIN PREDICTS EARLY RELAPSE IN HIGH-GRADE DIFFUSE LARGE B-CELL LYMPHOMA WITH MYC AND BCL2 REARRANGEMENTS	Tom van den Bosch	Received

1072-PF	BRIGATINIB RESISTANCE IN PEDIATRIC ALK-POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA IS DRIVEN BY GPX4-MEDIATED FERROPTOSIS SUPPRESSION	Gerardo Enrique Abarca Ríos	Received

1073-PF	THE STRESS-SENSING MARCH5 AXIS GOVERNS BLOOD CANCER APOPTOTIC RESILIENCE VIA TRACTABLE PROTEIN–PROTEIN INTERACTIONS	Daniel Zaldumbide	Received

1078-PF	PD-L1 AMPLIFICATION BUILDS AN IMMUNE FORTRESS IN EBV+ DLBCL: SPATIAL MULTI-OMICS REVEALS PHYSICAL T-CELL EXCLUSION ALONGSIDE FUNCTIONAL SUPPRESSION	Axel Künstner	Received

1079-PF	ASSOCIATION OF GERMLINE IEI GENE MUTATIONS WITH DISEASE SUBTYPES AND PROGNOSIS IN PEDIATRIC LYMPHOMA	Keyan Yang	Received

1085-PF	PATIENT-DERIVED LYMPHOMA SPHEROIDS AS PRECLINICAL MODELS FOR PREDICTING PATIENT RESPONSES TO ADVANCED THERAPIES IN B-NHL: EXAMPLE OF GLOFITAMAB IN FOLLICULAR LYMPHOMA	christine Bezombes	Received

1087-PF	INTEGRATIVE MULTI-OMICS FRAMEWORK IDENTIFIES TGFB1–CXCL12 SIGNALING AS A CONSERVED IMMUNOREGULATORY NETWORK IN HIGH-GRADE B-CELL LYMPHOMA AND REACTIVE LYMPHOID TISSUES	Keisuke Kidoguchi	Received

1088-PF	PERIPHERAL PROTEOMIC SIGNATURES ASSOCIATED WITH CYTOKINE RELEASE SYNDROME (CRS) IN PATIENTS (PTS) WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) AND FOLLICULAR LYMPHOMA (FL) TREATED WITH ODRONEXTAMAB	Stefano Luminari	Received

1089-PF	PRETREATMENT CTDNA-BASED RISK PREDICTION IN DLBCL: PANEL-INDEPENDENT COPY-NUMBER ANALYSIS OVERCOMES INTER-ASSAY THRESHOLD VARIABILITY	Rebecca Goodhew	Received

1091-PF	RITUXIMAB-MODIFIED MNO2-COATED ZIF-8 NANOPLATFORM LOADED WITH DOXORUBICIN FOR TARGETED THERAPY OF B-CELL LYMPHOMA	Hao Yao	Received

1092-PF	PATIENTS WITH T CELLS MAINTAINING AN IMMUNE SIGNATURE FEATURING EARLY DIFFERENTIATION STAGE EXHIBIT A SUPERIOR CLINICAL RESPONSE TO PEMBROLIZUMAB IN RELAPSED LOW-GRADE LYMPHOMA	Zhi-Zhang Yang	Received

1094-PF	TARGETING HELLS-MCM5 AXIS TO EXPLOIT TRANSCRIPTION-REPLICATION CONFLICTS AS NOVEL THERAPEUTIC STRATEGY IN ANAPLASTIC LARGE CELL LYMPHOMA	Valentina Fragliasso	Received

1095-PF	DIOSCIN INHIBITS DIFFUSE LARGE B-CELL LYMPHOMA BY MODULATING ACACA-DEPENDENT HISTONE H3K27 ACETYLATION AND INDUCING MITOPHAGY	Qianqian Guo	Received

1096-PF	INTEGRATED MOLECULAR AND METABOLIC PROFILING IDENTIFIES DETERMINANTS OF OUTCOME WITH LONCASTUXIMAB TESIRINE IN RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA	Ciro Maria Improta	Received

1100-PF	CLINICAL AND MOLECULAR CHARACTERISTICS AND THEIR IMPACT ON PROGNOSIS IN CHINESE PEDIATRIC MATURE B-CELL NON-HODGKIN LYMPHOMA	Qinlong Zheng	Received

1105-PF	TARGETING RNF20 INHIBITS THE PROGRESSION OF DIFFUSE LARGE B-CELL LYMPHOMA THROUGH REGULATING UBIQUITINATION-DEPENDENT PHASE SEPARATION OF FUS	Qianqian Guo	Received

1106-PF	PHASED VARIANTS REVEAL PROTO-ONCOGENE PROMOTER HYPERMUTATION AND CFDNA FRAGMENTATION PATTERNS IN DLBCL	Luca Varga	Received

1112-PF	EPIGENETIC MODULATION ENABLES EXPANSION OF FUNCTIONAL HUMAN HSPCS IN A CHEMICALLY DEFINED SYSTEM FOR CELL AND GENE CLINICAL APPLICATIONS	Nobuchika Yamamoto	Received

1114-PF	PROLIFERATING TCF1LOW PD-1HIGH POPULATION IN HUMAN CD8+ T-CELLS IS ASSOCIATED WITH THE ONSET OF AGVHD AND SUPPRESSED BY PTCY	Kazuya Asano	Received

1117-PF	ROMIPLOSTIM N01 FOR PLATELET RECOVERY AFTER UNRELATED UMBILICAL CORD BLOOD TRANSPLANTATION IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES: A PHASE II, SINGLE-ARM STUDY	Wanjie Wang	Received

1119-PF	PHASE II STUDY OF AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION COMBINED WITH AUTOLOGOUS CD19-CAR T CELL INFUSION IN ADULTS WITH HIGH-RISK B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: CLINICAL OUTCOMES	Rongli Zhang	Received

1120-PF	LONG-TERM EFFICACY AND SAFETY OF DONOR-DERIVED CAR-T CELLS INTEGRATED INTO ALLOGENEIC HSCT CONDITIONING FOR ULTRA-HIGH-RISK R/R B-NHL, T-LBL, AND MULTIPLE MYELOMA: A 5-YEAR FOLLOW-UP STUDY	Fan Yang	Received

1121-PF	SUPERIOR OUTCOMES WITH B-LEADER-MATCHED HAPLOIDENTICAL VERSUS MATCHED SIBLING DONORS IN AL/MDS PATIENTS AGED =40 YEARS	Yujun Wei	Received

1123-PF	GENETIC ABNORMALITIES INFLUENCE THE PROGNOSTIC VALUE OF PRE-TRANSPLANT MEASURABLE RESIDUAL DISEASE IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKAEMIA: A MULTICENTRE STUDY	Yue Jin	Received

1126-PF	THIOTEPA-FLUDARABINE-TREOSULFAN VS THIOTEPA-FLUDARABINE-BUSULFAN IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR ADULT AML PATIENTS IN CR. A STUDY FROM THE ACUTE LEUKEMIA WORKING PARTY OF EBMT.	Enrico Maffini	Received

1127-PF	HOSPITAL BASED OUTPATIENT DAILY DOSING MYELOABLATIVE INTRAVENOUS AND PHARMACOKINETICALLY GUIDED BUSULFAN BASED CONDITIONING FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT – SINGLE CENTER EXPERIENCE	Mathias Palmer	Received

1132-PF	IMPACT OF CONCURRENT GRAFT-VERSUS-HOST DISEASE ON LONG-TERM SURVIVAL IN CRITICALLY ILL PATIENTS FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR HEMATOLOGICAL MALIGNANCIES	Zhixue Li	Received

1133-PF	BURDEN, SPECTRUM, AND PROGNOSTIC IMPACT OF INFECTIONS AFTER ALLOHSCT IN PATIENTS =65 YEARS: A GETH-TC STUDY	Sara Fernandez-Luis	Received

1138-PF	EFFICACY OF LOW-DOSE ATG COMBINED WITH PTCY IN CHILDREN WITH CHRONIC GRANULOMATOUS DISEASE UNDERGOING HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION	Yingjian Si	Received

1139-PF	MYELOABLATIVE FRACTIONATED BUSULFAN, FLUDARABINE, CLADRIBINE, THIOTEPA, AND VENETOCLAX (CLADILLAC) CONDITIONING FOR HIGH-RISK AML: A PHASE 2 TRIAL	Uday R. Popat	Received

1140-PF	EXPLORATION OF A NOVEL AGVHD PROPHYLAXIS REGIMEN BASED ON GECACITINIB IN THE PERITRANSPLANT PERIOD OF PATIENTS WITH MYELOFIBROSIS: A PILOT OPEN-LABEL STUDY	Na Xu	Received

1144-PF	POST-TRANSPLANT ASCIMINIB TREATMENT AS MAINTENANCE, PRE-EMPTIVE OR RELAPSE THERAPY IN PHILADELPHIA-POSITIVE ADVANCED LEUKEMIAS: MULTICENTER REAL-WORLD DATA ANALYSIS	Mohamed Isam Sharif	Received

1147-PF	ALLOGENEIC STEM CELL TRANSPLANTATION FOR SECONDARY HEMATOLOGIC MALIGNANCIES ARISING FROM PLASMA CELL NEOPLASM	Masaya Maegaki	Received

1148-PF	LONGITUDINAL ASSESSMENT OF COMPLEMENT FACTOR BA AND CLINICAL RESPONSE IN ADULT TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY	Min Wu	Received

1151-PF	ASSESSMENTS OF BONE HEALTH AMONG PATIENTS WITH CHRONIC GRAFT-VERSUS-HOST DISEASE RECEIVING AXATILIMAB IN THE AGAVE-201 TRIAL	Amandeep Salhotra	Received

1153-PF	PREDICTIVE VALUE OF EASIX SCORES AT DIFFERENT TIME POINTS FOR PTLD AND SURVIVAL IN PATIENTS WITH EBV REACTIVATION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION	Luxin Yang	Received

1154-PF	PIRCHE SCORES AND RECIPIENT HLA-B LEADER INFLUENCE RELAPSE AND CHRONIC GVHD AFTER 9/10 UNRELATED DONOR ALLO-HCT WITH CLASS I MISMATCH	Rodrigo Gil Manso	Received

1155-PF	ADENOVIRUS INFECTION AFTER ALLO-HSCT: PERSISTENT VIRAL POSITIVITY INDICATES T-CELL DYSFUNCTION AND PREDICTS POOR OUTCOME	Zhihui Li	Received

1157-PF	DEEP LEARNING–BASED PREDICTION OF CD34? CELL MOBILIZATION IN HEALTHY DONORS: AN EXPLAINABLE ARTIFICIAL NEURAL NETWORK MODEL WITH SUPERIOR PREDICTIVE PERFORMANCE	Bedrettin Orhan	Received

1158-PF	MEASURABLE RESIDUAL DISEASE (MRD) EVALUATION AND OUTCOMES IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) UNDERGOING THEIR SECOND ALLOGENEIC STEM CELL TRANSPLANTATION	Jule Ussmann	Received

1159-PF	TWO-TUBE 12-COLOR FLOW CYTOMETRY–BASED PRE-TRANSPLANT IMMUNOPHENOTYPIC LSC-MRD STRATIFIES RELAPSE RISK AND SURVIVAL AFTER ALLO-HCT FOR AML	Tzu-Ting Chen	Received

1161-PF	HEMATOPOIETIC STEM CELL TRANSPLANTATION AND LATENT TUBERCULOSIS INFECTION	Ana Pilar Gonzalez Rodríguez	Received

1164-PF	EVALUATION OF THE EAM CONDITIONING REGIMEN IN AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR HODGKIN LYMPHOMA	Amal Bendimerad	Received

1165-PF	KANGFUXIN COMBINED WITH G-CSF ICE-CUBE CRYOTHERAPY EFFECTIVELY PREVENTS THIOTEPA-BASED CONDITIONING–INDUCED ORAL MUCOSITIS IN ALLOGENEIC HSCT: A PROSPECTIVE OPEN-LABEL COHORT STUDY	Li Wang	Received

1166-PF	STUDY ON THE EFFECTS OF ENHANCED IMMUNE-NUTRIENT INTERVENTION IN PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION	Xueqian Yan	Received

1167-PF	IMMUNE RECONSTITUTION KINETICS AND CLINICAL OUTCOMES AFTER ALLOGENEIC HSCT FOR CHRONIC MYELOMONOCYTIC LEUKEMIA: A MATCHED VERSUS HAPLOIDENTICAL DONOR COMPARISON	Mengtong Zang	Received

1168-PF	UMBILICAL CORD BLOOD MONONUCLEAR CELL INFUSION FOR SECONDARY POOR GRAFT FUNCTION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A PHASE I DOSE-ESCALATION STUDY	Yigeng Cao	Received

1171-PF	HIGH-SENSITIVITY NEXT GENERATION SEQUENCING (HS-NGS)-MEASURABLE RESIDUAL DISEASE (MRD) ASSAY AT DAY?+100 POST- ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT (ALLO-HCT) PREDICTS RELAPSE RISK IN AML AND MDS	Madiha Iqbal	Received

1174-PF	OUTCOMES OF HEMATOPOIETIC STEM CELL TRANSPLANTATION IN INBORN ERRORS OF IMMUNITY (IEI) IN A SINGLE CENTER FROM CORDOBA, ARGENTINA	Maria Laura Herrera Andino	Received

1184-PF	DRIVERS SHAPING PRE-NEOPLASTIC CLONAL EVOLUTION	Kristina Kirschner	Received

1186-PF	CHRONIC INFLAMMATION DRIVES HSC AGING, CLONAL EXPANSION, AND ALTERED INFECTION RESPONSE IN MICE	Srdjan Grusanovic	Received

1188-PF	BLOOD-BASED EPIGENETIC INSTABILITY LINKED TO HUMAN AGING AND DISEASE	Sagi Abelson	Received

1192-PF	AN IPSC-LCH MODEL AS PLATFORM TO IDENTIFY NEW STRATEGIES IN TARGETING BRAFV600E HEMATOPOIETIC PROGENITORS	Giulio Abagnale	Received

1195-PF	HIGHLY SELECTIVE JAK1 INHIBITION FOR HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS IN MURINE MODELS WITH PRELIMINARY CLINICAL INVESTIGATION	Yijun Wu	Received

1196-PF	CHIP-ASSOCIATED MUTATIONS ARE LINKED TO POOR SURVIVAL IN SOLID MALIGNANCIES AND DRIVE PRO-TUMORIGENIC MACROPHAGE CROSSTALK	Jan Vorwerk	Received

1197-PF	WHO SHAKES HANDS WITH THE ENEMY? UNDERSTANDING THE MECHANISMS OF STROMAL SUPPORT OF B PRECURSOR ACUTE LYMPHOBLASTIC LEUKAEMIA CELLS.	Lucas Wing	Received

1201-PF	PREVALENCE OF CYTOPENIA AND CLONAL CYTOPENIA OF UNDETERMINED SIGNIFICANCE (CCUS) IN PATIENTS WITH CARDIAC ARRHYTHMIAS	Jan Vorwerk	Received

1205-PF	THERAPY INTENSITY SHAPES EPIGENETIC AGING TRAJECTORIES IN CAYA SURVIVORS OF HEMATOLOGIC MALIGNANCIES	Sanem Özayral	Received

1207-PF	PRECLINICAL DEVELOPMENT OF AN ALLOGENEIC KIR3DL2-TARGETED CAR-T CELL THERAPY FOR MATURE T-CELL LYMPHOMAS	Xiao Jing Ong	Received

1210-PF	MICROENVIRONMENT-DIRECTED NANOBODY-BASED FAP CAR-T CELLS TARGET PATHOGENIC STROMA IN MYELOFIBROSIS	Zhipeng Zhou	Received

1226-PF	IDENTIFICATION OF PREDICTIVE AND PROGNOSTIC BIOMARKERS IN PATIENTS UNDERGOING CAR-T CELL THERAPY FOR HAEMATOLOGICAL MALIGNANCIES	Francesca Vaglio	Received

1238-PF	EFFICACY AND SAFETY OF ALLOGENEIC CD19-DIRECTED CAR-T CELL THERAPY DERIVED FROM UMBILICAL CORD BLOOD IN RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA	Xiao Wang	Received

1240-PF	HYPER-FRACTIONATED RADIOTHERAPY AS A BRIDGING STRATEGY ATTENUATES T-CELL EXHAUSTION TO ENHANCE CD19 CAR-T EFFICACY IN RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA	Jing Ruan	Received

1242-PF	MINIMAL CARDIOVASCULAR COMPLICATIONS FOLLOWING CAR T-CELL THERAPY: INSIGHTS FROM REAL-WORLD DATA	David Baden	Received

1244-PF	PREDICTIVE PERFORMANCE OF MODELS FOR ICAHT IN REAL-WORLD COHORTS OF RELAPSED/REFRACTORY B-CELL MALIGNANCY TREATED WITH CAR-T	Yuting Gong	Received

1245-PF	L-IPM: A NOVEL MODEL FOR PREDICTING LATE NEUTROPENIA IMMUNE EFFECTOR CELL-ASSOCIATED HEMATOTOXICITY (N-ICAHT) AFTER CAR-T THERAPY WITH MULTICENTER VALIDATION	Ao-ran Zhang	Received

1246-PF	SECONDARY PERIPHERAL T-CELL LYMPHOMA IN A PATIENT OF DLBCL HARBORING CANCER SUSCEPTIBILITY GENE MUTATION FOLLOWING CD19/CD22 BISPECIFIC CAR-T CELL THERAPY	Liang Wang	Received

1247-PF	OUT-OF-SPECIFICATION ANTI-BCMA CAR-T IN HEAVILY PRETREATED MULTIPLE MYELOMA: OUTCOMES FROM A SINGLE TRANSPLANT CENTER	James Di Palma-Grisi	Received

1248-PF	A PROSPECTIVE, SINGLE-ARM CLINICAL STUDY OF CTDNA-GUIDED EARLY SECOND INFUSION OF AXI-CEL IN RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA	Sanfang Tu	Received

1249-PF	PRE-TREATMENT WHITE MATTER CHANGES ON BRAIN MRI SUGGESTING SMALL VESSEL DISEASE PREDICT IMMUNE EFFECTOR CELL–ASSOCIATED NEUROTOXICITY AFTER CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY	Tomohiro Nagano	Received

1250-PF	CURING TRANSFUSION-DEPENDENT HEMOGLOBIN H-CONSTANT SPRING VIA EX VIVO GENE EDITING OF AUTOLOGOUS HEMATOPOIETIC STEM CELLS	Hui Xu	Received

1251-PF	EFFICACY AND SAFETY OF AVATROMBOPAG IN THE MANAGEMENT OF PROLONGED CYTOPENIAS FOLLOWING CAR-T CELL THERAPY: A GETH-TC STUDY	Daniel Gil-Alós	Received

1253-PF	CAR-T FITNESS INDEX (CAR-FIT): INTEGRATING COMORBIDITY AND FRAILTY ASSESSMENT TO GUIDE RISK-ADAPTED DELIVERY IN PATIENTS WITH BORDERLINE PHYSIOLOGICAL RESERVE.	Kye Ling Wong	Received

1256-PF	DIVERGENT PATHWAYS: COMPARATIVE LOGISTICAL AND PERCEPTUAL BARRIERS TO GENE THERAPY ADOPTION IN HEMOPHILIA VERSUS HEMOGLOBINOPATHIES IN THE UNITED STATES	Sam Young	Received

1258-PF	CURRENT CLINICAL TRIALS FOR NEW THERAPIES IN SICKLE CELL DISEASE DO NOT ADEQUATELY REPRESENT THE PATIENT POPULATION	DZ DZ	Received

1260-PF	AFTER TWO DECADES OF HYDROXYUREA: LEUKEMIC RISK IN SICKLE CELL DISEASE ASSESSED BY INTEGRATED MARROW MORPHOLOGY, CYTOGENETICS AND GENOMICS	Aurelio Maggio	Received

1263-PF	CHRONIC KIDNEY DISEASE IN ADULTS WITH SICKLE CELL DISEASE: INSIGHTS FROM A LARGE UK MULTI-CENTRE COHORT	Naomi Cornish	Received

1264-PF	METABOLIC DYSREGULATION OF ENERGY, ARGININE METABOLISM AND INFLAMMATION ASSOCIATED WITH POINT OF SICKLING IN PATIENTS WITH SICKLE CELL ANEMIA	Amira Idrizovic	Received

1266-PF	MEMAGEM PHASE IIA/IIB CLINICAL TRIAL: RESPONSES OF RED BLOOD CELLS OF ADULT AND ADOLESCENT PATIENTS WITH SICKLE CELL DISEASE TO MEMANTINE TREATMENT	Anna Bogdanova	Received

1267-PF	EFFECT OF HEMATOPOIETIC CELL TRANSPLANTATION ON INFLAMMATORY AND ANGIOGENIC PLASMA PROTEINS IN SICKLE CELL DISEASE	Maud Zwolsman	Received

1269-PF	IMPAIRED FUNCTION OF PYRUVATE KINASE IS ASSOCIATED WITH HEMOLYSIS-RELATED INFLAMMATION, INEFFECTIVE ERYTHROPOIESIS, AND ENDOTHELIAL DYSFUNCTION IN ADULTS WITH SICKLE CELL ANEMIA	Minke Rab	Received

1270-PF	PRESERVATION OF ADAPTIVE IMMUNITY AFTER NONMYELOABLATIVE HEMATOPOIETIC CELL TRANSPLANTATION IN ADULTS WITH SICKLE CELL DISEASE (PROTECT STUDY)	Lisa Dovern	Received

1271-PF	STEROID PRE-BUSULFAN REDUCED INTENSITY CONDITIONING MATCH RELATED HEMATOPOIETIC STEM CELL TRANSPLANTATION OUTCOME OF PATIENTS WITH SICKLE CELL DISEASE	Abdulrahman Nasiri	Received

1272-PF	CHRONIC PAIN, FUNCTIONAL IMPAIRMENT, AND GENERALIZED MECHANICAL HYPERSENSITIVITY IN ADULTS WITH SICKLE CELL DISEASE	Glenda Feldberg	Received

1275-PF	RELATIVE CONTRIBUTION OF VASO-OCCLUSIVE CRISES AND NON-CRISIS SYMPTOMS TO DAILY DISEASE BURDEN IN ADULTS WITH SICKLE CELL DISEASE: REGIONAL ANALYSIS FROM THE GLOBAL LISTEN SURVEY	Johnny Mahlangu	Received

1278-PF	NON-MALIGNANT CLONAL HEMATOPOIETIC EXPANSION DRIVEN BY 11P15 IMPRINTING MAY EXPLAIN LATE-ONSET SICKLE CELL DISEASE	Lucie Donaty	Received

1279-PF	ANALYSIS OF PSYCHOSOCIAL FACTORS ASSOCIATED WITH INCREASEDEMERGENCY DEPARTMENT VISITS FOR OPIOID USE IN PATIENTS WITHSICKLE CELL DISEASE	Dahra Teles Soares Cruz	Received

1281-PF	EFFICACY OF MITAPIVAT IN PATIENTS WITH NON–TRANSFUSION-DEPENDENT ALPHA OR BETA-THALASSEMIA WITH BASELINE HEMOGLOBIN =9.5 G/DL: SUBGROUP ANALYSIS FROM THE PHASE 3 ENERGIZE TRIAL	Khaled M. Musallam	Received

1282-PF	LIVER STIFFNESS AND ITS DETERMINANTS IN TRANSFUSION-DEPENDENT THALASSEMIA: A CROSS-SECTIONAL STUDY USING TRANSIENT ELASTOGRAPHY	Antonella Meloni	Received

1284-PF	MATCHED SIBLING VS ALTERNATIVE DONOR HSCT FOR ?-THALASSEMIA MAJOR: A SYSTEMATIC REVIEW AND META-ANALYSIS	Shankar Biswas	Received

1285-PF	LONGITUDINAL EVALUATION OF ANEMIA SEVERITY AND MORBIDITY IN PATIENTS WITH NON-TRANSFUSION DEPENDENT ?-THALASSEMIA (HBH THALASSEMIA)	Konstantinos Bistas	Received

1286-PF	EFFECT OF SGLT2 INHIBITORS ON PRE-TRANSFUSION HEMOGLOBIN AND TRANSFUSION REQUIREMENTS IN TRANSFUSION-DEPENDENT ?-THALASSEMIA: A LONGITUDINAL CASE SERIES STUDY	Theodora Maria Venou	Received

1288-PF	HEPATIC FAT AND IRON QUANTIFICATION BY MRI IN NON-TRANSFUSION-DEPENDENT THALASSEMIA: RESULTS FROM A MULTICENTER COHORT	Antonella Meloni	Received

1290-PF	MULTIOMIC PROFILING UNCOVERS HEME METABOLISM DYSFUNCTION IN CONGENITAL DYSERYTHROPOIETIC ANEMIAS	Antonella Nostroso	Received

1298-PF	CLINICAL VARIABILITY OF ATP11C-RELATED HEMOLYTIC ANEMIA: EXPANDING THE PHENOTYPIC AND DIAGNOSTIC SPECTRUM	Vanessa D´Onofrio	Received

1302-PF	FERRITIN DYNAMICS AND BURDEN OF IRON DEFICIENCY IN PREGNANCY: RESULTS OF A PAIRED, REAL-WORLD, SINGLE CENTER COHORT	Richard C. Godby	Received

1304-PF	CLINICAL CHARACTERISTICS AND NOVEL PREDICTORS OF IRON DEPOSITION IN CHINESE PATIENTS WITH UNEXPLAINED HYPERFERRITINEMIA: A SINGLE-CENTER RETROSPECTIVE STUDY	Junyu Zhang	Received

1305-PF	THE FERROCLEAR PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY: ADDRESSING PATIENT NEEDS IN HEREDITARY HEMOCHROMATOSIS THROUGH A NOVEL TARGETED APPROACH	Rachael Gillies	Received

1308-PF	IDENTIFYING MF PATIENTS AT HIGH INFECTION RISK DURING RUXOLITINIB: THE HIDDEN ROLE OF TRANSFUSIONS, IRON OVERLOAD, AND INFLAMMATORY STATUS	Francesca Palandri	Received

1309-PF	DISENTANGLING INFECTION FROM IMMUNE TOXICITY: PLASMA MICROBIAL CELL-FREE DNA SEQUENCING DURING CAR T-CELL–ASSOCIATED CRS	Sigrun Einarsdottir	Received

1311-PF	MODERN AML THERAPY SAVES LIVES, BUT INFECTION STILL DRIVES MORTALITY: EPIAMLINF EXPERIENCE FROM SWG IN AML AND INFECTIONS	Jon Salmanton-García	Received

1312-PF	RATE OF INFECTIOUS COMPLICATIONS IN AZACITIDINE-VENETOCLAX TREATED AML PATIENTS WITH OR WITHOUT FLUOROQUINOLONE AND POSACONAZOLE PROPHYLAXIS: INTERIM ANALYSIS OF REAL LIFE PROVENZA STUDY	ADELE SANTONI	Received

1313-PF	NEBULIZED AMPHOTERICIN B VERSUS POSACONAZOLE FOR PROPHYLAXIS OF INVASIVE FUNGAL DISEASE DURING POST-CHEMOTHERAPY NEUTROPENIA IN ACUTE LEUKEMIA: A PROPENSITY SCORE–MATCHED NONINFERIORITY COHORT STUDY	jingyu wang	Received

1314-PF	DOES MASK TYPE MATTER? A THREE-COHORT COMPARISON OF NO MASKING, FFP2, AND SURGICAL MASKS IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION	Tim Richardson	Received

1317-PF	HBV-DNA–GUIDED MONITORING FOR HEPATITIS B VIRUS REACTIVATION ENABLES SAFE MANAGEMENT WITHOUT ROUTINE ANTIVIRAL PROPHYLAXIS AFTER CAR T-CELL THERAPY IN R/R LBCL	Risa Nishiyama	Received

1320-PF	INTRAVENOUS IMMUNOGLOBULIN REPLACEMENT THERAPY IS ASSOCIATED WITH REDUCTION IN BOTH SEVERE AND ALL GRADE INFECTIONS IN PATIENTS WITH B-CELL MALIGNANCIES	Konstantinos Christofyllakis	Received

1321-PF	E-IMPACT: EUROPEAN MULTICENTER PRACTICE ASSESSMENT OF CELL THERAPY AND BISPECIFICS – CHARACTERIZING INFECTION MANAGEMENT AND PROPHYLAXIS IN THE REAL-WORLD SETTING.	Maria Stefania Infante	Received

1324-PF	THE HEALTHCARE BURDEN OF SECONDARY CARE INFECTIONS IN MM AND CLL: A REAL-WORLD ANALYSIS IN SWEDEN	Ingrid Glimelius	Received

1326-PF	PATTERNS OF INFECTION AND THEIR IMPACT ON THE OUTCOMES OF NEXT-GENERATION B-CELL DEPLETING IMMUNOTHERAPIES IN NON-HODGKIN´S LYMPHOMAS: FINDINGS FROM A MULTICENTER RETROSPECTIVE REAL-LIFE COHORT.	Lorenzo Nigri	Received

1328-PF	IMMUNOGLOBULIN PROPHYLAXIS REDUCES SEVERE INFECTIONS IN MULTIPLE MYELOMA: A SYSTEMATIC REVIEW AND META-ANALYSIS	Federico Spataro	Received

1330-PF	GENOMIC CHARACTERIZATION OF BLOOD CELL ANTIGEN DIVERSITY IN SOUTH-EAST ASIAN POPULATION WITH EUROPEAN AND AFRICAN COMPARATORS	Natasha Anthony	Received

1332-PF	DONOR-INTRINSIC MEMBRANE PROTEOME ALTERATIONS PRECEDE HIGH END-STORAGE HEMOLYSIS IN STORED RED BLOOD CELLS	Katerina Nikolaidou	Received

1334-PF	PLATELET CONCENTRATES CONSERVE THEIR CAPABILITY TO RESTORE HAEMOSTASIS DESPITE UNDERGOING PHENOTYPIC CHANGES DURING COLD STORAGE	Günalp Uzun	Received

1338-PF	SECONDARY FINDINGS FROM WHOLE GENOME SEQUENCING: A CAUSE FOR CONCERN?	Nehal Joshi	Received

1342-PF	EARLY PREDICTION OF THROMBOTIC THROMBOCYTOPENIC PURPURA FROM ROUTINE LABORATORY DATA USING MACHINE LEARNING	Ella Derkzen	Received

1343-PF	CHARACTERISTICS AND MANAGEMENT OF HIV-ASSOCIATED IMMUNE THROMBOCYTOPENIA: UPDATE IN THE COMBINED ANTIRETROVIRAL THERAPY ERA	Guillaume Moulis	Received

1345-PF	EFFECTIVENESS AND SAFETY OF FIRST-LINE TREATMENT WITH DEXAMETHASONE VERSUS PREDNISONE IN ELDERLY PATIENTS WITH IMMUNE THROMBOCYTOPENIA: AN EMULATED TRIAL IN THE CARMEN-FRANCE REGISTRY	Guillaume Moulis	Received

1348-PF	FATIGUE IN ADULTS WITH IMMUNE THROMBOCYTOPENIA (ITP): A CROSS-SECTIONAL OBSERVATIONAL STUDY	David J. Kuter	Received

1351-PF	PLATELET FUNCTION DEFECTS IN DEPRESSION: LIGHT TRANSMISSION AGGREGOMETRY PATTERNS IN PATIENTS TREATED WITH SSRIS AND SNRIS	Nikolaos Kotsiou	Received

1352-PF	EFFICACY AND SAFETY OF LUSUTROMBOPAG IN PERSISTENT OR CHRONIC PRIMARY IMMUNE THROMBOCYTOPENIA: A PROSPECTIVE, OPEN-LABEL, SINGLE-ARM PHASE II STUDY	Rongfeng Fu	Received

1353-PF	COMBINATION OF ANTI-CD38 AND ANTI-CD20 MONOCLONAL ANTIBODIES IN THE TREATMENT OF REFRACTORY/RELAPSED IMMUNE THROMBOCYTOPENIA: A PROSPECTIVE CLINICAL STUDY	Chen Li	Received

1354-PF	PLATELET COUNT DYNAMICS AFTER COVID19 INFECTION VS. COVID19 VACCINATION IN PATIENTS WITH ITP: DATA FROM THE ITP NATURAL HISTORY STUDY REGISTRY	Taylor Bowles	Received

1355-PF	DEVELOPMENT OF A CATALYTICALLY INACTIVE BIVALENT FVII-FC FUSION PROTEIN FOR SELECTIVE MODULATION OF TF–FVIIA INITIATION	shifeng lou	Received

1356-PF	ADAPT-BLEED: A PRACTICAL MACHINE LEARNING–BASED BLEEDING RISK SCORE WITH A BEDSIDE DIGITAL APPLICATION	Tamar Tadmor	Received

1357-PF	DISTINCT CLINICAL PROFILES AND BLEEDING SEVERITY IN CONGENITAL AND ACQUIRED FACTOR XIII DEFICIENCY: A SINGLE-CENTER EXPERIENCE	Alfadil Haroon	Received

1358-PF	DIAGNOSTIC VALUE OF THROMBIN GENERATION USING DIFFERENT TRIGGER REAGENTS IN PATIENTS WITH BLEEDING DISORDER OF UNKNOWN CAUSE	Emma Urlings	Received

1359-PF	MATCHING-ADJUSTED INDIRECT COMPARISON OF RIX-FP VERSUS MARSTACIMAB FOR THE PROPHYLAXIS OF SEVERE HEMOPHILIA B	Songkai Yan	Received

1360-PF	WHEN PLATELETS TURN AGAINST HEMOSTASIS: PREDICTORS OF ACQUIRED VON WILLEBRAND SYNDROME IN MPN AND ISTH-BAT SCORE-BASED BLEEDING RISK	Uros Markovic	Received

1361-PF	REAL-WORLD EVIDENCE: LEUKEMIA BURDEN DRIVES HEMORRHAGIC RISK IN IBRUTINIB-TREATED CLL PATIENTS	Jelena Ivanovic	Received

1362-PF	HEMORRHAGIC RISK EVALUATION AND MANAGEMENT OF PEDIATRIC PATIENTS AFFECTED BY MILD FACTOR VII DEFICIENCY UNDERGOING SURGERY	Beatrice Borsellino	Received

1365-PF	ELICITING EXPERT RECOMMENDATIONS ON THE DOSING OF FACTOR REPLACEMENT THERAPY WITH MARSTACIMAB FOR BREAKTHROUGH BLEEDING & PERIOPERATIVE SITUATIONS IN HAEMOPHILIA: INTERIM RESULTS OF A DELPHI STUDY	Hae Kyung Kim	Received

1368-PF	EFFECTIVENESS AND SAFETY OF PRIMARY THROMBOPROPHYLAXIS IN ANTIPHOSPHOLIPID ANTIBODY CARRIERS ACCORDING TO THE SEROLOGICAL 2023 ACR/EULAR DOMAINS	Rodrigo Cantera Estefanía	Received

1369-PF	REAL-WORLD THROMBOTIC OUTCOMES AND MANAGEMENT STRATEGIES IN SEVERE SECONDARY ERYTHROCYTOSIS: A RETROSPECTIVE COHORT STUDY	Shamsher Sandhu	Received

1371-PF	EFFECTIVENESS AND SAFETY OF DIRECT ORAL ANTICOAGULANTS IN HIGH-RISK CANCER PATIENTS WITH ATRIAL FIBRILLATION AND/OR VENOUS THROMBOEMBOLISM: REAL-WORLD EVIDENCE	Agata Ogloza-Puchowska	Received

1373-PF	PREVENT THE PREVENTABLE: A MULTIFACETED QUALITY IMPROVEMENT INITIATIVE TO REDUCE HOSPITAL-ACQUIRED THROMBOSIS	Abdulrahman Al Raizah	Received

1374-PF	UTILIZATION AND EFFICACY OF THERAPEUTIC PLASMA EXCHANGE IN THROMBOTIC MICROANGIOPATHIES: A REAL-WORLD ANALYSIS FROM A NATIONWIDE REGISTRY	Paschalis Evangelidis	Received

1375-PF	CEREBRAL VENOUS SINUS THROMBOSIS IN MYELOPROLIFERATIVE NEOPLASMS: A PREDOMINANCE IN YOUNGER JAK2-MUTATED FEMALES WITH POLYCYTHAEMIA VERA AND A POTENTIAL RISK OF LATE RECURRENT THROMBOSIS	Tarik Rosun	Received

1376-PF	ADAMTS13 INHIBITOR TESTING: EVALUATION OF A CHEMILUMINESCENCE BASED MIXING ASSAY FOR MONITORING IMMUNE THROMBOTIC THROMBOCYTOPENIC PURPURA. STUDY OF THE SPANISH APHERESIS GROUP (GEA)	Cristina Pascual-Izquierdo	Received

1379-PF	THE EVALUATION OF ANTI-FACTOR XA LEVELS IN HOSPITALISED PATIENTS RECEIVING LOW MOLECULAR WEIGHT HEPARIN (LMWH): A PROSPECTIVE STUDY	Nancy Okinda	Received

1380-PF	HOW CERTAIN CAN THE DASH AND HERDOO2 SCORES IDENTIFY LOW-RISK PATIENTS?	Jasper van Miert	Received

1381-PF	EVALUATION OF EFFECTIVENESS AND SAFETY OF DIRECT ORAL ANTICOAGULANTS IN SPLANCHNIC VENOUS THROMBOSIS	Rodrigo Cantera Estefanía	Received

1382-PF	MANAGEMENT OF VENOUS THROMBOEMBOLISM (VTE) IN SICKLE CELL DISEASE: A COMPARATIVE STUDY ON THE USE OF DIRECT ORAL ANTICOAGULANTS (DOACS) AND WARFARIN	Turki Alshuaibi	Received

1388-PF	ASSISTING PATIENTS DURING CAR-T THERAPY: A DYNAMIC SCORE-BASED ANALYSIS OF NURSING BURDEN, CLINICAL COMPLEXITY, AND FUNCTIONAL DECLINE	Eugenio Galli	Received

1389-PF	AMBULATORY DELIVERY OF BISPECIFIC ANTIBODIES IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) VIA A VIRTUAL WARD PATHWAY: REDUCED INPATIENT BED-DAYS AND PRESERVED SAFETY	Victor Ling	Received

1392-PF	REAL-WORLD OUTCOMES OF SICKLE CELL DISEASE PATIENTS TRANSITIONING FROM PEDIATRIC TO ADULT CARE: IMPACT ON ACUTE CARE UTILIZATION	Heidi Cho	Received

1393-PF	FAVORABLE HEALTHCARE RESOURCE UTILIZATION (HCRU) WITH TAGRAXOFUSP (TAG) VS VENETOCLAX (VEN) IN PATIENTS WITH BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM (BPDCN): RESULTS OF A REAL-WORLD (RW) ANALYSIS	Anthony Stein	Received

1394-PF	SLEEP DISTURBANCES AFTER HEMATOLOGICAL MALIGNANCIES DIAGNOSIS: PREVALENCEAND SEVERITY IN A PATIENT SURVEY	Esther N. Oliva	Received

1396-PF	EMOTIONAL DISTRESS DOMINATES QUALITY OF LIFE BURDEN IN CML: PSYCHOMETRIC VALIDATION OF PATIENT REPORTED OUTCOMES IN A GLOBAL LEUKEMIA EXPERIENCE SURVEY	Samantha Nier	Received

1397-PF	IMPACT OF TRIAL BLINDING ON DIFFERENCES IN PATIENT-REPORTED OUTCOMES IN RANDOMIZED CLINICAL TRIALS OF HEMATOLOGIC MALIGNANCIES	Fabio Efficace	Received

1398-PF	A LONGITUDINAL ANALYSIS OF PATIENTS WITH CLL/SLL WITH IMPAIRED HEALTH-RELATED QUALITY OF LIFE SCORES AT BASELINE WHO WERE TREATED WITH ZANUBRUTINIB VERSUS IBRUTINIB: A POST HOC ANALYSIS OF ALPINE	Loic Ysebaert	Received

1399-PF	FAMILY CARER BURDEN AND THEIR PROXY CONCORDANCE OF PATIENT-REPORTED OUTCOMES: A GLOBAL LEUKEMIA EXPERIENCE SURVEY	Samantha Nier	Received

1400-PF	THE IDIOPATHIC MULTICENTRIC CASTLEMAN DISEASE SYMPTOM BURDEN SCALE (ISBUS): PRELIMINARY FINDINGS IN THE GENERATION OF A NOVEL INSTRUMENT	Kelly Makarounas-Kirchmann	Received

1401-PF	MENTAL HEALTH OF ADULT PATIENTS WITH MASTOCYTOSIS: A DANISH NATIONWIDE MATCHED COHORT STUDY	Maren Jørgensen	Received

1402-PF	OUTCOME FOLLOWING CARDIAC ARREST AND/OR INTENSIVE CARE IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES: A SWEDISH NATIONWIDE REGISTRY-BASED STUDY	Malin Petersson	Received

1403-PF	OPERATIONAL INTEGRATION OF T-CELL–ENGAGING BISPECIFIC ANTIBODIES IN COMMUNITY HEMATOLOGY: A LONGITUDINAL MIXED-METHODS ANALYSIS	Carmine DeLuca	Received

1404-PF	REAL-WORLD EXPERIENCES OF FAMILY CARERS SUPPORTING PEOPLE WITH MYELOMA	Eilidh Duncan	Received

1406-PF	SYMPTOM BURDEN OF PATIENTS WITH MULTIPLE MYELOMA DURING THE LAST WEEK OF LIFE COMPARED TO OTHER HAEMATOLOGICAL MALIGNANCIES- A POPULATION-BASED REGISTRY STUDY	Emma Freij	Received

1407-PF	REAL - WORLD EVIDENCE ON THE IMPACT OF RELATIVE DOSE INTENSITY (RDI) ON SURVIVAL IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES IN A MIDDLE – INCOME COUNTRY.	Carlos Gomez - Calcetero	Received

1408-PF	ACCESS AND OUTCOMES FOR 2ND LINE AXICABTAGENE CILOLEUCEL IN PATIENTS WITH LARGE B-CELL LYMPHOMA ACCORDING TO SOCIOECONOMIC DEPRIVATION, DISTANCE AND ETHNICITY IN THE UK	Emil Kumar	Received

1409-PF	TIME BURDEN, TIME SPENT AT HOME, AND PERSISTENCE WITH AZACITIDINE OR DECITABINE PLUS VENETOCLAX IN NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA IN THE UNITED STATES	Amer M. Zeidan	Received

1416-PF	COMPREHENSIVE CHARACTERIZATION OF HEALTHCARE RESOURCE UTILIZATION AFTER OUTPATIENT ADMINISTRATION OF LISOCABTAGENE MARALEUCEL IN THE REAL-WORLD SETTING (THE HELIOS STUDY)	Jennifer Huang	Received

1418-PF	THE COST OF SAFETY: A REAL-WORLD COMPARATIVE ANALYSIS OF EARLY HEALTH CARE UTILIZATION IN CLL PATIENTS TREATED WITH FIRST- VS. SECOND-GENERATION BTK INHIBITORS	Jelena Ivanovic	Received

1419-PF	CALM: BUILDING A COMPREHENSIVE ATLAS OF LEUKEMIA AND ITS MICROENVIRONMENT TO ENABLE MECHANISTIC AND THERAPEUTIC DISCOVERIES FOR PRECISION MEDICINE	Hussein Abbas	Received

1420-PF	UNSUPERVISED CLUSTERING FOR MRD FLOW CYTOMETRY IN AML: MULTICENTRIC VALIDATION AND PROGNOSTIC IMPACT AT SUB-ELN THRESHOLDS.	Aguirre MIMOUN	Received

1421-PF	DISTINGUISHING MYELOPROLIFERATIVE NEOPLASMS AND PREDICTING JAK2 AND CALR MUTATION STATUS FROM BONE MARROW WHOLE SLIDE IMAGES USING SELF-SUPERVISED VISION TRANSFORMERS AND MULTI-INSTANCE LEARNING	Jan-Niklas Eckardt	Received

1426-PF	DYNAMIC REMODELING OF HSC LINEAGE BIAS DURING INFECTION	Katerina Vecerkova	Received

1427-PF	PREDICTION OF SF3B1 MUTATION FROM DIGITIZED BONE MARROW ASPIRATION SMEARS OF MYELODYSPLASTIC SYNDROMES USING SUPERVISED MACHINE LEARNING	Theerin Lanamtieng	Received

1428-PF	EVALUATION OF RAPID EPIGENOMICS PROFILING OF ACUTE LEUKEMIA BY NANOPORE SEQUENCING	Ka Ngai Lau	Received

1432-PF	AN INTEGRATED COMPUTATIONAL AND SINGLE-CELL SCREENING WORKFLOW FOR RAPID GENERATION OF NOVEL CAR CONSTRUCTS	Alexandra Mayr	Received

1433-PF	HEMATRACK ALL: UMI-CORRECTED NANOPORE SEQUENCING FOR HIGHLY SENSITIVE MEASURABLE RESIDUAL DISEASE (MRD) MONITORING IN ALL	Claudia Pahlke	Received

1435-PS	MENINGEAL STROMAL NICHE REWIRES THYMIDYLATE SYNTHESIS AND THYMIDINE SALVAGE IN METHOTREXATE-RESISTANT CENTRAL NERVOUS SYSTEM ACUTE LYMPHOBLASTIC LEUKEMIA	Shirley Lam	Received

1438-PS	LIPIDOMIC REPROGRAMMING LINKS VEGF-DEPENDENT CNS ADAPTATION TO FERROPTOSIS SENSITIVITY IN ACUTE LYMPHOBLASTIC LEUKEMIA	Vera Muench	Received

1439-PS	IKZF1 LOSS ESTABLISHES A SELF-RENEWING THYMOCYTE POOL DRIVING T-ALL	Maaike Van Trimpont	Received

1448-PS	SERTRALINE MODULATES CHOLESTEROL METABOLISM AND SYNERGIZES WITH PROTEASOME AND HDAC INHIBITORS TO TARGET SERINE/GLYCINE METABOLIC ADDICTION IN T-CELL MALIGNANCIES	Anaís Sánchez-Castillo	Received

1450-PS	TARGETING HMOX1 EXPLOITS A FERROPTOSIS VULNERABILITY IN HIGH-RISK ETP-ALL	Martina Portaluri	Received

1453-PS	BCG MOBILIZES SYSTEMIC IMMUNITY TO RESTRAIN B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA	Mina NF Morcos	Received

1454-PS	COOPERATIVITY OF KMT2A-MLLT1 WITH KMT2C LOSS ENABLES DUAL MYELOID-LYMPHOID LEUKEMIC POTENTIAL AND INDUCES CYTOSKELETAL REPROGRAMMING IN A ZEBRAFISH MODEL OF INFANT LEUKEMIA	Sarada Ketharnathan	Received

1457-PS	VENETOCLAX-BASED COMBINATIONS TARGET HIGH-RISK ADULT ACUTE LYMPHOBLASTIC LEUKEMIA: SYNERGISTIC ACTIVITY WITH PONATINIB AND BLINATUMOMAB ACROSS MOLECULAR SUBGROUPS	Federico Lo Schiavo	Received

1464-PS	EFFICACY OF BIOMIMETIC NANODRUG CX4945 IN B-ALL PATIENT-DERIVED XENOGRAFT MOUSE MODEL	Zheng Ge	Received

1465-PS	SHORT PEPTIDE INHIBITORS AGAINST DUX4-R LEUKEMIA	Mara Salomè	Received

1466-PS	IGH::ID4-REARRANGEMENTS ARE THE MOST FREQUENT DRIVER ABERRATIONS OF ADULT PAX5ALT B-ALL AND DEFINE A DISTINCT MOLECULAR ENTITY	Sonja Bendig	Received

1467-PS	INFLUENCE OF AGE AND CYTOGENETIC RISK GROUP ON THE PROGNOSTIC EFFECT OF KEY COPY NUMBER ALTERATIONS IN B-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA, INSIGHTS FROM THE HARMONY PLATFORM	Anthony Moorman	Received

1470-PS	PREVALENCE AND IMPACT OF INCIDENTALLY DETECTED GERMLINE VARIANTS IN PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA	Borbála Péterffy	Received

1473-PS	SAFETY AND PRELIMINARY EFFICACY OF OLVEREMBATINIB (HQP1351) COMBINED WITH LISAFTOCLAX (APG-2575) IN PEDIATRIC PATIENTS WITH RELAPSED/REFRACTORY (R/R PH+ ALL): RESULTS OF A PHASE 1B STUDY	DA DA	Received

1474-PS	DIFFERENCES IN GENOMIC AND TRANSCRIPTOMIC FEATURES BETWEEN ADULTS WITH NEWLY DIAGNOSED BCR::ABL1-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA WITH MULTILINEAGE AND LYMPHOID-ONLY INVOLVEMENT	Zhenzhen Jiang	Received

1476-PS	COMBINATION OF VENETOCLAX AND CHEMOTHERAPY IN NEWLY DIAGNOSED ADULT T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: INTERIM ANALYSIS OF A MULTICENTER PROSPECTIVE STUDY	Lijun Peng	Received

1478-PS	A PHASE 2 STUDY OF VENETOCLAX PLUS MINI-HYPER-CVD IN OLDER ADULTS WITH DE NOVO PHILADELPHIA NEGATIVE ALL	Marlise Luskin	Received

1479-PS	UPDATED RESULTS OF POLARIS-1 (PART 1), A GLOBAL REGISTRATIONAL PHASE 3 STUDY: OLVEREMBATINIB COMBINED WITH LOW-INTENSITY CHEMOTHERAPY IN NEWLY DIAGNOSED PH+ ALL	Daniel Daniel	Received

1481-PS	SUBCUTANEOUS BLINATUMOMAB FOR PATIENTS WITH RELAPSED/REFRACTORY PHILADELPHIA CHROMOSOME–POSITIVE B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: RESULTS FROM A PHASE 1/2 STUDY	Elias Jabbour	Received

1482-PS	REAL-WORLD EFFICACY AND SAFETY OF INOTUZUMAB OZOGAMICIN IN B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: A MULTICENTER OK-1 COHORT STUDY	Jiaxin Zheng	Received

1485-PS	COMBINATION THERAPY WITH BLINATUMOMAB AND ASCIMINIB FOR PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA: RESULTS FROM A PHASE I/II STUDY	Nicholas Short	Received

1488-PS	DEEPER REMISSION ACHIEVEMENT AND LONGER LEUKEMIA-FREE SURVIVAL WITH INATI-CEL AS CONSOLIDATION THERAPY IN ALLOGENEIC TRANSPLANT-INELIGIBLE ADOLESCENT AND ADULT PATIENTS WITH B-ALL	Sanfang Tu	Received

1489-PS	PHASE II STUDY OF DOSE-ADJUSTED EPOCH ± RITUXIMAB (R) + TAFASITAMAB (TAFA) IN NEWLY-DIAGNOSED (ND) ADULTS WITH PHILADELPHIA CHROMOSOME NEGATIVE (PH-) B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL)	Ryan Cassaday	Received

1490-PS	LONG-TERM SURVIVAL AND IMMUNOGLOBULIN PATTERNS FOLLOWING BLINATUMOMAB IN INFANTS WITH KMT2A-REARRANGED ALL	Miguel Vieira Martins	Received

1491-PS	CLINICAL EFFICACY ANALYSIS OF CAR-T THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY B-ALL WITH CENTRAL NERVOUS SYSTEM LEUKEMIA	Zhao defeng	Received

1492-PS	DONOR AGE =50 YEARS COMBINED WITH DONOR-CI =3 IDENTIFIES A HIGH-RISK COHORT FOR ADVERSE OUTCOMES AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA	Yu Wang	Received

1495-PS	FATIGUE AND HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH NEWLY DIAGNOSED PH+ ALL TREATED WITH FRONTLINE PONATINIB PLUS BLINATUMOMAB. RESULTS OF THE PHASE III GIMEMA ALL2820 TRIAL	Fabio Efficace	Received

1497-PS	THE BLINATUMOMAB ERA IN PHILADELPHIA CHROMOSOME POSITIVE B-ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ B-ALL): A SINGLE-CENTER ANALYSIS OF TREATMENT EVOLUTION AND SURVIVAL	Valerie Hui Shan Tan	Received

1499-PS	DONOR-DERIVED CAR-T THERAPY FOR RELAPSE OF B-ALL AFTER SECOND ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION	Zhao defeng	Received

1503-PS	IMPACT OF MRD AND BRIDGING THERAPHY BEFORE ALLO-SCT IN B-ALL: 20-YEAR REAL-WORLD DATA	Jorge Nuñez Zuno	Received

1505-PS	EFFICACY AND TOXICITY OF INOTUZUMAB OZOGAMICIN BRIDGING TO CELLULAR THERAPIES IN A REAL-WORLD SETTING	Mohit Vijayakumar	Received

1506-PS	EVALUATION OF BONE METABOLISM PARAMETERS AND BONE MINERAL DENSITY IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA: A RETROSPECTIVE SINGLE-CENTER STUDY	Ugur Mete	Received

1510-PS	CSN5I-3 TARGETING OF JAB1 DISRUPTS FLT3-ITD SIGNALING AND IMPAIRS LEUKEMIC PROGRESSION IN ACUTE MYELOID LEUKEMIA	Jian-Chuan Deng	Received

1511-PS	HPCAL1-PPIL2 INTERACTION DRIVES GLYCOLYSIS AND REPRESENTS A THERAPEUTIC TARGET IN AML	Linna Cheng	Received

1512-PS	ULTRA-HIGH-SENSITIVITY NEXT-GENERATION SEQUENCING–BASED MRD PREDICTS OUTCOME IN INTENSIVELY TREATED OLDER PATIENTS WITH ACUTE MYELOID LEUKEMIA: RESULTS FROM THE ALFA-1200 COHORT	Augustin Boudry	Received

1514-PS	MULTI-OMICS CLASSIFICATION OF ACUTE MYELOID LEUKEMIA GUIDES DRUG COMBINATIONS TO OVERCOME VENETOCLAX RESISTANCE	Runyu Yang	Received

1516-PS	FLT3-ITD REPROGRAMS LEUCINE ANABOLISM TO DRIVE ACUTE MYELOID LEUKEMIA PROGRESSION	Jun Long	Received

1517-PS	KMT2E/SWI-SNF-INDUCED CHROMATIN REMODELING ENHANCES TRANSFORMATION BUT ALSO ENABLES ATRA-INDUCED DIFFERENTIATION IN ACUTE MYELOID LEUKEMIA	Isabel Weinhäuser	Received

1518-PS	OVERCOMING THE UNDRUGGABLE: AN AI-DRIVEN DESIGN PEPTIDE INHIBITOR TARGETING THE TBK1-OPTN INTERACTION SUPPRESSES AML AND REVERSES VENETOCLAX RESISTANCE	Fan Niu	Received

1522-PS	TREATING ACUTE MYELOID LEUKEMIA BY COMBINING CAR T CELL THERAPY AND LILRB2 TARGETING	Silvan Brunn	Received

1523-PS	SYNERGISTIC EFFECT OF COMBINED CK2 AND XPO1 INHIBITION IN PRECLINICAL MODELS OF ACUTE MYELOID LEUKEMIA: MECHANISM AND THERAPEUTIC POTENTIAL	Zheng Ge	Received

1525-PS	INTEGRATED ANALYSIS OF DRUG RESPONSE ACROSS TRANSCRIPTOMIC CELL STATES IDENTIFIES VENETOCLAX-BASED COMBINATION STRATEGIES IN AML	Jie Zhu	Received

1534-PS	AML-INDUCED MACROPHAGE-TREG CROSSTALK CREATES A SELF-REINFORCING IMMUNOSUPPRESSIVE LOOP VIA CD44 AND TIM-3	Alicia Perzolli	Received

1535-PS	A DUAL STRATEGY FOR AML: CAR T CELLS DERIVED FROM A NOVEL, HIGH-AFFINITY ANTI-CLL-1 MONOCLONAL ANTIBODY AND SENSITIZATION BY A MENIN INHIBITOR	Shuhei Kida	Received

1536-PS	TARGETING MCL-1 WITH CARDIO-SAFE DEGRADER CT-03P EXERTS ACTIVITY IN AML AND OVERCOMES VENETOCLAX RESISTANCE	Bing Carter	Received

1537-PS	PROGNOSTIC VALIDATION OF POST CONSOLIDATION MEASURABLE RESIDUAL DISEASE AND CD34+CD38- ACUTE MYELOID LEUKEMIA STEM CELLS: TOOLS FOR CLINICAL INTERVENTION	DZ DZ	Received

1538-PS	TRANSCRIPTIONAL REWIRING TO A MONOCYTIC STATE REVEALS THERAPEUTIC VULNERABILITIES IN MENIN INHIBITOR RESISTANCE AML	Lanpeng Chen	Received

1540-PS	AGE-DRIVEN REMODELLING OF THE TRANSCRIPTOMIC CELL-CELL INTERACTION LANDSCAPE IN THE BONE MARROW NICHE OF TP53-AML PATIENTS	Rebecca Andersson	Received

1544-PS	OVERCOMING GENETIC OR ADAPTIVE RESISTANCE TO MENIN INHIBITORS IN MUTANT NPM1 AML WITH NOVEL ´DRUGGABLE´ TARGETS IDENTIFIED VIA NPM1A-TURBOID FUSION AND MASS SPECTROMETRY	Christopher Mill	Received

1545-PS	SH2B3 EXPRESSION PREDICTS SELINEXOR SENSITIVITY IN ACUTE MYELOID LEUKEMIA	Donghua Zhang	Received

1546-PS	EPIGENETIC REGULATION OF CD52 INFLUENCES THE EXPRESSION OF AKT AND MODULATES THE CELLULAR RESPONSE TO VENETOCLAX AND UPROSERTIB IN ACUTE MYELOID LEUKEMIA	Carlos Quero-Dotor	Received

1547-PS	A NOVEL DECITABINE ANALOGUE WITH ENHANCED ANTI-LEUKEMIA ACTIVITY AND REDUCED TOXICITY IN VIVO	Irmela Jeremias	Received

1551-PS	INHIBITORS OF IRE1A ENHANCE VENETOCLAX ACTIVITY IN DE NOVO AND SECONDARY ACUTE MYELOID LEUKEMIA	Orsola di Martino	Received

1552-PS	SPATIAL CHARACTERIZATION OF THE IMMUNE MICROENVIRONMENT IN BONE MARROW AND EXTRAMEDULLARY ACUTE MYELOID LEUKEMIA	Hossein Emami	Received

1554-PS	NOVEL FRAGMENTATION ASSAY ENABLES COMPREHENSIVE FLT3-INTERNAL TANDEM DUPLICATION DETECTION IN AML: AT DIAGNOSIS AND IN FOLLOW-UP	Lisanne Beugelink	Received

1555-PS	DEVELOPMENT AND VALIDATION OF AN RWD-BASED MACHINE LEARNING MODEL PREDICTING FEBRILE NEUTROPENIA WITH DAY-LEVEL ACCURACY IN PATIENTS WITH NEWLY DIAGNOSED AML UNDERGOING INTENSIVE CHEMOTHERAPY	Anna Mervaala-Muroke	Received

1556-PS	DUAL BET/HAT INHIBITOR–BASED COMBINATIONS EXERT SYNERGISTIC LETHALITY AGAINST MYELOPROLIFERATIVE NEOPLASMS (MPN) TRANSFORMED TO AML	Warren Fiskus	Received

1561-PS	CSF3R MEDIATES VENETOCLAX RESISTANCE IN ACUTE MYELOID LEUKEMIA VIA ACTIVATION OF THE JAK-STAT PATHWAY	Zi-Yuan Nie	Received

1564-PS	UNRAVELLING THE MECHANISM OF CHEMORESISTANCE IN AML: THE ROLE OF ATF4-PPP1R15A AXIS	Vasiliki Pappa	Received

1566-PS	THERAPEUTIC EFFICACY AND SAFETY OF KIT-TARGETED APTAMER–MONOMETHYL AURISTATIN E CONJUGATE IN ACUTE MYELOID LEUKEMIA	Tingting Liu	Received

1567-PS	PROTEOMICS REVEALS HSP90-ENRICHED FERROEVS ASSOCIATED WITH SERIAL TRANSMISSION OF FERROPTOSIS IN AML CELLS	Hiroki Doi	Received

1568-PS	UNLOCKING VULNERABILITIES: BCL2 INHIBITORS TARGET BCOR-MUTATED AML	Sylvain Garciaz	Received

1570-PS	FOXC1 MEDIATES DRUG RESISTANCE AND MHC-II SUPPRESSION: A NOVEL DUAL MECHANISM IN RELAPSED/REFRACTORY AML	Xiaoxuan Lu	Received

1571-PS	SINGLE-CELL LANDSCAPE OF CEBPANTERM-MUTATED ZEBRAFISH REVEALS PROGENITOR DIFFERENTIATION BLOCK AND GRANULOCYTE DYSREGULATION	Zhangjie Chen	Received

1572-PS	C-TERMINAL CEBPA MUTATIONS IMPOSE A DOSE-DEPENDENT MYELOID DIFFERENTIATION BLOCKADE IN ISOGENIC IPSC-DERIVED AML MODELS	Antonio Benedetto Ventura	Received

1575-PS	SINGLE-HIT AND MULTI-HIT DNMT3A, TET2 AND ASXL1 MUTATIONS SHAPE DISTINCT PATHWAYS TO AML	Wencke Walter	Received

1576-PS	ACUTE MYELOID LEUKEMIA WITH NORMAL KARYOTYPE AND MYELODYSPLASIA-RELATED MUTATIONS: PROGNOSTIC IMPACT OF A PATHWAY-BASED STRATIFICATION	Guadalupe Oñate	Received

1577-PS	PATHOGENIC ROLE AND THERAPEUTIC IMPLICATIONS OF CYTOPLASMIC P53 AGGREGATES IN TP53-MUTATED ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROMES	Tadashi Okamura	Received

1578-PS	SHIKONIN EXERTS ANTI-LEUKEMIC ACTIVITY AGAINST FLT3-ITD-MUTATED ACUTE MYELOID LEUKEMIA BY PROMOTING CBL-MEDIATED DEGRADATION OF THE FLT3 RECEPTOR	SuJun Gao	Received

1583-PS	DDX41-MUTATED MYELOID NEOPLASMS IN A LARGE CHINESE COHORT:DISTINCT GERMLINE HOTSPOTS, CLINICAL OUTCOMES, AND SUPERIOR RESPONSE TO HSCT	YUEQI SUN	Received

1584-PS	THE NOVEL LYSOSOME INHIBITOR LYS05 SYNERGIZES WITH VENETOCLAX TO EXERT ANTI-AML ACTIVITY BY NEGATIVELY REGULATING AUTOPHAGY	Xia Jiang	Received

1586-PS	SYNERGISTIC EFFICACY OF HDACI CHIDAMIDE WITH GL-V9 BY SUPPRESSING MYBL2 EXPRESSION IN ACUTE MYELOID LEUKEMIA	Zheng Ge	Received

1588-PS	CLINICAL AND MOLECULAR CHARACTERIZATION OF THERAPY-RELATED AML: INSIGHTS FROM THE HARMONY PLATFORM	Luca Guarnera	Received

1589-PS	REFINING PROGNOSTIC STRATIFICATION IN ACUTE MYELOID LEUKEMIA WITH MYELODYSPLASIA-RELATED GENE MUTATIONS ACCORDING TO VARIANT ALLELE FREQUENCY	Yu-Sung Chang	Received

1591-PS	CLINICAL AND TRANSCRIPTOMIC IMPACTS OF TET2 MUTATIONS IN DE NOVO ACUTE MYELOID LEUKEMIA: A MAJOR DETERMINANT OF SURVIVAL BEYOND CURRENT RISK MODELS	Tsung-Han Li	Received

1593-PS	PROGNOSTIC RISK INTEGRATION FOR SURVIVAL MODELING IN ACUTE MYELOID LEUKEMIA (PRISM-AML): A MULITNATIONAL COHORT STUDY	Curtis Lachowiez	Received

1594-PS	DDX41-MUTATED ACUTE MYELOID LEUKEMIA DEFINES A DISTINCT AML ENTITY	Carolin Seeling	Received

1597-PS	RUXOLITINIB AND DEXAMETHASONE COMBINATION THERAPY EFFECTIVELY PREVENTS DIFFERENTIATION SYNDROME IN ACUTE PROMYELOCYTIC LEUKEMIA	Hongming Zhu	Received

1598-PS	REAL WORLD CHARACTERISTICS AND OUTCOMES IN A LARGE COHORT OF FIT PATIENTS WITH CBF-AML: A MULTINATIONAL PETHEMA-GPLA-ACHO-GRELAM STUDY	Evelyn Acuña-Cruz	Received

1599-PS	ALIDHE: A PHASE 3B STUDY ASSESSING IVOSIDENIB + AZACITIDINE IN ADULTS WITH NEWLY DIAGNOSED MIDH1 ACUTE MYELOID LEUKAEMIA WHO ARE INELIGIBLE FOR INTENSIVE INDUCTION CHEMOTHERAPY	Paresh Vyas	Received

1600-PS	BEYOND BCL-2: QUANTITATIVE BCL-XL/MCL-1 AND BH3 PROTEIN PROFILING IDENTIFIES VENETOCLAX RESISTANCE IN ELDERLY AML PATIENTS	Chia-Jen Liu	Received

1601-PS	HMA PLUS VENETOCLAX FOR 7- VS 14- VS 21- VS 28-DAY CYCLES IN NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA: ELN- AND MAYO GENETIC RISK–STRATIFIED ANALYSIS IN 540 PATIENTS.	Naseema Gangat	Received

1605-PS	THE EFFICACY AND SAFETY OF THE DECITABINE, VENETOCLAX, AND SELINEXOR REGIMEN IN PATIENTS WITH NEWLY DIAGNOSED AML UNFIT FOR INTENSIVE CHEMOTHERAPY: A PROSPECTIVE, SINGLE-ARM CLINICAL STUDY	Shukai Qiao	Received

1608-PS	UPDATED SAFETY AND EFFICACY RESULTS OF A PHASE IB INVESTIGATION OF THE LSD1 INHIBITOR IADADEMSTAT (ORY-1001) IN COMBINATION WITH AZACITIDINE AND VENETOCLAX IN NEWLY DIAGNOSED AML	Curtis Lachowiez	Received

1610-PS	MRD-GUIDED TREATMENT WITH PEMBROLIZUMAB AND AZACITIDINE IN NPM1-MUTATED AML PATIENTS WITH IMMINENT HEMATOLOGICAL RELAPSE – RESULTS OF THE PROSPECTIVE PEMAZA TRIAL	Madlen Jentzsch	Received

1612-PS	CLINICAL AND MOLECULAR FEATURES AND CLONAL EVOLUTION OF AML WITH KMT2A-PTD: CONCURRENT KMT2A-PTD AND FLT3-ITD MAY REFINE THE ELN 2022 RISK STRATIFICATION	Yi-Tsung Yang	Received

1615-PS	FIRST-STAGE RESULTS OF SELINEXOR COMBINED WITH DECITABINE AND DOSE-ADJUSTED CMG (CYTARABINEÞ+MITOXANTRONE+G-CSF) IN VENETOCLAX-EXPOSED R/R AML: A PROSPECTIVE, SINGLE-ARM, MULTICENTER STUDY	Zi-Yuan Nie	Received

1627-PS	LONG-TERM FOLLOW UP OF ORAL DECITABINE/CEDAZURIDINE (ASTX727) PLUS VENETOCLAX IN NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA: A PHASE 2 STUDY	THURA WIN HTUT	Received

1628-PS	FRONTLINE LOW-INTENSITY VAH ACHIEVES HIGH MRD-NEGATIVE REMISSION RATES IN YOUNGER PATIENTS WITH NEWLY DIAGNOSED AML	Yannan Jia	Received

1633-PS	VENETOCLAX COMBINED WITH MODIFIED INTENSIVE CHEMOTHERAPY IN NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA: A PROPENSITY SCORE-MATCHED ANALYSIS	Qiaoyi Zhou	Received

1634-PS	VENETOCLAX-BASED REGIMENS IMPROVE OUTCOMES IN ACUTE MYELOID LEUKEMIA WITH U2AF1 MUTATION: A REAL-WORLD EFFICACY COMPARATIVE ANALYSIS	Xiangli Chen	Received

1636-PS	SWEET SYNDROME IN ACUTE MYELOID LEUKEMIA: THE THREE-SITE MAYO CLINIC EXPERIENCE	Noah Takacs	Received

1637-PS	A PROSPECTIVE CLINICAL STUDY OF VENETOCLAX PLUS AZACITIDINE AS MAINTENANCE TREATMENT FOR POST-REMISSION ACUTE MYELOID LEUKEMIA	Jinqiang Guo	Received

1639-PS	EVOLVING TREATMENT PATTERNS AND SURVIVAL IN OLDER ADULTS WITH ACUTE MYELOID LEUKEMIA: A POPULATION-BASED STUDY	Brittany Salter	Received

1640-PS	CPX-351 CONFERS SURVIVAL ADVANTAGE AS BRIDGE TO TRANSPLANT IN PATIENTS WITH TP53 MUTATED ACUTE MYELOID LEUKEMIAS THERAPY RELATED AND WITH MYELODISPLASTIC RELATED CHANGES ACHIEVING COMPLETE REMISSION	Elisabetta Todisco	Received

1642-PS	MOLECULAR PATTERNS AND THERAPY-SPECIFIC SURVIVAL OF PATIENTS (PTS) WITH IDH1-MUTATED ACUTE MYELOID LEUKEMIA (AML) WITH RESPECT TO SELF-REPORTED RACE-ETHNICITY	Jennifer Marvin-Peek	Received

1643-PS	INTENSIFIED INDUCTION CHEMOTHERAPY DOES NOT APPEAR TO IMPROVE OUTCOMES FOR PATIENTS WITH UPSTREAM BINDING TRANSCRIPTION FACTOR TANDEM DUPLICATIONS (UBTF-TD) AML: RESULTS FROM THE UK NCRI AML19 TRIAL.	Katie Lewis	Received

1644-PS	GENETIC CHARACTERISTICS AND PROGNOSTIC IMPACT OF MYC AND/OR KMT2A AMPLIFICATION MANIFESTING AS DOUBLE MINUTES IN ACUTE MYELOID LEUKEMIA	Tong Wang	Received

1645-PS	FRONTLINE TREATMENT INTENSITY MAY NOT SIGNIFICANTLY INFLUENCE SURVIVAL IN IDH-MUTATED AML	Tariq Kewan	Received

1646-PS	CLINICAL CHARACTERISTICS AND OUTCOMES OF ACUTE MYELOID LEUKEMIA WITH MECOM REARRANGEMENT: THE THREE-SITE MAYO CLINIC EXPERIENCE	Emma St Martin	Received

1647-PS	EPIDEMIOLOGY, CLINICAL AND BIOLOGICAL CHARACTERISTICS OF UNFIT PATIENTS WITH CBF-AML: RESULTS FROM THE MULTINATIONAL PETHEMA REGISTRY	Evelyn Acuña-Cruz	Received

1648-PS	PERIPHERAL BLOOD FLOW CYTOMETRIC MRD MONITORING IS FEASIBLE FOR AML PATIENTS	Nicholas McCarthy	Received

1651-PS	PATIENT TAILORED AZACITIDINE, VENETOCLAX AND GILTERITINIB TRIPLET THERAPY ACHIEVES DURABLE DISEASE CONTROL AND IMPROVES TOLERABILITY IN FLT3-MUTATED AML	Matilda Arvidsson Kvissberg	Received

1652-PS	ACUTE MYELOID LEUKEMIA WITH KMT2A AMPLIFICATION: A TP53-ALTERNATION ENRICHED, CHROMOANAGENESIS-DRIVEN ENTITY WITH POOR PROGNOSIS	THURA WIN HTUT	Received

1653-PS	OLDER AGE AND STAG2 MUTATIONS PREDICT SUPERIOR POST-TRANSPLANT SURVIVAL IN NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA TREATED WITH HMA-VENETOCLAX	Daniel Daniel.	Received

1658-PS	A PHASE 1/2 STUDY OF THE MENIN INHIBITOR REVUMENIB WITH THE CELMOD MEZIGDOMIDE IN RELAPSED/REFRACTORY KMT2A-REARANGED, NPM1-MUTANT, AND NUP98-REARRANGED ACUTE LEUKEMIAS	Kuo-Kai Chin	Received

1659-PS	EFFECT OF NPM1 MUTATION SUBTYPES AND CO-MUTATION PATTERN IN ACUTE MYELOID LEUKEMIA: A REAL-WORLD ANALYSIS FROM INTERNATIONAL COLLABORATION	Christopher Tham	Received

1666-PS	PATIENT-SPECIFIC DIGITAL PCR MEASURABLE RESIDUAL DISEASE PREDICTS POST-TRANSPLANT OUTCOMES IN MYELODYSPLASIA-RELATED ACUTE MYELOID LEUKEMIA	Caroline Arvé	Received

1668-PS	OUTCOMES OF ACUTE PROMYELOCYTIC LEUKEMIA IN PATIENTS AGED =70 YEARS: A MULTICENTER REAL-WORLD ANALYSIS OF FIRST-LINE ATO-BASED THERAPY	Joana Infante	Received

1677-PS	MALT1 IS REQUIRED FOR IN VIVO CHRONIC LYMPHOCYTIC LEUKEMIA DEVELOPMENT	Nakhle Saba	Received

1678-PS	MATURE B-CELL NEOPLASMS ARE ASSOCIATED WITH A PROLONGED PRECURSOR PHASE CHARACTERIZED BY IGH GENE REPERTOIRE CLONALITY	Pieter Martijn Kolijn	Received

1681-PS	SPATIAL TRANSCRIPTOMICS UNCOVERS A BONE MARROW NICHE SUPPORTING BI-DIRECTIONAL CROSSTALK BETWEEN MONOCYTES/MACROPHAGES AND T-CELL LARGE GRANULAR LYMPHOCYTIC LEUKEMIA CELLS	Mischa Vervoordeldonk	Received

1682-PS	ZNF292 MUTATIONS IMPACT CELL CYCLE DYNAMICS AND COMPROMISE REPLICATION STRESS RESPONSE, DEFINING A POOR PROGNOSTIC SUBGROUP IN CHRONIC LYMPHOCYTIC LEUKEMIA	Alberto Rodríguez-Sánchez	Received

1684-PS	RESTORATION OF MIR-146B IN T-CELL LARGE GRANULAR LYMPHOCYTE LEUKEMIA (T-LGLL): SELECTIVE MOLECULAR REPROGRAMMING TOWARD AN RNA-BASED TARGETED THERAPEUTIC STRATEGY	Elisa Rampazzo	Received

1688-PS	ANALYSIS OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS WITH 11Q DELETION: CLINICOBIOLOGICAL PROFILE AND GENOMIC CHARACTERIZATION BY OGM	Joanna Kamaso	Received

1690-PS	UPDATED RESULTS FROM A PHASE 1B STUDY OF NON-COVALENT PAN-MUTANT BTK INHIBITOR DOCIRBRUTINIB (AS-1763) IN PATIENTS WITH PREVIOUSLY TREATED B-CELL MALIGNANCIES	Nitin Jain	Received

1695-PS	ACALABRUTINIB TREATMENT ACHIEVES DURABLE RESPONSES AND QUALITY OF LIFE IMPROVEMENTS IN OLDER (=80Y) AND/OR FRAIL PATIENTS WITH CLL – FINAL ANALYSIS OF THE CLL-FRAIL TRIAL	Florian Simon	Received

1696-PS	INCIDENCE OF REAL-WORLD CARDIOVASCULAR (CV) EVENTS IN PATIENTS INITIATING COVALENT BTK INHIBITORS (CBTKI) IN 1L CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) IN THE UNITED STATES	David Dingli	Received

1698-PS	REAL-WORLD CARDIOVASCULAR BURDEN, TREATMENT (TX) SEQUENCES, AND CLINICAL OUTCOMES IN PATIENTS INITIATING 1L COVALENT BRUTON´S TYROSINE KINASE INHIBITORS (CBTKIS) IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)	David Dingli	Received

1699-PS	SECONDARY CANCERS IN CLL PATIENTS TREATED WITH TARGETED THERAPIES AT FIRST LINE: A REAL-WORLD COMPARATIVE STUDY	Liron Hofstetter	Received

1700-PS	TREATMENT AND OUTCOMES OF ACCELERATED CHRONIC LYMPHOCYTIC LEUKEMIA/ SMALL LYMPHOCYTIC LYMPHOMA IN THE TARGETED THERAPY ERA	Robert Puckrin	Received

1701-PS	PIRTOBRUTINIB IN TREATMENT-NAÏVE PATIENTS WITH CLL/SLL: POOLED RESULTS FROM BRUIN CLL-313 AND BRUIN CLL-314	Jennifer Woyach	Received

1705-PS	CARDIOVASCULAR TOXICITY OF CONTEMPORARY FIRST-LINE CLL TREATMENT REGIMENS: A POOLED ANALYSIS OF THE GERMAN CLL STUDY GROUP	Florian Simon	Received

1706-PS	QUALITY OF LIFE AND SYMPTOMS WITH FIXED-DURATION ACALABRUTINIB + VENETOCLAX ± OBINUTUZUMAB VS CHEMOIMMUNOTHERAPY IN TREATMENT-NAIVE CHRONIC LYMPHOCYTIC LEUKEMIA: PATIENT-REPORTED OUTCOMES FROM AMPLIFY	Arnon Philip Kater	Received

1707-PS	NEMTABRUTINIB PLUS VENETOCLAX IN PARTICIPANTS WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA: PART 1 OF THE PHASE 3 BELLWAVE-010 STUDY	Paolo Ghia	Received

1708-PS	BRUTON TYROSINE KINASE INHIBITORS NEUTRALIZE THE ADVERSE PROGNOSIS IMPACT OF THE IGLV3-21R110 MUTATION IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA	Juan A. Piñeyroa	Received

1709-PS	MATURE LYMPHOID NEOPLASMS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: RESULTS FROM THE SPANISH MULTICENTER GELLC STUDY	Miguel Argüello de Tomás	Received

1712-PS	REAL WORLD OUTCOMES IN OF 50 PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) TREATED WITH PIRTOBRUTINIB AFTER A COVALENT BRUTON TYROSINE KINASE INHIBITOR AND A BCL2 INHIBITOR: A GIMEMA STUDY	Antonio Cuneo	Received

1713-PS	CORRELATION OF BASELINE CHARACTERISTICS WITH PROGNOSIS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL) TREATED WITH LISAFTOCLAX (APG-2575) IN A PIVOTAL PHASE 2 STUDY	DZ DZ	Received

1714-PS	BTKI-FIRST VERSUS VENETOCLAX-OBINUTUZUMAB-FIRST SEQUENCING IN CLL: A PROPENSITY SCORE-MATCHED TOTAL DISEASE MANAGEMENT ANALYSIS	Shankar Biswas	Received

1717-PS	TREATMENT OUTCOMES WITH FIRST-LINE VENETOCLAX+OBINUTUZUMAB THERAPY IN YOUNGER ADULTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA: A REAL-WORLD, INTERNATIONAL STUDY	Andres Chang	Received

1719-PS	MORPHOLOGY-BASED CELL SORTING USING AI-DRIVEN GHOST CYTOMETRY COMBINED WITH SINGLE-CELL RNA SEQUENCING REVEALS POTENTIAL THERAPEUTIC TARGETS IN CML LEUKEMIC STEM CELLS	Tomoiku Takaku	Received

1720-PS	CITE-SEQ RESOLVES THE LEUKEMIC STEM CELL HIERARCHY AND IMMUNE MICROENVIRONMENT IN CML DISEASE PROGRESSION VIA MACHINE LEARNING MODELS	Kristina Kirschner	Received

1727-PS	EFFICACY OF OLVEREMBATINIB IN PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) WITH PRIOR RESISTANCE TO PONATINIB OR ASCIMINIB AND ASXL1 MUTATIONS	DA DA	Received

1728-PS	THE EFFICACY AND SAFETY OF SWITCHING TO OLVEREMBATINIB OR CONTINUING ORIGINAL TKI THERAPY IN CML-CP PATIENTS TREATED WITH AT LEAST TWO PRIOR TKIS: A PROSPECTIVE, MULTICENTER, CONTROLLED TRIAL	Bingbing Wen	Received

1731-PS	CHARACTERISTICS, TREATMENT AND OUTCOME OF 15 TO 18-YEAR-OLD ADOLESCENTS WITH CHRONIC MYELOID LEUKEMIA (CML): THE EXPERIENCE OF THE INTERNATIONAL REGISTRY OF CHILDHOOD CML (I-CML-PED STUDY)	Frédéric Millot	Received

1733-PS	UPDATED EFFICACY AND SAFETY OF OLVEREMBATINIB (HQP1351) AS SECOND-LINE THERAPY IN PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML)	Daniel Daniel	Received

1736-PS	AGE-STRATIFIED ANALYSIS OF CML-CP IN ADOLESCENT AND YOUNG ADULT (AYA) PATIENTS: A MULTICENTER RETROSPECTIVE STUDY	Jian Huang	Received

1737-PS	HOW MANY CHRONIC-PHASE CML PATIENTS STARTING TYROSINE KINASE INHIBITORS CAN ACHIEVE A PERSISTENT TREATMENT FREE REMISSION AND BE POTENTIALLY CURED? A SINGLE CENTER REAL-LIFE EXPERIENCE.	Mariella D´Adda	Received

1738-PS	THERAPEUTIC STRATEGIES IN ADVANCED OR TKI-REFRACTORY CHRONIC MYELOID LEUKEMIA IN THE ERA OF TYROSINE KINASE INHIBITORS: THE ITALIAN EXPERIENCE	Elisa Quinti	Received

1740-PS	LUSPATERCEPT REDUCES CARDIAC STRESS AND IMPROVES CARDIAC FUNCTION IN TET2-DEFICIENT HFPEF-LIKE MOUSE MODEL: TRANSLATIONAL EVIDENCE FROM PRECLINICAL STUDIES AND PHASE 3 COMMANDS TRIAL	Guillermo Garcia-Manero	Received

1741-PS	DISTINCT IMMUNE AND TRANSCRIPTOMIC PROGRAMS UNDERLIE ESA RESPONSE ACCORDING TO TIMING OF INITIATION IN LOWER-RISK MDS: CORRELATIVE BIOLOGICAL RESULTS OF THE EPO-PRETAR TRIAL	Sophie Park	Received

1746-PS	SINGLE-CELL JOINT PROFILING OF GENOTYPES, EPIGENOME, AND TRANSCRIPTOMES IN TET2-MUTANT CLONAL PRE-LEUKEMIC LESIONS	Masanori Motomura	Received

1750-PS	ASXL1 MUTATIONS ARE A NOVEL RISK FACTOR FOR MAJOR BLEEDING IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES	Elay Amidor	Received

1751-PS	A NEW MURINE CMML-LIKE MODEL: INDUCIBLE HSC-SPECIFIC UTX DELETION MIMICS KEY DISEASE FEATURES	Iryna Kovtun	Received

1755-PS	LONGITUDINAL EVALUATION OF CLONAL HEMATOPOIESIS DYNAMICS IN OVARIAN CANCER PATIENTS DURING PARP INHIBITORS TREATMENT	Elisabetta Todisco	Received

1758-PS	VEXAS PROGNOSTIC SCORE: PERSONALIZED MACHINE LEARNING DERIVED RISK STRATIFICATION MODEL	Tariq Kewan	Received

1760-PS	HYPOMETHYLATING AGENTS WITH OR WITHOUT VENETOCLAX IN TREATMENT-NAÏVE MYELODYSPLASTIC SYNDROMES WITH EXCESS BLASTS: RESULTS FROM A LARGE RETROSPECTIVE COHORT	Alex Bataller	Received

1761-PS	UPDATED PHASE 2 RESULTS OF ELRITERCEPT IN PATIENTS (PTS) WITH TRANSFUSION-DEPENDENT (TD) LOWER-RISK MYELODYSPLASTIC NEOPLASMS (LR-MDS)	María Díez Campelo	Received

1762-PS	A FOUR-GENE STEMNESS SCORE PREDICTS HMA RESISTANCE AND IDENTIFIES RATIONAL 5-AZACITIDINE COMBINATION STRATEGIES IN MYELODYSPLASTIC SYNDROMES	Yu-Hung Wang	Received

1764-PS	SEQUENTIAL THERAPY WITH DECITABINE AND AN XPO-1 INHIBITOR FOLLOWED BY ALLO-HSCT IN PATIENTS WITH MYELODYSPLASTIC NEOPLASM WITH BIALLELIC TP53 INACTIVATION : A PRELIMINARY CASE SERIES.	yanling Ren	Received

1765-PS	IMPACT OF VENETOCLAX BRIDGING ON HEMATOPOIETIC STEM CELL TRANSPLANTATION OUTCOMES IN ADVANCED MYELODYSPLASTIC NEOPLASMS	Yu Wang	Received

1766-PS	HETROMBOPAG FOR THROMBOCYTOPENIA IN LOWER-RISK MYELODYSPLASTIC SYNDROMES: A PROSPECTIVE SINGLE-CENTER STUDY	Rong Fu	Received

1767-PS	CLINICAL AND SURVIVAL IMPACT OF PRIOR IMMUNE AND ONCOLOGIC EXPOSURES IN ZRSR2-MUTATED MYELOID NEOPLASMS AND CCUS	Aref Al-Kali	Received

1768-PS	LONG-TERM RISK OF HEMATOLOGIC MALIGNANCIES IN PATIENTS WITH UNEXPLAINED LEUKOPENIA: A 10-YEAR RETROSPECTIVE GLOBAL COHORT STUDY	Ruyi Huang	Received

1772-PS	IPSS-M OUTPERFORMS IPSS-R IN PREDICTING TIME TO TRANSFUSION DEPENDENCY IN PATIENTS WITH LOW RISK MYELODYSPLASTIC SYNDROMES	Federica Pilo	Received

1774-PS	BORTEZOMIB COMBINED WITH AZACITIDINE AND VENETOCLAX IN HIGH-RISK MYELODYSPLASTIC NEOPLASMS: A SINGLE-CENTER RETROSPECTIVE STUDY	Zi-Yuan Nie	Received

1776-PS	GENOMIC LANDSCAPE AND SURVIVAL OUTCOMES IN MYELODYSPLASTIC SYNDROMES WITH FIBROSIS: A REAL-WORLD ANALYSIS FOR REFINING THE HIGH-RISK PHENOTYPE IN THE IPSS-M ERA	Arda Bayar	Received

1782-PS	THE ROLE OF NEUTROPHIL EXTRACELLULAR TRAPS IN THROMBOSIS OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA	Rong Fu	Received

1783-PS	BONE MARROW BIOPSIES AND PLASMA REVEAL A DISRUPTED ANGIOGENIC LANDSCAPE IN SHWACHMAN–DIAMOND SYNDROME PATIENTS	Jennifer Romagnoli	Received

1784-PS	DISSOCIATION BETWEEN VISCERAL AND SKELETAL DISEASE IN MILD GENOTYPES OF GAUCHER DISEASE TYPE 1	Irene Serrano-Gonzalo	Received

1786-PS	EFFICACY AND SAFETY OF SWITCHING TO ORAL HSK39297 MONOTHERAPY IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA PATIENTS WITH PERSISTENT ANEMIA DESPITE ANTI-C5 THERAPY: A PHASE 3 STUDY (HSK39297-302)	Gaixiang Xu	Received

1788-PS	IPTACOPAN DEMONSTRATES SUSTAINED EFFICACY AND SAFETY IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: UP TO 4 YEARS OF FOLLOW-UP IN PATIENTS FROM APPLY, APPOINT AND ROLL-OVER EXTENSION PROGRAM	Régis Peffault de Latour	Received

1789-PS	HEMATOLOGIC MANIFESTATIONS OF NON-TINF2 AUTOSOMAL DOMINANT TELOMERE BIOLOGY DISORDERS	Emma Groarke	Received

1790-PS	ROMIPLOSTIM IN CHEMORADIOTHERAPY-ASSOCIATED APLASTIC ANAEMIA: A PROSPECTIVE SINGLE-ARM STUDY	qi wang	Received

1793-PS	MOMELOTINIB IN VEXAS SYNDROME: A PRELIMINARY REPORT EVALUATION OF SAFETY AND EFFECTIVENESS	Elisa Diral	Received

1795-PS	TRANSPLANT OUTCOMES FOR PATIENTS WITH SEVERE ACQUIRED APLASTIC ANEMIA OVER THE AGE OF 40 USING BUSULFAN, FLUDARABINE, REDUCED-DOSE CYCLOPHOSPHAMIDE, AND ANTI-THYMOCYTE GLOBULIN CONDITIONING REGIMEN.	Fan Lin	Received

1798-PS	ANDROGEN TREATMENT FOR TELOMERE BIOLOGY DISORDERS: LONG-TERM RESULTS FROM A RETROSPECTIVE REGISTRY ANALYSIS	Fabian Beier	Received

1799-PS	COMPARISON OF EFFICACY BETWEEN INTENSIFIED IMMUNOSUPPRESSION COMBINED WITH UMBILICAL CORD BLOOD THERAPY AND ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH SAA AGED OVER 40 YEARS	Fang Zhou	Received

1801-PS	CLINICAL CHARACTERISTICS AND HEMATOPOIETIC STEM CELL TRANSPLANTATION PROGNOSIS IN SHWACHMAN-DIAMOND SYNDROME: A REPORT OF 116 CASES FROM A SINGLE CHINISE CENTER	Jiao Chen	Received

1803-PS	MANAGEMENT OF CARDIOVASCULAR RISK IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATED WITH IPTACOPAN	Isla Storey	Received

1804-PS	CLINICAL HETEROGENEITY AND LONG-TERM OUTCOMES OF CHILDHOOD AUTOIMMUNE NEUTROPENIA: ? 20-YEAR COHORT STUDY	Alexandros Makis	Received

1811-PS	REDUCED DOSE OF GLUCOCORTICOIDS FOR PROPHYLAXIS OF SERUM SICKNESS IN APLASTIC ANEMIA POST ANTI-HUMAN T-LYMPHOCYTE GLOBULIN (ATG) TREATMENT: A RANDOMIZED TRIAL	Guangsheng He	Received

1812-PS	LATE AND SUSTAINED RESPONSES TO IMMUNOSUPPRESSIVE THERAPY PLUS ROMIPLOSTIM IN TREATMENT-NAÏVE APLASTIC ANEMIA	Kohei Hosokawa	Received

1816-PS	TEMPI SYNDROME PATIENT MONOCLONAL ANTIBODIES ARE PATHOGENIC DRIVERS OF ERYTHROPOIETIN PRODUCTION	David Sykes	Received

1818-PS	IRF2 IS AN ESSENTIAL TRANSCRIPTION FACTOR WITH PATHOGENIC AND PROGNOSTIC IMPACT IN MULTIPLE MYELOMA	Nahia Gomez-Echarte	Received

1819-PS	CIRCULATING TUMOR CELLS AND PLASMA MYD88 ?AF AS PROGNOSTIC MARKERS FOR STAGING AND IBRUTINIB RESPONSE IN WALDENSTRÖM MACROGLOBULINEMIA	Tina Bagratuni	Received

1820-PS	IMMUNE EXCLUSION IN EXTRAMEDULLARY MYELOMA VERSUS SOLITARY BONE PLASMACYTOMA DEPICTED VIA IMAGING MASS CYTOMETRY	Maximilian Steinhardt	Received

1823-PS	IDENTIFICATION OF PRECURSOR CELLS OF EXTRAMEDULLARY DISEASE IN MULTIPLE MYELOMA AND THEIR THERAPEUTIC TARGETS BY INTEGRATED OMICS ANALYSIS	Shojiro Haji	Received

1824-PS	HIGH-RISK GENOMIC FEATURES PREDICTING EXTRAMEDULLARY PROGRESSION IN MULTIPLE MYELOMA WITH PARASKELETAL PLASMACYTOMAS	Martin Stork	Received

1826-PS	LOSS OF LET-7C INCURRED BY PROMOTER HYPERMETHYLATION DRIVES MM DEVELOPMENT	Yonghuai Feng	Received

1827-PS	INTEGRATED SINGLE-CELL AND IMMUNE PROFILING IDENTIFIES DETERMINANTS OF MRD OUTCOME IN MULTIPLE MYELOMA	Anna Maria Corsale	Received

1834-PS	TARGETING THE DNA DAMAGE RESPONSE IN DORMANT MYELOMA CELLS	Abigail Foston	Received

1836-PS	EXPLORING THE CELL-FREE TRANSCRIPTOME AS A BIOMARKER SOURCE IN IGM GAMMOPATHIES: AN ANALYSIS FROM THE "BIO-WM" TRIAL OF THE FONDAZIONE ITALIANA LINFOMI (FIL)	Philippe Decruyenaere	Received

1844-PS	DR4/DR5 AGONISTS SYNERGIZE WITH BH3 MIMETICS VENETOCLAX TO PROMOTE APOPTOSIS IN MULTIPLE MYELOMA	Yiwen Jiang	Received

1846-PS	MONOCLONAL LIGHT CHAIN N-GLYCOSYLATION IS A RISK FACTOR FOR NEWLY DIAGNOSED MULTIPLE MYELOMA PROGRESSION	Min Yang	Received

1853-PS	CD38 EXPRESSION IN PARASKELETAL AND EXTRAMEDULLARY PLASMACYTOMAS IN MULTIPLE MYELOMA: ASSESSMENT IN RELATION TO ANTI-CD38 THERAPY	Martin Stork	Received

1856-PS	PREDICTIVE IMMUNE BIOMARKERS OF RESPONSE TO BISPECIFIC ANTIBODIES IN TRIPLE-CLASS REFRACTORY MULTIPLE MYELOMA PATIENTS	Elena Tofacchi	Received

1858-PS	THE NOVEL INDIRUBIN DERIVATIVE I3MV-8B AUGMENTS ANTI-CD38 MONOCLONAL ANTIBODY THERAPY IN MULTIPLE MYELOMA: A DUAL MECHANISM INVOLVING NK CELL IMMUNOMODULATION AND INCREASED CD38 EXPRESSION	Xiaoyu Zhang	Received

1859-PS	REVERTING OF MICROENVIRONMENTAL INVASIVENESS AND IMMUNESUPPRESSION THROUGH A NOVEL ANTI-CD138 ANTIBODY NANOPLATFORM FOR TARGETING OF MULTIPLE MYELOMA	Carmela Tangredi	Received

1861-PS	EXPLORING THE EPIGENETIC ROLE OF PRDM1: A TARGET FOR IMID-RESISTANT MULTIPLE MYELOMA?	Sophie Ball	Received

1862-PS	BELANTAMAB MAFODOTIN, BORTEZOMIB, AND DEXAMETHASONE VS DARATUMUMAB, BORTEZOMIB, AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: UPDATED 4-YEAR RESULTS OF THE PHASE 3 DREAMM-7 TRIAL	Vania Hungria	Received

1866-PS	FIRST INTERIM ANALYSIS OF DOMAIN 1 – TECLISTAMAB (TEC) AND TALQUETAMAB (TAL) OF THE CENTRALIZED PLATFORM FOR FUNCTIONAL HIGH-RISK MULTIPLE MYELOMA –– ZEPFHR STUDY AMARC 24-01.	Sueh-Li Lim	Received

1867-PS	DISTINCT MUTATIONAL NETWORK ARCHITECTURE DRIVES RACIAL GENOMIC DISPARITIES IN MULTIPLE MYELOMA RATHER THAN INDIVIDUAL MUTATIONS	Amin Turki	Received

1872-PS	SERIAL CIRCULATING TUMOR PLASMA CELL MONITORING DYNAMICALLY STRATIFIES PROGRESSION RISK IN A SCREENED SMOLDERING MULTIPLE MYELOMA COHORT	Sigrún Thorsteinsdóttir	Received

1876-PS	CIBMTR REAL-WORLD OUTCOMES OF FRAIL PATIENTS TREATED WITH IDECABTAGENE VICLEUCEL	Omar Nadeem	Received

1877-PS	BELANTAMAB MAFODOTIN, POMALIDOMIDE, AND DEXAMETHASONE (BPD) DEMONSTRATED IMPROVED OUTCOMES AS SECOND-LINE THERAPY VS POMALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE (PVD) IN PATIENTS WITH MULTIPLE MYELOMA	Meral Beksaç	Received

1878-PS	MRD-GUIDED MAINTENANCE THERAPY WITH BELANTAMAB MAFODOTIN AND LENALIDOMIDE AFTER AUTO-HCT IN NEWLY DIAGNOSED MULTIPLE MYELOMA: INTERIM ANALYSIS	Yosra Aljawai	Received

1879-PS	A REAL-WORLD STAGING SYSTEM FOR MYELOMA INTEGRATING AGE, PS, RENAL FUNCTION AND THE NEW HIGH-RISK IMS/IMWG SYSTEM OUTPERFORMS EXISTING MODELS: A MACHINE LEARNING STUDY BY THE GREEK MYELOMA STUDY GROUP	Eirini Katodritou	Received

1880-PS	REAL-WORLD OUTCOMES OF ZEVORCABTAGENE AUTOLEUCEL, A FULLY HUMAN BCMA-TARGETED CAR-T THERAPY, IN 136 PATIENTS WITH MULTIPLE MYELOMA (MM): A MULTICENTER EXPERIENCE FROM CHINA	Wanyan Ouyang	Received

1881-PS	SAFETY AND EFFICACY OF APONERMIN-BASED CHEMOTHERAPY AS BRIDGING THERAPY BEFORE CAR-T CELL TREATMENT IN RELAPSED/REFRACTORY MULTIPLE MYELOMA	Yi Wang	Received

1882-PS	ESTABLISHING FULLY OUTPATIENT CILTACABTAGENE AUTOLEUCEL FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA: FIRST CLINICAL DATA FROM EUROPE	Tim Richardson	Received

1884-PS	IMPACT OF IMMUNOMODULATORY CONTAINING HOLDING THERAPY REGIMENS ON OUTCOMES IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS RECEIVING CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY	Veena Krishnan	Received

1892-PS	SAFETY AND EFFICACY OF FIRST-LINE SELINEXOR PLUS BORTEZOMIB, LENALIDOMIDE AND DEXAMETHASONE (XVRD) IN HIGH RISK NEWLY DIAGNOSED MULTIPLE MYELOMA: A MULTI-CENTER, SINGLE-ARM, PHASE IB/II TRIAL	Zhongjun Xia	Received

1893-PS	PHASE 2 STUDY OF APONERMIN + BISPECIFIC ANTIBODIES IN PATIENTS(PTS) WITH RELAPSED/REFRACTORY MULTIPLE : A PROSPECTIVE SINGLE-ARM STUDY	Aijun Liu	Received

1895-PS	NEXT-GENERATION FLOW CYTOMETRY-BASED DETECTION OF CIRCULATING PLASMA CELLS PREDICTS CYTOGENETIC HIGH-RISK DISEASE AND DEPTH OF RESPONSE IN NEWLY DIAGNOSED MULTIPLE MYELOMA	Neha Singh	Received

1898-PS	LOW-DOSE VENETOCLAX PLUS WEEKLY DEXAMETHASONE IN T(11;14)-POSITIVE RELAPSED/REFRACTORY MULTIPLE MYELOMA: FINAL EFFICACY AND SAFETY RESULTS FROM THE PHASE II VICTORIA STUDY	Astrid Hundebøll Torpe	Received

1900-PS	PATTERNS OF MGUS IN MEN AND WOMEN PARTICIPATING IN THE SCREENED POPULATION-BASED ISTOPMM STUDY: EARLIER ONSET OR ACCELERATED M PROTEIN INCREASE IN MEN?	Anna Richardson	Received

1901-PS	TRENDS IN HOSPITALIZATION FOR MULTIPLE MYELOMA IN SPAIN (2016–2023): RISING HEALTHCARE BURDEN AND DECLINING IN-HOSPITAL MORTALITY	Ane Brieva Lopez	Received

1903-PS	DYNAMICS OF SARCOPENIA PARAMETERS PREDICT SURVIVAL IN OLDER PATIENTS WITH MULTIPLE MYELOMA	Febe Smits	Received

1905-PS	MRD-NEGATIVE RESPONSE AFTER VRD INDUCTION, HD-ASCT AND VRD CONSOLIDATION IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: PHASE 2 REMNANT STUDY WITH BROAD INCLUSION CRITERIA	Frida Bugge Askeland	Received

1906-PS	IMPACT OF BASELINE BONE MARROW IMMUNE CELL SUBSETS ON OUTCOMES IN MULTIPLE MYELOMA TREATED WITH DARATUMUMAB	Chunrui Li	Received

1908-PS	MRD–PET DISCORDANCE REVEALS COMPARTMENTALIZED DISEASE IN MULTIPLE MYELOMA: PROGNOSTIC IMPLICATIONS FROM 1138 PAIRED ASSESSMENTS	Max Mendez-Lopez	Received

1909-PS	BLEEDING EVENTS IN PATIENTS WITH MULTIPLE MYELOMA TREATED WITH BCMA-DIRECTED CAR T-CELLTHERAPY: A SYSTEMATIC REVIEW OF CLINICAL TRIALS	Pedro Henrique Fernandes do Carmo Las Casas	Received

1910-PS	DYNAMIC MONITORING OF CIRCULATING PLASMA CELLS IN NEWLY DIAGNOSED MULTIPLE MYELOMA: UPDATED RESULTS FROM A PROSPECTIVE MULTICENTER STUDY IN CHINA	Qun Li	Received

1911-PS	OUTCOMES OF THERAPY AFTER PROGRESSION ON TALQUETAMAB IN PATIENTS WITH HEAVILY PRETREATED RELAPSED REFRACTORY MULTIPLE MYELOMA	Gannon Ray	Received

1912-PS	HIGHER INCIDENCE OF SECONDARY EXTRAMEDULLARY DISEASE AFTER ANTI-CD38 THERAPY IN MULTIPLE MYELOMA: A CZECH NATIONAL REGISTRY REAL-WORLD MATCHED STUDY	Martin Stork	Received

1913-PS	ETENTAMIG IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) WITH PRIOR EXPOSURE TO B-CELL MATURATION ANTIGEN (BCMA)-TARGETED THERAPY	Saurabh Chhabra	Received

1922-PS	THE IMS-IMWG 2025 GENOMIC CLASSIFICATION IDENTIFIES HIGH-RISK MULTIPLE MYELOMA PATIENTS IN THE ERA OF BCMA-DIRECTED CAR-T CELL THERAPY.	Almudena Zaratiegui	Received

1923-PS	DOES DOSE FRACTIONATION IMPROVE TOLERABILITY IN AUTOLOGOUS STEM CELL TRANSPLANTATION FOR MULTIPLE MYELOMA? A PROPENSITY SCORE–MATCHED ANALYSIS	Ceren Uzunoglu Güren	Received

1924-PS	SEQUENTIAL TRANSITION TO ALL-ORAL IRD THERAPY FOLLOWING DARA-BASED INDUCTION IN TRANSPLANT-INELIGIBLE NDMM: DEEPENING RESPONSE AND MRD NEGATIVITY	Xibin Xiao	Received

1926-PS	RENAL OUTCOMES BY PALLADINI STAGE AND RESPONSE CRITERIA IN SYSTEMIC AL AMYLOIDOSIS TREATED WITH FIRST-LINE DARA-CYBORD: REAL-WORLD EXPERIENCE FROM A SINGLE AMYLOIDOSIS REFERRAL CENTER	James Di Palma-Grisi	Received

1930-PS	WHOLE-BODY DIFFUSION-WEIGHTED MRI VERSUS FDG PET/CT IN MULTIPLE MYELOMA: A PRISMA-BASED SYSTEMATIC REVIEW HIGHLIGHTING DISEASE STAGING AND CLINICAL VALUE IN GLOBAL HEMATOLOGY AND LOW-RESOURCE SETTINGS	KALYSTA BORGES	Received

1931-PS	EFFICACY AND SAFETY OF IXAZOMIB PLUS REDUCED-DOSE LENALIDOMIDE VERSUS IXAZOMIB MONOTHERAPY AS MAINTENANCE IN HIGH-RISK NEWLY DIAGNOSED MULTIPLE MYELOMA: AN INTERIM ANALYSIS OF A PROSPECTIVE STUDY	Xuzhao Zhang	Received

1933-PS	OVERALL SURVIVAL OF ANTI-BCMA THERAPIES: INDIRECT COMPARISON OF BELANTAMAB MAFODOTIN/BORTEZOMIB/DEXAMETHASONE (BVD) VS TECLISTAMAB/DARATUMUMAB (TEC-DARA) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)	Joshua Richter	Received

1934-PS	PROGRESSION OF DISEASE WITHIN 24 MONTHS (POD24) IS AN INDEPENDENT PROGNOSTIC FACTOR FOR SURVIVAL IN NEWLY DIAGNOSED PATIENTS WITH WALDENSTRÖM MACROGLOBULINEMIA TREATED WITH DRC	Maria Gavriatopoulou	Received

1937-PS	GAPS IN ACCESS TO CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY POST LEUKAPHERESIS: WAITING TIME AND TREATMENT PATTERNS IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: REAL-WORLD EVIDENCE FROM US CLAIMS	Molly Purser	Received

1938-PS	DEVELOPMENT AND PRELIMINARY CONTENT VALIDATION OF THE PROSIM-Q: A PATIENT-REPORTED OCULAR SYMPTOM AND IMPACT QUESTIONNAIRE FOR ONCOLOGY TRIALS	Farrah Pompilus	Received

1940-PS	BCMA-DIRECTED CAR-T CELL THERAPY IN MULTIPLE MYELOMA PATIENTS REQUIRING HEMODIALYSIS (HD): A MULTICENTER REAL-WORLD ANALYSIS	James Di Palma-Grisi	Received

1942-PS	DUAL-RISK ADJUSTED THERAPY FOR ELDERLY PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA BASED ON DYNAMIC FRAILTY ASSESSMENT AND R-ISS: A PROSPECTIVE CLINICAL TRIAL	Hua Xue	Received

1943-PS	EFFICACY OF VENETOCLAX-BASED THERAPY IN T(11;14)–POSITIVE RELAPSED/REFRACTORY MULTIPLE MYELOMA: A SYSTEMATIC REVIEW AND META-ANALYSIS.	Vasu Malhotra	Received

1944-PS	REAL-WORLD IMPACT OF ANTI-CD38 MONOCLONAL ANTIBODY THERAPY AND HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PRIMARY PLASMA CELL LEUKEMIA: A SINGLE-CENTER STUDY	Vincent Luong	Received

1952-PS	SUTIMLIMAB IN PATIENTS WITH COLD AGGLUTININ DISEASE AND PRIOR RITUXIMAB EXPOSURE: A POST-HOC ANALYSIS OF THE PHASE 3 CADENZA STUDY	Marc Michel	Received

1954-PS	EXPRESSION OF JAK2V617F IN ERYTHROBLASTIC ISLAND MACROPHAGES CONTRIBUTES TO THE PATHOGENESIS OF POLYCYTHEMIA VERA	xiuli An	Received

1956-PS	DISCOVERY OF A FIRST-IN-CLASS ALLELE-SELECTIVE XNAZYME THAT KNOCKS DOWN MUTANT JAK2 V617F MRNA IN A MOUSE MODEL OF POLYCYTHEMIA VERA	Joel Kaye	Received

1957-PS	METABOLIC REWIRING BY ONCOGENIC JAK2V617F CREATES A GLUCOSE TRANSPORT VULNERABILITY IN MYELOPROLIFERATIVE NEOPLASMS	Julian Baumeister	Received

1960-PS	RUXOLITINIB COMBINED WITH HOMOHARRINGTONINE SYNERGISTICALLY TARGETS CDK2 IN RUXOLITINIB-RESISTANT MYELOFIBROSIS AND SECONDARY ACUTE MYELOID LEUKEMIA	Jian Huang	Received

1961-PS	AI-QUANTIFIED BONE MARROW FIBROSIS AND MEGAKARYOCYTE FEATURES CORRELATE WITH DRIVER VAF AND OUTCOMES IN THE MOST MPN STUDY	Len Brandes	Received

1965-PS	JAK2 E837K. FIRST CHARACTERIZATION OF A NOVEL JH2-JH1 INTERDOMAIN LINKER MUTATION DRIVING STAT ACTIVATION AND METABOLIC REPROGRAMMING IN POST-POLYCYTHEMIA VERA MYELOFIBROSIS	Gloria Pasqualini	Received

1968-PS	MACHINE LEARNING-DERIVED CIRCULATING INFLAMMATORY PROTEIN SIGNATURE FOR RISK STRATIFICATION IN SYSTEMIC MASTOCYTOSIS	Jennifer Marvin-Peek	Received

1970-PS	IDENTIFICATION OF BIOMARKERS TO PREDICT DISEASE PROGRESSION VIA MOLECULAR ANALYSIS OF PATIENTS (PTS) WITH LOW-RISK MYELOFIBROSIS (MF) ENROLLED IN THE MOST STUDY	Naveen Pemmaraju	Received

1973-PS	BEYOND JAK INHIBITION: WT1 AS A BIOMARKER AND THERAPEUTIC TARGET IN HIGH-RISK PRIMARY MYELOFIBROSIS	Jian Huang	Received

1976-PS	FUNCTIONAL ANALYSIS OF A NOVEL GERMLINE JAK2 VARIANT ASSOCIATED WITH THROMBOCYTOSIS	Katerina Kuželová	Received

1979-PS	THE GENOMIC LANDSCAPE OF MYELOPROLIFERATIVE NEOPLASMS (MPNS) BY DISEASE SUBTYPE: BEYOND JAK2 V617F, CALR, AND MPL	Abhay Singh	Received

1980-PS	THE TUMOR-ASSOCIATED FIBROBLAST BIOMARKER PRO-C6 IS ELEVATED IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS	Caroline Norup Bistrup	Received

1982-PS	COEXISTENCE OF SF3B1 AND DRIVER MUTATIONS IN MYELOID NEOPLASMS: A CONTINUOUS CLINICAL-MOLECULAR SPECTRUM	Jose Antonio Farah Gamarra	Received

1984-PS	FEDRATINIB + NIVOLUMAB COMBINATION IMPROVES OUTCOMES IN MYELOFIBROSIS PATIENTS RESISTANT OR SUBOPTIMALLY RESPONDING TO JAK-INHIBITOR THERAPY – RESULTS FROM THE FRACTION TRIAL (IKF051)	Susanne Isfort	Received

1985-PS	INVESTIGATIONAL PIM1 INHIBITOR NUVISERTIB IN COMBINATION WITH MOMELOTINIB SHOWED PROMISING CLINICAL ACTIVITY IN PATIENTS WITH MYELOFIBROSIS AND ANEMIA: DATA FROM AN ONGOING GLOBAL PHASE 1/2 STUDY	James McCloskey	Received

1989-PS	QRISK3 SCORE REINFORCES ITS ROLE IN MPNWITH THE STANDARD 60-YEAR CUT-OFF AND PROVIDES ADDITIVE PROGNOSTIC VALUE TO REVISED-IPSET IN ESSENTIAL THROMBOCYTHEMIA	Andrea Duminuco	Received

1990-PS	A NOVEL JAK2 INHIBITOR OB756 FOR POLYCYTHEMIA VERA WITH SPLENOMEGALY: A PHASE IB/II, MULTICENTER STUDY	Jian Huang	Received

1992-PS	ESTIMATED PULSE WAVE VELOCITY (EPWV) INDEPENDENTLY PREDICTS CARDIOVASCULAR EVENTS IN BCR::ABL1-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS	Alessandro Costa	Received

1993-PS	INDIRECT TREATMENT COMPARISON: GECACITINIB VS. PACRITINIB, MOMELOTINIB, AND FEDRATINIB IN FIRST-LINE MYELOFIBROSIS	Yi Zhang	Received

1997-PS	UPDATE FROM THE PHASE 2 RESTORE TRIAL OF ELRITERCEPT IN PATIENTS WITH MYELOFIBROSIS (MF) RECEIVING RUXOLITINIB	Ciro Rinaldi	Received

2000-PS	LONG-TERM HEMATOLOGIC AND MOLECULAR RESPONSE TO ROPEGINTERFERON ALFA-2B AND CLINICAL VALIDATION OF Q-PCR FOR LOW-LEVEL JAK2 MONITORING IN POLYCYTHEMIA VERA	Sung-Eun Lee	Received

2002-PS	DYNAMIC CYTOPENIA PATTERNS IN MYELOFIBROSIS: A REAL-WORLD ANALYSIS FROM THE ERNEST-3 REGISTRY	Tiziano Barbui	Received

2003-PS	INTEGRATED CLINICAL AND MOLECULAR REGISTRY WITH LONGITUDINAL BIOREPOSITORY IN SYSTEMIC MASTOCYTOSIS: A SINGLE-INSTITUTION COHORT	Jennifer Marvin-Peek	Received

2004-PS	TP53 MUTATION CHARACTERIZES DIRECT AND ASXL1 AND EZH2 INDIRECT (VIA MYELOFIBROSIS) ET TO AML TRANSITION	Merry Nakhleh	Received

2005-PS	SHORESPAN-017: A PHASE 3 EXTENSION STUDY EVALUATING THE SAFETY OF CONTINUED BOMEDEMSTAT IN PARTICIPANTS WITH ESSENTIAL THROMBOCYTHEMIA	Jennifer Adam	Received

2006-PS	A PHASE II STUDY OF F182112 IN COMBINATION WITH DARATUMUMAB AND POMALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA	Tangrong Liu	Received

2007-PS	PHENOTYPE-SPECIFIC CHOLESTEROL ELEVATION FOLLOWING RUXOLITINIB IN MPN: ENRICHMENT IN POLYCYTHAEMIA VERA	Elena Torre	Received

2008-PS	ROMACICLIB (RVU120), A SELECTIVE CDK8/19 INHIBITOR, AS MONOTHERAPY OR IN COMBINATION WITH RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS: UPDATED RESULTS FROM THE PHASE II POTAMI-61 STUDY	Tomasz Sacha	Received

2011-PS	CLINICAL CHARACTERISTICS, MOLECULAR LANDSCAPE AND OUTCOMES OF NON-CMML MDS/MPN OVERLAP SYNDROMES	Yael Morgenstern	Received

2014-PS	COMPARISON OF JAK2-MUTATED ESSENTIAL THROMBOCYTHAEMIA AND POLYCYTHAEMIA VERA IN ADOLESCENTS AND YOUNG ADULTS: CHARACTERISTICS, VASCULAR EVENTS AND LONG-TERM OUTCOME	Maria Georgiou	Received

2015-PS	PEMBROLIZUMAB IN CHILDREN AND YOUNG ADULTS WITH HIGH-RISK CLASSIC HODGKIN LYMPHOMA WITH SLOW EARLY RESPONSE TO FRONT-LINE CHEMOTHERAPY: UPDATED RESULTS FROM KEYNOTE-667	Jennifer Adam	Received

2016-PS	PROGNOSTIC IMPACT OF METABOLIC TUMOR VOLUME AFTER TWO CYCLES OF ABVD IN EARLY-STAGE FAVORABLE HODGKIN LYMPHOMA: A POST-HOC ANALYSIS OF THE GHSG HD16 TRIAL	Justin Ferdinandus	Received

2017-PS	COMPARISON OF LONG-TERM EFFICACY BETWEEN THE BRECADD AND N+AVD REGIMENS IN ADVANCED-STAGE HODGKIN LYMPHOMA: A MATCHING-ADJUSTED INDIRECT TREATMENT COMPARISON OF THE HD21 AND SWOG S1826 TRIALS	Alexa Molinari	Received

2018-PS	FIVE-YEAR CONDITIONAL RELATIVE SURVIVAL UP TO 20 YEARS POST-DIAGNOSIS IN ADULT PATIENTS WITH HODGKIN LYMPHOMA: PERSISTENT EXCESS MORTALITY IN OLDER PATIENTS— A CONTEMPORARY, NATIONWIDE DUTCH STUDY	Fer de Wit	Received

2019-PS	PREMENOPAUSAL WOMEN WITH CLASSIC HODGKIN LYMPHOMA HAVE SUPERIOR LYMPHOMA-SPECIFIC SURVIVAL COMPARED TO MEN	Johanna Borg Bruchfeld	Received

2021-PS	PHARMACOKINETICS, EFFICACY, AND SAFETY OF SUBCUTANEOUS PEMBROLIZUMAB IN RELAPSED OR REFRACTORY CLASSIC HODGKIN LYMPHOMA (CHL) OR PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMBCL): A PHASE 2 STUDY	Jennifer Adam	Received

2022-PS	LATE CARDIOPULMONARY MORBIDITY IN THE PATIENTS WITH HODGKIN LYMPHOMA: A NATIONWIDE REGISTRY STUDY	Noora Hannuksela	Received

2023-PS	SURFACE TUMOR EXTENSION (STE) EXTRACTED FROM BASELINE PET/CT PREDICTS LONG-TERM ABVD THERAPY OUTCOME IN ADVANCED-STAGE HODGKIN LYMPHOMA WITH A NEGATIVE INTERIM PET.	Andrea Gallamini	Received

2026-PS	HEART FAILURE SURVIVAL IN PATIENTS WITH PRIOR HODGKIN LYMPHOMA: INCREASED ALL-CAUSE BUT NOT CARDIOVASCULAR MORTALITY	Sissel Johanne Godtfredsen	Received

2029-PS	INCIDENCE AND SURVIVAL OF CLASSIC HODGKIN LYMPHOMA: AN ENGLAND-WIDE COHORT STUDY FROM THE UNCOVER STUDY GROUP, 2014-2022	Sidhant Seth	Received

2030-PS	MINI-A(B)VD AS FIRST-LINE TREATMENT FOR OLDER PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA: RESULTS FROM A MULTICENTRE RETROSPECTIVE STUDY	Silvia Ferrari	Received

2031-PS	NON-INVASIVE PROGNOSTICATION AND MINIMAL RESIDUAL DISEASE (MRD) MONITORING OF MYD88L265P IN IGM-GAMMOPATHIES: INSIGHT FROM THE "BIO-WM" PROSPECTIVE TRIAL OF THE FONDAZIONE ITALIANA LINFOMI (FIL)	Simone Ferrero	Received

2034-PS	REAL WORLD ANALYSIS OF PIRTOBRUTINIB IN RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA (RRMCL) – AN ANALYSIS FROM THE EUROPEAN MANTLE CELL LYMPHOMA-REGISTRY (EMCL-R)	Linda Simon	Received

2036-PS	CONTEMPORARY TREATMENT AND SURVIVAL OUTCOMES IN 1,101 FOLLICULAR LYMPHOMA PATIENTS INCLUDED IN REALYSA, A PROSPECTIVE REAL-WORLD MULTICENTRIC LYSA COHORT	Anne Loap	Received

2037-PS	RISK-ADAPTED MANAGEMENT WITH OBINUTUZUMAB AND ORELABRUTINIB WITH OR WITHOUT LENALIDOMIDE IN UNTREATED MARGINAL ZONE LYMPHOMA: FIRST REPORT OF A PROSPECTIVE, PHASE II, MULTI-CENTRE (MAGIC) STUDY	Yujia Huo	Received

2039-PS	TREATMENT AND PROGNOSIS OF PRIMARY OCULAR ADNEXAL MUCOSA-ASSOCIATED LYMPHOID TISSUE LYMPHOMA IN CHINA: A COMPREHENSIVE NATIONAL RETROSPECTIVE STUDY OF 805 PATIENTS	Liang Wang	Received

2041-PS	IMPACT OF RECENT BENDAMUSTINE (BENDA) EXPOSURE IN PATIENTS (PTS) WITH RELPASED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL) TREATED WITH ODRONEXTAMAB (ODRO) IN THE PHASE 2 ELM-2 STUDY	Gloria Iacoboni	Received

2044-PS	HOSPITAL BURDEN OF CAR T INFUSION OF PATIENTS WITH FOLLICULAR LYMPHOMA OR MANTLE CELL LYMPHOMA IN FRANCE: A NATIONWIDE RETROSPECTIVE STUDY	Florian Colrat	Received

2049-PS	ZANUBRUTINIB PLUS RITUXIMAB AS FRONT-LINE TREATMENT FOR MUCOSA-ASSOCIATED LYMPHOID TISSUE (MALT) LYMPHOMA: A SINGLE-ARM, PHASE II STUDY (ZAMA)	Qingqing Cai	Received

2053-PS	PRELIMINARY RESULTS OF ORELABRUTINIB FOLLOWED BY RESPONSE-ADAPTED ULTRA-LOW-DOSE 4GY RADIOTHERAPY AS FIRST-LINE TREATMENT FOR LOCALIZED MALT LYMPHOMA: A PROSPECTIVE, OPEN-LABEL, PHASE II STUDY	Yizhen Liu	Received

2055-PS	MANAGEMENT AND OUTCOMES OF FOLLICULAR LYMPHOMA (FL) WITH GASTROINTESTINAL (GI) INVOLVEMENT: SPANISH REAL WORLD EXPERIENCE FROM GELTAMO GROUP	Paola Villafuerte Gutierrez	Received

2057-PS	CLINICAL CHARACTERISTICS AND TREATMENT PATTERNS IN PATIENTS WITH FOLLICULAR LYMPHOMA MANAGED WITH LONG-TERM INITIAL WATCH-AND-WAIT: A DANISH NATIONWIDE POPULATION-BASED STUDY	Ruth Salim Raaschou	Received

2058-PS	MACHINE LEARNING-BASED BODY COMPOSITION ANALYSIS FOR RISK STRATIFICATION IN MANTLE CELL LYMPHOMA (MCL) WITH NEED FOR SYSTEMIC TREATMENT	Marie-Kristin Tilch	Received

2059-PS	EFFICACY AND SAFETY OF NEMTABRUTINIB IN RELAPSED OR REFRACTORY MARGINAL ZONE LYMPHOMA: COHORT F OF THE PHASE 2 BELLWAVE-003 STUDY	Alessandra Tucci	Received

2060-PS	LONG TERM FOLLOW-UP OF THE FIRST REAL-LIFE SERIES OF OBINUTUZUMAB-CHEMOTHERAPY COMBINATIONS IN FRONT-LINE TREATMENT OF FOLLICULAR LYMPHOMA: A STUDY OF KROHEM	Sandra Bašic Kinda	Received

2065-PS	SELINEXOR IN COMBINATION WITH THE R-CHOP REGIMEN AS A FIRST-LINE TREATMENT FOR PATIENTS WITH HIGH-RISK GCB-SUBTYPE DIFFUSE LARGE B-CELL LYMPHOMA: A MULTI-CENTER, SINGLE-ARM, PHASE II STUDY	Zhiming Li	Received

2066-PS	RADIOTHERAPY AS BRIDGING, SALVAGE OR CONSOLIDATION STRATEGY IN CAR-T–TREATED LYMPHOMA PATIENTS: INSIGHTS FROM THE FRENCH DESCAR-T REGISTRY	Vincent Camus	Received

2069-PS	INTEGRATING VAF AND IMMUNE-COLLAGEN SUBTYPES IDENTIFIES A HIGH-RISK "SOFT" SUBTYPE IN TP53-MUTANT DLBCL WITH PRIMARY DOXORUBICIN RESISTANCE	Jinhua Liang	Received

2071-PS	IMPACT OF TP53 MUTATION ON CD19-CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY IN LARGE B-CELL LYMPHOMA	Lingshuang Sheng	Received

2073-PS	EXTRANODAL INVOLVEMENT AND SITE-SPECIFIC SURVIVAL IN EARLY-STAGE DIFFUSE LARGE B-CELL LYMPHOMA: A POPULATION-BASED STUDY	Antonios Balantinakis	Received

2074-PS	REAL-WORLD OUTCOMES OF GLOFITAMAB PLUS GEMCITABINE AND OXALIPLATIN IN RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA: A EUROPEAN MULTICENTER COHORT	Thomas Melchardt	Received

2075-PS	ORELABRUTINIB PLUS R-CHOP FOR THE TREATMENT OF NEWLY DIAGNOSED NON-GCB DOUBLE-EXPRESSOR DIFFUSE LARGE B-CELL LYMPHOMA: A MULTICENTER, SINGLE-ARM, PHASE II STUDY	Yang Yang	Received

2078-PS	NUTRITIONAL PARAMETERS AS PROGNOSTIC MARKERS IN OLDER PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA: A POST-HOC ANALYSIS OF THE ELDERLY PROJECT BY FONDAZIONE ITALIANA LINFOMI	Salvatrice Mancuso	Received

2081-PS	LONGITUDINAL SAFETY OF LISOCABTAGENE MARALEUCEL (LISO-CEL) IN PATIENTS WITH SECOND-LINE (2L) OR LATER (2L+) LARGE B-CELL LYMPHOMA (LBCL)	Stephan Mielke	Received

2085-PS	INFECTION RATES IN PATIENTS TREATED WITH CAR-T VERSUS AUTOLOGOUS STEM CELL TRANSPLANT FOR RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA AND IN THE GENERAL POPULATION: A SWEDISH POPULATION-BASED STUDY	Kristina Noring	Received

2088-PS	ORELABRUTINIB, RITUXIMAB, AND THIOTEPA (ORT) IN COMBINATION WITH OR WITHOUT HIGH-DOSE METHOTREXATE IN UNTREATED PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA	Chunmei Yang	Received

2090-PS	ORELABRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY PRIMARY OR SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA: A MULTICENTER, OPEN-LABEL, PHASE II STUDY	Lijuan Deng	Received

2093-PS	FIRST-LINE SELINEXOR IN COMBINATION WITH R-CHOP FOR EBV-POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA (XPLORE): A SINGLE-ARM, PHASE IB/II TRIAL	Qingqing Cai	Received

2095-PS	REAL-WORLD TREATMENT PATTERNS AND OUTCOMES OF FIRST-LINE (1L) TREATMENTS IN PATIENTS WITH NEWLY DIAGNOSED DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) IN THE UNITED STATES (US) COMMUNITY ONCOLOGY SETTING	David J. Andorsky	Received

2096-PS	TREATMENT FOR MALIGNANT LYMPHOMAS AND RISK OF THERAPY-RELATED MYELOID NEOPLASMS OVERALL AND WITH HIGH-RISK FEATURES	Joel Joelsson	Received

2098-PS	IMPACT OF BASELINE NEUTROPHIL-TO-LYMPHOCYTE RATIO (NLR) ON SURVIVAL OUTCOMES IN PATIENTS WITH LYMPHOMA FOLLOWING BISPECIFIC ANTIBODY TREATMENT	Allison Bock	Received

2099-PS	LENGTH OF STAY, HEALTHCARE RESOURCE UTILIZATION (HCRU) AND REHOSPITALIZATION OF PATIENTS TREATED WITH AXI-CEL OR LISO-CEL FOR SECOND-LINE LARGE B-CELL LYMPHOMA (LBCL) IN FRANCE	Florian Colrat	Received

2100-PS	OUTCOMES OF SECOND-LINE AXICABTAGENE CILOLEUCEL AND COMPARISON TO AUTOLOGOUS STEM CELL TRANSPLANTATION IN EARLY RELAPSED/PRIMARY REFRACTORY LARGE B-CELL LYMPHOMA PATIENTS	Lina Kolloch	Received

2104-PS	PHASE II STUDY OF LENALIDOMIDE MAINTENANCE AFTER RITUXIMAB-METHOTREXATE-BASED INDUCTION THERAPY IN PRIMARY CNS LYMPHOMA	Ji Yun Lee	Received

2105-PS	ESTABLISHMENT AND VALIDATION OF A PROGNOSTIC NOMOGRAM BASED ON THE PROGNOSTIC NUTRITIONAL INDEX FOR CAR-T THERAPY IN RELAPSED/REFRACTORY LYMPHOMA	Fan Yang	Received

2106-PS	THE PHS W-INDEX: A NOVEL PROGNOSTIC FRAMEWORK INTEGRATING NUTRITIONAL AND HEMATOLOGICAL MARKERS TO PREDICT OUTCOMES IN DLBCL PATIENTS TREATED WITH GLOFITAMAB	Vít Procházka	Received

2107-PS	PHASE 2 TRIAL OF GLOFITAMAB, POLATUZUMAB VEDOTIN AND ZANUBRUTINIB IN UNTREATED ELDERLY DLBCL PATIENTS: SAFETY RUN-IN RESULTS	Yuhong Ren	Received

2111-PS	SINGLE-TARGET (CD19) VERSUS DUAL-TARGET (CD19/CD22 OR CD19/CD20) CAR T-CELL THERAPY IN RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: A SYSTEMATIC REVIEW AND META-ANALYSIS	Ying He	Received

2113-PS	SAFETY AND EFFICACY OF RELMACABTAGENE AUTOLEUCEL (RELMA-CEL) IN ADULT PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA:RESULTS FROM AN OPEN-LABEL, SINGLE-ARM STUDY	Xiangrui Meng	Received

2114-PS	EARLY SILTUXIMAB RESCUE FOR PERSISTENT CRS IN PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA RECEIVING AXICABTAGENE CILOLEUCEL: A REAL-WORLD EXPERIENCE	Adolfo Jesus Saez Marin	Received

2117-PS	OUTCOMES OF SECOND-LINE CAR-T THERAPY IN STARGLO-ELIGIBLE PATIENTS: A COMPARATIVE ANALYSIS	Gil Fridberg	Received

2118-PS	IMPACT OF VINCRISTINE DOSE MODIFICATIONS OR SUBSTITUTION ON CLINICAL OUTCOMES IN R-CHOP TREATED PATIENTS WITH DLBCL	Paw Jensen	Received

2120-PS	REAL-WORLD EFFICACY, SAFETY, AND MOLECULAR CHARACTERIZATION OF POLATUZUMAB VEDOTIN–BASED FIRST-LINE THERAPY IN DIFFUSE LARGE B-CELL LYMPHOMA: A SINGLE-CENTER STUDY WITH COMPREHENSIVE NGS PROFILING	Liang Wang	Received

2121-PS	AGE-INDEPENDENT OUTCOMES AND COMPETING RISK DYNAMICS IN RELAPSED/REFRACTORY LBCL: A REAL-WORLD ANALYSIS	Massimiliano Marinoni	Received

2125-PS	CONTIGUOUS SPREAD, NOT HEMATOGENOUS DISSEMINATION: RETHINKING CNS RISK AND TREATMENT INTENSITY IN PRIMARY SINONASAL DLBCL—A 94-PATIENT REAL-WORLD EVIDENCE STUDY	Na Yao	Received

2127-PS	BRUTON TYROSINE KINASE INHIBITOR MAINTENANCE THERAPY IN FIRST-LINE DIFFUSE LARGE B-CELL LYMPHOMA: A MULTICENTER REAL-WORLD STUDY CHALLENGING CONVENTIONAL PARADIGMS	Na Yao	Received

2128-PS	MAPPING THE METHODOLOGY & ATTRIBUTES OF GLOBAL LYMPHOMA REGISTRIES: A LYMPHOMA REGISTRY ALLIANCE (LYRA) INITIATIVE	Eliza Chung	Received

2132-PS	REAL-WORLD INSIGHTS INTO CLINICAL FEATURES AND OUTCOMES IN EXTRANODAL T-CELL LYMPHOMAS: RESULTS FROM THE INTERNATIONAL T-CELL PROJECT 2.0 PROSPECTIVE COHORT STUDY.	Maryna Bushuieva	Received

2133-PS	TEMPORAL TRENDS AND RISK FACTORS FOR TUBERCULOSIS IN LYMPHOMA PATIENTS: A SWEDISH POPULATION-BASED STUDY (2002–2024)	Torsten Dahlén	Received

2134-PS	LYMPHOMA-ASSOCIATED HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS: INCIDENCE, CLINICAL PHENOTYPE, AND OUTCOMES IN A GLOBAL DATABASE STUDY	Phyo Thazin Myint	Received

2136-PS	AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION FOR PLASMABLASTIC LYMPHOMA: A STUDY FROM THE EBMT LYMPHOMA WORKING PARTY	Joseph Kauer	Received

2138-PS	PHASE I STUDY OF TR115, A NOVEL SELECTIVE EZH2 INHIBITOR, IN RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMA AND ADVANCED SOLID TUMORS	Juying Wei	Received

2139-PS	INCIDENCE AND OUTCOMES OF BURKITT LYMPHOMA: AN ENGLAND-WIDE COHORT STUDY FROM THE UNCOVER STUDY GROUP	Matthew R. Wilson	Received

2140-PS	LINPERLISIB PLUS CHOP FOR NEWLY DIAGNOSED PERIPHERAL T-CELL LYMPHOMA: A SINGLE-ARM, PHASE IB/II STUDY (LINCH TRIAL)	Qingqing Cai	Received

2142-PS	DIFFERENCES IN OUTCOMES FOR ELDERLY PATIENTS WITH DLBCL TREATED AT AMERICAN ACADEMIC VS COMMUNITY PROGRAMS: A 10-YEAR SURVIVAL ANALYSIS	Luis Villela	Received

2144-PS	RANDOMIZED PHASE 3 TRIAL OF WATCHFUL WAITING VERSUS INTERFERON-ALFA AND ZIDOVUDINE FOR INDOLENT ADULT T-CELL LEUKEMIA-LYMPHOMA: JCOG1111C	Kenji Ishitsuka	Received

2145-PS	DETERMINANTS OF SURVIVAL IN AGGRESSIVE NK-CELL LEUKEMIA (ANKL): ANALYSIS OF AN UPDATED REAL-WORLD POOLED DATABASE	Philip Haddad	Received

2146-PS	A NOVEL TRIPLET REGIMEN OF TISLELIZUMAB, GOLIDOCITINIB, AND SELINEXOR FOR RELAPSED/REFRACTORY EXTRANODAL NK/T-CELL LYMPHOMA: PRELIMINARY SAFETY AND EFFICACY FROM A PHASE IB/II STUDY	Rong Tao	Received

2150-PS	PROVISIONAL PROGNOSTIC SCORE FOR HEPATOSPLENIC T-CELL LYMPHOMA	Philip Haddad	Received

2153-PS	BRENTUXIMAB VEDOTIN WITH CHEMOTHERAPY IN FRONTLINE TREATMENT FOR CHINESE PATIENTS WITH CD30-POSITIVE PERIPHERAL T-CELL LYMPHOMA	Yuqin Song	Received

2154-PS	HIGH PRETREATMENT ABSOLUTE LYMPHOCYTE COUNT PREDICTS INFERIOR OUTCOMES IN NK/T-CELL LYMPHOMA PATIENTS TREATED WITH PD-1 INHIBITORS: DEVELOPMENT AND VALIDATION OF A NOVEL PROGNOSTIC MODEL	Xindi Liu	Received

2155-PS	PRIMARY THYROID LYMPHOMA: CLINICAL FEATURES AND OUTCOME ANALYSIS IN A MULTICENTRIC RETROSPECTIVE ITALIAN STUDY	Mariella Lo Schirico	Received

2156-PS	PREDICTORS OF CHEMORESISTANCE IN ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA: A MULTICENTER RETROSPECTIVE STUDY FROM THREE FRENCH UNIVERSITY HOSPITALS	Aurélia Chacon	Received

2158-PS	SAFETY AND PRELIMINARY EFFICACY OF GOLIDOCITINIB COMBINED WITH POMALIDOMIDE IN RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA (JACKPOT25): A MULTICENTER, PHASE I/II STUDY	Peng Sun	Received

2159-PS	CLINICAL FEATURES, TREATMENTS AND OUTCOME OF PLASMABLASTIC LYMPHOMA: RESULTS FROM A PRELIMINARY ANALYSIS OF THE RETROSPECTIVE INTERNATIONAL PLALY STUDY ON BEHALF OF FIL, LEO/MER REGISTRY AND PLRG	Emanuele Ravano	Received

2160-PS	AN INTEGRATIVE CLINICAL-IMMUNOGENETIC-GENOMIC INDEX (MCL-CIGI) IMPROVES THE RISK STRATIFICATION OF PATIENTS WITH MANTLE CELL LYMPHOMA	Ferran Nadeu	Received

2162-PS	MEASURABLE RESIDUAL DISEASE (MRD) BY CIRCULATING TUMOR (CT) DNA IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL) TREATED WITH LISOCABTAGENE MARALEUCEL (LISO-CEL) IN TRANSCEND FL	Franck Morschhauser	Received

2164-PS	SPATIALLY ORGANIZED MACROPHAGE PHENOTYPES DEFINE TREATMENT RESPONSE IN AGGRESSIVE B-NHL	Christina Schniederjohann	Received

2171-PS	SPATIAL PROTEOMICS IDENTIFIES T CELL CENTERED SPATIAL PATTERNS IN HIGH-RISK MANTLE CELL LYMPHOMA BY THE MULTIPLY CONSORTIUM	Sarah Koziel	Received

2173-PS	INTEGRATIVE MULTI-OMICS ANALYSIS OF MICRORNA REGULATION IN RICHTER TRANSFORMATION	Julien Broseus	Received

2175-PS	CIRCULATING TUMOR DNA BASED MOLECULAR TUMOR BURDEN DYNAMICS IN A REAL-WORLD COHORT OF PATIENTS WITH FOLLICULAR LYMPHOMA	Santiago Barrio	Received

2177-PS	INTEGRATED GENOMIC AND TRANSCRIPTOMIC PROFILING REVEALS DISTINCT MECHANISMS IN EARLY- AND LATE-ONSET PT-DLBCL	Ana-Lucía Rocha	Received

2182-PS	THE MSZ REGIMEN (SELINEXOR, HIGH-DOSE METHOTREXATE, AND ZANUBRUTINIB) IN CENTRAL NERVOUS SYSTEM LYMPHOMA: A PHASE II TRIAL WITH NOVEL CNS PHARMACOKINETIC PROFILING	Li LI	Received

2187-PS	GENOMIC DETERMINANTS OF RESPONSE AND RESISTANCE TO ZANUBRUTINIB IN RELAPSED/REFRACTORY PRIMARY CNS LYMPHOMA: BASELINE BIOMARKER ANALYSIS FROM THE PRIZM+ TRIAL	Donatella Talotta	Received

2190-PS	CD20-POSITIVE EXTRACELLULAR VESICLES ACT AS ANTIGEN DECOYS AND REDUCE RITUXIMAB ACTIVITY IN DIFFUSE LARGE B-CELL LYMPHOMA	Seok Jin Kim	Received

2191-PS	ALTERED CHROMATIN PATTERNING AS A PREDISPOSING FACTOR FOR ERRONEOUS REARRANGEMENTS IN B-CELL LYMPHOMAS	Prakruti Uday	Received

2192-PS	DECIPHERING THE SPATIAL ARCHITECTURE OF PRIMARY BREAST DLBCL: IDENTIFICATION OF ECTOPIC MICROGLIA AND SPECIALIZED BOUNDARY IMMUNE HUBS	Chaowei Zhang	Received

2195-PS	MECHANISMS OF BCOR MUTATION IN PROMOTING RESISTANCE TO ANTI-PD-1 THERAPY IN NK/T-CELL LYMPHOMA	Linna Cheng	Received

2203-PS	SINGLE-CELL ATLAS OF PCNSL REVEALS A BCR-DOMINANT SIGNALING ARCHITECTURE AND UPREGULATION OF CD79B: A BIOLOGICAL RATIONALE FOR CD79B-DIRECTED THERAPIES	Byung Woo Yoon	Received

2206-PS	THE MICROBIOME-LYMPHOMA AXIS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF GUT DYSBIOSIS PATTERN IN DIFFUSE LARGE B-CELL LYMPHOMA	Sarah Elkorashy	Received

2207-PS	PERIPHERAL CIRCULATING IMMUNE CELL SUBSETS: PROGNOSTIC VALUE AND CORRELATION WITH CLINICAL FEATURES IN TREATMENT-NAIVE DIFFUSE LARGE B-CELL LYMPHOMA	Li LI	Received

2210-PS	BROAD MULTI-TARGET INFLAMMATORY MARKER SILENCING IN A TRANSLATIONAL MODELLING OF OCULAR CHRONIC GRAFT-VERSUS-HOST DISEASE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION	Alessia Cavalleri	Received

2212-PS	DECODING THE GVL/GVHD PARADOX IN HSCT : A MULTI-OMICS APPROACH FOR SELECTIVE IMMUNOTHERAPY	Romane Bariseel	Received

2218-PS	EFFICACY OF CAR-T BRIDGING TO ALLO-HSCT IN ADULT TCF3::PBX1+ ALL: IMPACT OF INFUSION FREQUENCY	Jingyu Wang	Received

2223-PS	CD7 CAR-T THERAPY AS A BRIDGE TO ALLO-HSCT IN R/R T-ALL/LBL: POST-TRANSPLANT PERSISTENCE OF DONOR-DERIVED CAR-T CELLS PREDICTS POOR OUTCOME	Zhihui Li	Received

2226-PS	REAL-WORLD USE OF POST-TRANSPLANT CYCLOPHOSPHAMIDE FOR GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SURVEY FROM THE CTIWP OF EBMT	Shlomo Elias	Received

2230-PS	A RETROSPECTIVE STUDY EVALUATING THE ROLE OF ALLOGENEIC STEM CELL TRANSPLANTATION IN PATIENTS WITH MYELODYSPLASTIC SYNDROME INITIALLY DIAGNOSED AS LOWER RISK	Alexandre Bazinet	Received

2231-PS	BELUMOSUDIL IN PEDIATRIC PATIENTS WITH STEROID-REFRACTORY CHRONIC GRAFT-VERSUS-HOST DISEASE	Lipeng Liu	Received

2232-PS	A PHASE 2 TRIAL OF MYELOABLATIVE FRACTIONATED BUSULFAN, FLUDARABINE, CLADRIBINE, THIOTEPA, AND VENETOCLAX (CLADILLAC) CONDITIONING FOR HIGH-RISK MDS	Uday R. Popat	Received

2234-PS	OUTCOMES AFTER STANDARD- VS. REDUCED-DOSE TREOSULFAN IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION	Johanne Schovsbo	Received

2238-PS	UPFRONT ALLOGENEIC STEM CELL TRANSPLANTATION USING ARCHIVE CONDITIONING IN ACUTE MYELOID LEUKEMIA	Andrius Žucenka	Received

2239-PS	LINEAGE-SPECIFIC CHIMERISM ANALYSIS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT) IN LYMPHOPROLIFERATIVE DISORDERS: EVOLUTION, OUTCOMES AND IMPACT OF DONOR LYMPHOCYTE INFUSIONS	Jesus Feliu	Received

2243-PS	AXATILIMAB IN COMBINATION WITH RUXOLITINIB IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC GRAFT-VERSUS-HOST DISEASE: UPDATED SAFETY ANALYSIS OF A RANDOMIZED PHASE 2 STUDY	Robert Zeiser	Received

2245-PS	STUDY ON THE DIFFERENCE OF FINE IMMUNE INDEXES OF DIFFERENT CONDITIONING REGIMENS IN MICROTRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA	Lijuan Li	Received

2247-PS	FACTORS PREDICTING RELAPSE AFTER AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION IN SYSTEMIC DIFFUSE LARGE B-CELL LYMPHOMA AND PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA: A FINNISH MULTICENTER STUDY	Lotta Ravattinen	Received

2248-PS	VENETOCLAX AND AZACITIDINE TREATMENT FOR HIGH RISK MYELODYSPLASTIC SYNDROME AND CHRONIC MYELOMONOCYTIC LEUKEMIA AS A BRIDGE THERAPY TO TRANSPLANT. REAL-LIFE EXPANDED GESMD STUDY.	Inés Zugasti	Received

2250-PS	OPTIMAL DONOR DIRECTION IN HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION: OFFSPRING-TO-PARENT VERSUS PARENT-TO-OFFSPRING	Yu Wang	Received

2255-PS	AZACITIDINE PLUS VENETOCLAX AS POST-TRANSPLANT MAINTENANCE THERAPY IN HIGH-RISK MYELOID MALIGNANCIES: A PROPENSITY SCORE-MATCHED ANALYSIS	xinxin Xia	Received

2256-PS	CLINICAL IMPLICATIONS OF SUSTAINED HYPOBARIC HYPOXIA ON NEUTROPHIL ENGRAFTMENT AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION	Yigeng Cao	Received

2258-PS	COMPARATIVE OUTCOMES OF PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR MYELODYSPLASTIC NEOPLASM (MDS)/MYELOPROLIFERATIVE NEOPLASM (MPN) OVERLAP VERSUS DE NOVO MDS	Alastair Williams	Received

2259-PS	SURVIVAL IMPACT AND PREDICTORS OF GRAFT DYSFUNCTION AFTER HAPLOIDENTICAL ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH PTCY: A MEXICAN TERTIARY CENTER EXPERIENCE	Mistral Castellanos-Mares	Received

2260-PS	THE POWER OF DONOR AGE: A SINGLE-CENTER ANALYSIS OF SURVIVAL FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION	Taner Tan	Received

2261-PS	IMPACT OF CPE/ESBL ENTEROBACTERALES COLONIZATION AND ANTIBIOTIC DE-ESCALATION ON OUTCOMES AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A SINGLE-CENTER STUDY	Roberto Bono	Received

2265-PS	ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR CHILDHOOD B-ALL WITH TCF3::PBX1: A RETROSPECTIVE ANALYSIS OF 70 PATIENTS FROM A SINGLE CENTER	YUN WANG	Received

2267-PS	ALLOGENEIC STEM CELL TRANSPLANTATION FOR ADVANCED CUTANEOUS T-CELL LYMPHOMA: EXPERIENCE WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE-BASED GVHD PROPHYLAXIS	Seda Cakmak	Received

2268-PS	YOUNG PATIENTS WITH STANDARD-RISK MULTIPLE MYELOMA UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION ARE EXPECTED TO ACHIEVE FUNCTIONAL CURE:A REAL-WORLD MULTICENTER ANALYSIS	Li Bao	Received

2269-PS	A MULTICENTER CLINICAL STUDY COMPARING HETROMBOPAG AND ELTROMBOPAG FOR PLATELET ENGRAFTMENT AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION	Aoxue Tan	Received

2272-PS	IMPACT OF AGE ON OUTCOME OF VENETOCLAX-BASED CONDITIONING REGIMEN FOR OLDER PATIENTS WITH AML/MDS FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION	Panpan Zhu	Received

2275-PS	UMBILICAL CORD-DERIVED MESENCHYMAL STEM CELLS: ELEVATING EARLY EFFICACY IN GASTROINTESTINAL ACUTE GRAFT-VERSUS-HOST DISEASE	Fang Zhou	Received

2276-PS	PSYCHIATRIC STATUS IN CHRONIC GRAFT-VERSUS-HOST DISEASE: A REAL-WORLD DATA.	Jan Puchowski	Received

2278-PS	EFFECTS OF TWO ANTITHYMOCYTE GLOBULIN CONDITIONING REGIMENS ON IMMUNE RECONSTITUTION AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION	Hui Wang	Received

2279-PS	AI BASED FLT3-ITD SENSITIVITY PREDICTION AND ITS CORRELATION WITH CLINICAL OUTCOMES IN FLT3-ITD AML PATIENTS RECEIVED ALLOGENEIC HCT +/- FLT3 INHIBITOR MAINTENANCE	Seda Cakmak	Received

2280-PS	THE CRL4-DCAF13 UBIQUITIN E3 LIGASE MAINTAINS RIBOSOME BIOGENESIS AND PROTEIN TRANSLATION IN HEMATOPOIETIC STEM CELLS BY STABILIZING RRS1 THROUGH K27-LINKED NON-DEGRADATIVE UBIQUITINATION.	Mengke Li	Received

2284-PS	IMPAIRED INTERFERON RESPONSE IN BRAFV600E MYELOID PROGENITORS OF LANGERHANS CELL HISTIOCYTOSIS	Maki Sakuma	Received

2287-PS	ALTERED GLUTAMINE METABOLISM IMPAIRS THE HAEMATOPOIETIC STEM CELL RESPONSE TO INFECTION	Charlotte Hellmich	Received

2298-PS	DECODING BLOOD FORMATION: LINKING CODON USAGE, TRANSFER RNA EXPRESSION AND CELL IDENTITY IN HEMATOPOIESIS	Marius Külp	Received

2300-PS	IRON DEFICIENCY IS ASSOCIATED WITH REDUCED TRANSFERRIN RECEPTOR 2 EXPRESSION IN EARLY HEMATOPOIETIC PROGENITORS	João Vitor Facco	Received

2302-PS	THE EFFECT OF STATIN THERAPY AND SMALL DENSE LIPOPROTEINS ON CLONAL HAEMATOPOIESIS OF INDETERMINATE POTENTIAL: A TWO SAMPLE MENDELIAN RANDOMISATION STUDY.	Ellen Nuttall Musson	Received

2303-PS	A STANDARDIZED IN VITRO BONE NICHE MODEL FOR QUANTITATIVE ANALYSIS OF OSTEOCLAST-MEDIATED MICROENVIRONMENT REMODELING RELEVANT TO HEMATOLOGIC MALIGNANCIES	Min Wu	Received

2304-PS	FLT3 INHIBITION SYNERGIZES WITH DNA DAMAGING AGENTS TO ELIMINATE HEMATOPOIETIC STEM AND PROGENITOR CELLS BY SUPPRESSING DNA REPAIR PATHWAYS	Samuel Taylor	Received

2305-PS	P-TERT RELATED ADAPTIVE SOMATIC HEMATOPOIETIC MOSAICISM IN PATIENTS WITH TELOMERE BIOLOGY DISORDERS	Madeline Franke	Received

2309-PS	LONG-TERM SAFETY OF CAR T-CELL THERAPY WITH LISOCABTAGENE MARALEUCEL AND IDECABTAGENE VICLEUCEL: ANALYSIS OF SECOND PRIMARY MALIGNANCY (SPM) AND VECTOR-ASSOCIATED OUTCOMES	Matthew Lunning	Received

2310-PS	CD1C-RESTRICTED TCR COMBINED WITH CD38-CCR ENABLES POTENT DUAL-TARGETING IMMUNOTHERAPY IN ACUTE LEUKEMIA	Ivan Civettini	Received

2320-PS	SCREENING AND VALIDATION OF TCR–PEPTIDE INTERACTIONS USING INTEGRATED BULK AND SINGLE-CELL IMMUNE RECEPTOR SEQUENCING	Alex Chenchik	Received

2323-PS	CD4/CD8 BALANCE IN CIRCULATING CAR T-CELLS SHOWS BIPHASIC PROGNOSTIC IMPACT ON OVERALL SURVIVAL IN LARGE B-CELL LYMPHOMAS	Ludovic Gabellier	Received

2324-PS	A TOOLBOX TO VISUALIZE AND QUANTIFY CHIMERIC ANTIGEN RECEPTORS USING SUPERRESOLUTION MICROSCOPY	Thomas Nerreter	Received

2326-PS	CAR-T CELL THERAPY FOR THE TREATMENT OF A HIGH-RISK PEDIATRIC AMKL: PRECLINICAL RESULTS	Marta Tassoni	Received

2328-PS	ALLOGENEIC BCMA-TARGETED CAR-INKT CELLS WITH PD-1 DISRUPTION EXHIBIT ENHANCED ANTITUMOR POTENCY IN A MULTIPLE MYELOMA PRECLINICAL MODEL	Hua Zhang	Received

2330-PS	EFFICACY AND SAFETY OF COMMERCIAL CD19 CAR-T (INATICABTAGENE AUTOLEUCEL) IN RELAPSED/REFRACTORY EXTRAMEDULLARY B-ALL: A LARGE MULTICENTER REAL-WORLD STUDY	Suning Chen	Received

2331-PS	CTD402 ALLOGENEIC ANTI-CD7 CAR T-CELL THERAPY IS SAFE AND EFFECTIVE IN ADOLESCENT/PEDIATRIC PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) T-ALL/LBL	Xian Zhang	Received

2332-PS	RISTOGLOGENE AUTOGETEMCEL TREATMENT RESTORED RED BLOOD CELL HEALTH AND FUNCTION IN PATIENTS WITH SICKLE CELL DISEASE, WITH SICKLING AND RHEOLOGY PARAMETERS COMPARABLE TO SICKLE CELL TRAIT	Priya S. Chockalingam	Received

2335-PS	PD-1AB21-EXPRESSING, ANTI-CD19 CAR T CELLS FOR PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: AN OPEN-LABEL, SINGLE-ARM, PHASE 1 STUDY	Bo Peng	Received

2337-PS	SECONDARY MALIGNANCIES AFTER CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY: A REPORT FROM THE EBMT REGISTRY ON 509 CASES.	Annalisa Ruggeri	Received

2340-PS	SEVERE DELAYED NON-ICANS NEUROTOXICITY AFTER BCMA-DIRECTED CAR-T CELLS IN MULTIPLE MYELOMA: REAL-WORLD OUTCOMES AND IMPLICATIONS FOR STRUCTURED NEUROLOGY–ONCOLOGY CARE	Tim Richardson	Received

2341-PS	EFFICACY AND SAFETY OF CD19 CAR-T INATICABTAGENE AUTOLEUCEL IN OLDER ADULTS WITH B-ALL IN FIRST COMPLETE REMISSION: A MULTICENTER REAL-WORLD STUDY FROM CHINA	Jin WANG	Received

2342-PS	MAINTENANCE THERAPY WITH PD-1 INHIBITOR AND SELINEXOR FOLLOWING CD19/CD22 BISPECIFIC CAR-T CELL THERAPY IN RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: A RETROSPECTIVE ANALYSIS	Liang Wang	Received

2346-PS	CAR T-CELL THERAPY FOR POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE, A REAL-WORLD ANALYSIS ON BEHALF OF THE EBMT LYMPHOMA WORKING PARTY	Fabio Andreozzi	Received

2347-PS	REAL-WORLD USE OF RECOMBINANT HUMAN THROMBOPOIETIN (RHTPO) FOR SEVERE THROMBOCYTOPENIA AFTER CAR T-CELL THERAPY: PLATELET RECOVERY AND TRANSFUSION BURDEN STRATIFIED BY CAR-HEMATOTOX	Zixun Yan	Received

2348-PS	RELEVANT STUDY BETWEEN CYTOKINE LEVEL OF PATIENTS TREATED WITH CD7 CAR-T THERAPY AND GVHD AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION	Dongchu Wang	Received

2351-PS	COMPARATIVE EFFICACY AND SAFETY OF BCMA-TARGETED VERSUS GPRC5D-TARGETED CAR-T CELL THERAPY IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: A META-ANALYSIS	Yanling Li	Received

2352-PS	LATER CAR-T INFUSIONS INCREASE CYTOKINE RELEASE SYNDROME (CRS): EVIDENCE FOR CIRCADIAN MODULATION OF IMMUNOTHERAPY-RELATED TOXICITY	Danielle DeCicco	Received

2355-PS	INTERNATIONAL EXPERT CONSENSUS ON THE USE OF IMMUNOGLOBULIN REPLACEMENT THERAPY FOR SECONDARY IMMUNODEFICIENCY: A MODIFIED DELPHI STUDY	Michel Delforge	Received

2358-PS	BIOLOGICAL DRIVERS AND FUNCTIONAL IMPACT OF MITOCHONDRIA-RETAINING RED BLOOD CELLS IN SICKLE CELL DISEASE	Alkmini Anastasiadi	Received

2360-PS	SICKLE CELL DISEASE IN GERMANY - TRENDS IN EPIDEMIOLOGY, HEALTHCARE UTILIZATION AND DISEASE BURDEN FROM 2015 TO 2024: A CLAIMS DATA ANALYSIS	Nils Schulze	Received

2364-PS	A METHOD FOR MONITORING RED CELL ENGRAFTMENT POST BONE MARROW TRANSPLANT FOR SICKLE CELL DISEASE	Azalea Khan	Received

2371-PS	ADVERSE MATERNAL AND PERINATAL OUTCOMES ASSOCIATED WITH SICKLE CELL TRAIT IN PREGNANCY: A SYSTEMATIC REVIEW AND META-ANALYSIS	Luisa Medeiros Visentini	Received

2374-PS	A NOVEL, CLINICALLY APPLIED SCORING SYSTEM FOR FAT EMBOLISM SYNDROME IN SICKLE CELL DISEASE	Abdulrahman Nasiri	Received

2375-PS	IMPROVING RETINAL SCREENING IN SICKLE CELL DISEASE USING A NOVEL IN-OFFICE SCAN (A QUALITY IMPROVEMENT INITIATIVE)	DZ DZ	Received

2376-PS	BRIDGING GAPS IN SICKLE CELL DISEASE CARE: ERN-EUROBLOODNET´S COMPARATIVE ANALYSIS OF NATIONAL RECOMMENDATIONS ACROSS EUROPE	Anna Collado Gimbert	Received

2380-PS	COMBINED ATRIOVENTRICULAR COUPLING INDEX IN TRANSFUSION-DEPENDENT THALASSEMIA	Antonella Meloni	Received

2382-PS	BONE DISEASE IN ADULTS WITH THALASSAEMIA: CHARACTERISTICS, INVESTIGATION AND MANAGEMENT INSIGHTS FROM A TERTIARY SERVICE IN THE UK	Chloe Merrion	Received

2383-PS	IMPACT OF EMPAGLIFLOZIN ON THE OUTCOMES OF ?-THALASSEMIA MAJOR IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: THE THALEMPA OBSERVATIONAL STUDY	Anas Ibraheem	Received

2384-PS	SAFETY AND EXPECTED BENEFIT DRIVE GENE THERAPY ACCEPTANCE IN ?-THALASSEMIA AND SICKLE CELL DISEASE: A MULTICENTER MEDIATION ANALYSIS	Stefania Mistretta	Received

2386-PS	TRACKING MYOCARDIAL NATIVE T1 OVER TIME IN TRANSFUSION-DEPENDENT THALASSEMIA	Antonella Meloni	Received

2387-PS	EFFICACY AND SAFETY OF ALTERNATING DEFERIPRONE AND DEFERASIROX COMBINATION CHELATION THERAPY IN PATIENTS WITH TRANSFUSION-DEPENDENT THALASSEMIA	Nihan Avcu Oral	Received

2388-PS	ADJUNCT RESVERATROL OR OMEPRAZOLE IN NON-TRANSFUSION DEPENDENT THALASSEMIA PATIENTS WITH SECONDARY HEMOCHROMATOSIS: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL	Thanapong Chopetgool	Received

2389-PS	REFINED CLASSIFICATION AND PHENOTYPE-DRIVEN ANALYSIS OF PIEZO1 VARIANTS REVEAL DOMAIN-SPECIFIC PATHOGENIC MECHANISMS	Barbara Eleni Rosato	Received

2392-PS	ZANUBRUTINIB FOR THE TREATMENT OF COLD AGGLUTININ DISEASE: PRIMARY ANALYSIS OF THE PHASE II HOVON169 STUDY	Anne-Marie Becking	Received

2393-PS	DYNAMIC ANALYSIS OF GLUCOSE UTILIZATION IN RED BLOOD CELLS FROM PATIENTS WITH GLUCOSE PHOSPHATE ISOMERASE DEFICIENCY	Titine Ruiter	Received

2394-PS	ADDITIONAL SAFETY AND EFFICACY RESULTS FROM HELIOS: A PHASE 2, OPEN-LABEL, LONG-TERM EXTENSION STUDY OF BITOPERTIN IN ERYTHROPOIETIC PROTOPORPHYRIA	Amy Yeung	Received

2398-PS	WHOLE-GENOME SEQUENCING IN THE DIAGNOSTIC EVALUATION OF PATIENTS WITH SUSPECTED HEREDITARY ANEMIA	Thomas Doeven	Received

2399-PS	PRECISE EDITING OF THE TFR2 GENE AS POSSIBLE THERAPEUTIC APPROACH FOR HEMOGLOBINOPATHIES	Antonella Nai	Received

2401-PS	DXO-1801, A HEPATOCYTE-TARGETED GALNAC-SIRNA, DEMONSTRATES HEPCIDIN PATHWAY MODULATION, IRON MOBILIZATION, AND A FAVORABLE SAFETY PROFILE IN NON-HUMAN PRIMATES	Lilach Steiner	Received

2405-PS	SERVICE EVALUATION OF PRE OPERATIVE ANAEMIA OPTIMISATION IN NHS AND PRIVATE PATIENTS	Silvia Lovato	Received

2407-PS	PERIPHERAL BLOOD MNGS VERSUS BLOOD CULTURE FOR POLYMICROBIAL BLOODSTREAM INFECTIONS IN HEMATOLOGICAL MALIGNANCY: A COMPARISON OF DIAGNOSTIC YIELD AND CLINICAL IMPACT	Rong Fu	Received

2408-PS	HEMASHIELD STUDY: INCIDENCE OF SEVERE INFECTIONS AND CMV REACTIVATION IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES TREATED WITH BISPECIFIC ANTIBODIES: A PROSPECTIVE STUDY.	Maria Stefania Infante	Received

2409-PS	RAPID DIAGNOSTICS AND TARGETED COLONIZATION MANAGEMENT FOR CARBAPENEM-RESISTANT ENTEROBACTERIACEAE IN PEDIATRIC ONCOLOGY: IMPACT ON CLINICAL OUTCOMES	Sally Mahfouz	Received

2410-PS	ECTOPIC EBV INFECTION OF HEMATOPOIETIC STEM CELLS DRIVES T-CELL DIFFERENTIATION BLOCKADE VIA STAT2/IRF9-MEDIATED SENESCENCE	Zhuojun Liu	Received

2411-PS	INTEGRATIVE BIOINFORMATIC AND REAL-WORLD DATA ANALYSIS REVEAL MECHANISTIC ASSOCIATIONS BETWEEN LETERMOVIR PROPHYLAXIS AND EBV REACTIVATION AFTER ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION	Zhangjie Chen	Received

2412-PS	RATES OF INFECTION IN PATIENTS (PTS) WITH B-CELL NON-HODGKIN LYMPHOMA (B-NHL): A REAL-WORLD ANALYSIS	Evgenii Shumilov	Received

2413-PS	MID-REGIONAL PROADRENOMEDULLIN IDENTIFIES HIGH-RISK INFECTIOUS AND TRANSPLANT-RELATED COMPLICATIONS IN PEDIATRIC ALLOGENEIC HSCT: A PROSPECTIVE MULTICENTER STUDY	Manuela Spadea	Received

2415-PS	TORQUE TENO VIRUS: AN EMERGING BIOMARKER ASSOCIATED WITH ADVERSE PROGNOSIS AND THE RISK OF GRAFT-VERSUS-HOST DISEASE IN PATIENTS UNDERGOING ALLO-HSCT	Xiujuan Ma	Received

2416-PS	INCORPORATION OF RITUXIMAB INTO CONDITIONING PREVENTS EBV INFECTION AFTER HAPLOIDENTICAL STEM CELL TRANSPLANTATION DURING THE ERA OF LETERMOVIR FOR CYTOMEGALOVIRUS PROPHYLAXIS	xiaoning wang	Received

2420-PS	CLINICAL AND PROGNOSTIC IMPLICATIONS OF HYPOGAMMAGLOBULINEMIA IN B-CELL NON-HODGKIN LYMPHOMA (B-NHL).	Amagoia Ruiz Martin	Received

2422-PS	VANCOMYCIN-RESISTANT ENTEROCOCCI COLONIZATION IN HEMATOLOGIC PATIENTS: IS IT STILL A PROBLEM? RESULTS OF A SURVEY AMONG THE CENTERS PARTICIPATING IN THE RETE EMATOLOGICA LOMBARDA (REL)	Chiara Cattaneo	Received

2423-PS	RISK FACTORS, CLINICAL OUTCOMES AND IMMUNE DYNAMICS OF CANDIDEMIA IN PATIENTS WITH HEMATOLOGICAL DISORDER	Zhangjie Chen	Received

2427-PS	DYNAMIC WHOLE-BLOOD TRANSCRIPTOMIC CHARACTERISTICS OF INFECTION EVOLUTION IN HEMATOLOGIC MALIGNANCY PATIENTS WITH CHEMOTHERAPY-INDUCED NEUTROPENIA	Dairong Xie	Received

2428-PS	EFFICACY AND SAFETY OF CIDOFOVIR FOR ADENOVIRUS INFECTION IN PEDIATRIC PATIENTS AFTER HEMATOPOIETIC STEM CELL TRANSPLANT: A SINGLE-CENTER RETROSPECTIVE STUDY	Anqi Zhou	Received

2429-PS	A SINGLE CENTRE 10 YEAR RETROSPECTIVE AUDIT ON USE OF HUMAN LEUKOCYTE ANTIGEN MATCHED PLATELET TRANSFUSIONS: USAGE, COST, WASTAGE AND EFFECTIVENESS	Shreyans Gandhi	Received

2432-PS	MULTI-PHASE ASSESSMENT OF HYPOXIC RED BLOOD CELL STORAGE: FROM THE UNIT TO RECIPIENT-MIMICKING CONDITIONS	Vasileios Tzounakas	Received

2433-PS	TRANSFUSIONAL OPTIMIZATION IN LIVER TRANSPLANTATION USING VISCOELASTIC TEST GUIDED THERAPY, A USEFUL TOOL FOR PATIENT BLOOD MANAGEMENT	José María García Gala	Received

2434-PS	ESTABLISHING EXPERT CONSENSUS ON DIAGNOSIS AND TREATMENT GUIDELINES FOR COLD AGGLUTININ DISEASE (CAD) – AN INTERNATIONAL DELPHI STUDY	DZ DZ	Received

2436-PS	MODULATING MEGAKARYOPOIESIS: A HEAD-TO-HEAD COMPARISON OF RECOMBINANT TPO AND RECEPTOR AGONISTS ON MEGAKARYOCYTE DEVELOPMENT AND PLATELET OUTPUT?	SHUHONG HU	Received

2437-PS	LPC(16:0/0/0) DRIVES MACROPHAGE DYSFUNCTION IN ITP: A SYNERGISTIC DEXAMETHASONE-ATORVASTATIN THERAPY	Nan Jiang	Received

2441-PS	REAL-WORLD CLINICAL BURDEN AMONG PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA WHO DEVELOPED RESISTANCE OR INTOLERANCE TO HYDROXYUREA	Evan Chen	Received

2442-PS	COGNITIVE DYSFUNCTION IN ADULTS WITH IMMUNE THROMBOCYTOPENIA (ITP): A CROSS-SECTIONAL OBSERVATIONAL STUDY	Nichola Cooper	Received

2443-PS	EFFICACY AND SAFETY OF HETROMBOPAG IN INCREASING PLATELET COUNTS IN PATIENTS WITH HEPATOCELLULAR CARCINOMA UNDERGOING HEPATECTOMY: A RANDOMIZED, PLACEBO-CONTROLLED STUDY	Ning Zhang	Received

2444-PS	CLINICAL CHARACTERISTICS, TREATMENT STRATEGIES, AND RESPONSE PATTERNS IN EVANS SYNDROME: INITIAL ANALYSIS FROM THE SPANISH RESTI COHORT	María Eva Mingot Castellano	Received

2445-PS	AVATROMBOPAG IN TPO-RA–NAIVE ADULTS IN ACUTE, PERSISTENT, AND CHRONIC PHASES OF ITP: RESULTS FROM THE REAL-AVA 3.0 RETROSPECTIVE STUDY	Sandhya Panch	Received

2448-PS	CHARACTERIZING EARLY AND LATE RESPONDERS TO MULTI-IMMUNE MODULATOR RILZABRUTINIB IN PERSISTENT/CHRONIC IMMUNE THROMBOCYTOPENIA: FINDINGS FROM THE PHASE 3 LUNA3 STUDY	Nichola Cooper	Received

2451-PS	REAL-WORLD EFFECTIVENESS AND SAFETY OF A PREPARATION OF INTRAVENOUS IMMUNOGLOBULIN FOR IMMUNE THROMBOCYTOPENIA	Guillaume Moulis	Received

2452-PS	ADHERENCE TO DIAGNOSTIC GUIDELINES IN IMMUNE THROMBOCYTOPENIA: A 10-YEAR CLINICAL AUDIT AT A UK TERTIARY CENTER.	Lara D´ Orleans Kapps	Received

2453-PS	EFFICACY AND SAFETY OF EFGARTIGIMOD IN PRIMARY IMMUNE THROMBOCYTOPENIA(ITP): META-ANALYSIS OF PHASE III RANDOMIZED CONTROLLED TRIALS	Mehak Dang	Received

2456-PS	COMPETING CAUSES OF DEATH IN HEMOPHILIA IN THE UNITED STATES: A NATIONAL MULTIPLE-CAUSE-OF-DEATH ANALYSIS, 2005–2024	Mohammad Ahsen Soomro	Received

2457-PS	RISK OF BLEEDING IN MANTLE CELL LYMPHOMA PATIENTS TREATED WITH COVALENT BRUTON TYROSINE KINASE INHIBITORS AND CONTEMPORARY ANTICOAGULANT OR ANTIPLATELET AGENTS: REAL-WORLD DATA INSIGHTS	Vladimir Otasevic	Received

2460-PS	PHARMACOLOGIC INHIBITION OF THE APELIN RECEPTOR (APJ) IS PROTECTIVE IN MURINE MODELS OF HEREDITARY HEMORRHAGIC TELANGIECTASIA	Jaime Darce	Received

2461-PS	EVOLVING TREATMENT PRIORITIES IN HEMOPHILIA: PHYSICIAN AND PATIENT PERSPECTIVES ON CONVENIENCE, QUALITY OF LIFE, AND THE EMERGING ROLE OF REBALANCING AGENTS ACROSS THE US AND EU5	Sarah Hendry	Received

2462-PS	WHEN HYPOCOAGULABILITY MEETS THROMBOSIS: A SINGLE-CENTER COMPARATIVE STUDY OF CONGENITAL AND ACQUIRED PROTHROMBIN DEFICIENCY	Alfadil Haroon	Received

2464-PS	THROMBOELASTOGRAM-GUIDED BLEEDING RISK ASSESSMENT AND PERIOPERATIVE MANAGEMENT OF CONGENTIAL FACTOR VII DEFICIENCY	Kai Shen	Received

2466-PS	ISTH BLEEDING SCORE (ISTH-BAT) IN DIAGNOSTIC PROFILE OF BLEEDING PATIENTS RELATED TO SCORING IN CLINICAL DIAGNOSIS PRACTICE 2015-2025 IN TWO CENTRES IN ESTONIA	Ines Vaide	Received

2469-PS	PREDICTIVE ROLE OF ENDOTHELIAL-DERIVED EXTRACELLULAR VESICLES IN RECURRENT VENOUS THROMBOEMBOLISMPREDICTIVE ROLE OF ENDOTHELIAL-DERIVED EXTRACELLULAR VESICLES IN RECURRENT VENOUS THROMBOEMBOLISM	Aashal Shah	Received

2470-PS	IDENTIFICATION OF CLEC4E AS A FUNCTIONAL PATTERN RECOGNITION RECEPTOR MEDIATING ?-GLUCOSYLCERAMIDE–INDUCED PLATELET ACTIVATION VIA SYK SIGNALING	xuemei jia	Received

2472-PS	CLINICAL OUTCOMES ASSOCIATED WITH INAPPROPRIATE DIRECT ORAL ANTICOAGULANT PRESCRIBING IN A TERTIARY HOSPITAL	Nulee Yun	Received

2474-PS	HEALTH CARE UTILIZATION AND MANAGEMENT PATTERNS OF ASYMPTOMATIC INCIDENTAL PULMONARY EMBOLISM IN CANCER PATIENTS	Neha Agrawal*	Received

2476-PS	MONOCYTE-TO-RED CELL DISTRIBUTION WIDTH RATIO PREDICTS PULMONARY EMBOLISM IN PATIENTS WITH DEEP VEIN THROMBOSIS: A PROPENSITY SCORE–MATCHED ANALYSIS	Bulent Kantarcioglu	Received

2479-PS	INCIDENCE, PATIENT PROFILE, AND 3-MONTH SURVIVAL OF VENOUS THROMBOEMBOLISM IN INTERNAL MEDICINE INPATIENTS: A PILOT STUDY FROM TURKEY	Bulent Kantarcioglu	Received

2480-PS	PLATELET HYPERREACTIVITY OVERRIDES THROMBIN DYSREGULATION AS THE MAIN THROMBOTIC DRIVER IN AFIBRINOGENEMIA WITH A NOVEL FGA MUTATION (P.TRP248*)	Xiao Shuai	Received

2481-PS	SYK Y342 AND Y346 PHOSPHORYLATION IS ESSENTIAL FOR OPTIMAL ITAM AND HEMITAM-MEDIATED SIGNALING IN PLATELETS	Satya Kunapuli	Received

2483-PS	A DIAGNOSTIC SAFETY GAP IN THROMBOPHILIA TESTING: UNRELIABLE TIMING AND DOWNSTREAM HARM	Abdulrahman Al Raizah	Received

2485-PS	ICANS AFTER CAR-T THERAPY: PERSISTENT COGNITIVE BUT NOT PSYCHIATRIC RISK - A PROPENSITY SCORE-MATCHED ANALYSIS	Heidi Cho	Received

2486-PS	PATIENT-REPORTED FATIGUE AND IMPAIRED COGNITIVE FUNCTION AFTER ALLOGENEIC-HSCT: SIGNIFICANT CORRELATIONS WITH RETURN TO SOCIO-PROFESSIONAL ACTIVITIES – THE SOPRALLO STUDY	Yana Stepanishyna	Received

2487-PS	VTE RISK ASSESSMENT MODELS (RAM), THROMBOPROPHYLAXIS USE & OUTCOMES IN ATOMM: ANTICOAGULATION FOR THROMBOSIS PREVENTION IN MULTIPLE MYELOMA, A LARGE REAL-WORLD COHORT OF NEWLY DIAGNOSED MYELOMA (NDMM)	Marquita Camilleri	Received

2488-PS	NEONATAL AND INFANT OUTCOMES FOLLOWING PREGNANCY-ASSOCIATED HAEMATOLOGICAL MALIGNANCIES: AN OBSERVATIONAL NATIONWIDE COHORT STUDY.	Justine De Croocq	Received

2493-PS	CHANGES IN BODY COMPOSITION PARAMETERS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA UNDERGOING INTENSIVE CHEMOTHERAPY PRIOR TO AN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION	Sofia Voigt	Received

2495-PS	PRESCRIBING PRACTICE, RISK ASSESSMENT MODEL (RAM) USE, AND PERCEIVED GUIDELINE GAPS IN VENOUS THROMBOEMBOLISM (VTE) PROPHYLAXIS FOR NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): UK NATIONAL SURVEY RESULTS	Marquita Camilleri	Received

2496-PS	WORKLOAD AND BURNOUT AMONG HEMATOLOGISTS IN THE COMMUNITY OF MADRID (SPAIN): KEY FINDINGS OF THE 2024–2027 STRATEGIC PLAN OF THE MADRID ASSOCIATION OF HEMATOLOGY AND HEMOTHERAPY	Adrian Alegre Amor	Received

2498-PS	QOL-BLINA PROTOCOL OF AIEOP STUDY GROUP: PRELIMINARY DATA ON QOL AND PSYCHOSOCIAL RISK IN PATIENTS AND CAREGIVERS.	Fara Petruzziello	Received

2499-PS	BURDEN OF DISEASE MANAGEMENT AMONG PATIENTS WITH MULTIPLE MYELOMA AND THEIR CARE PARTNERS	Robin Tuohy	Received

2500-PS	AQUALIS: AN OBSERVATIONAL QUALITY OF LIFE STUDY IN FRANCE ON PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) TREATED WITH ACALABRUTINIB:RAPID GAINS IN FUNCTION AND SYMPTOMS WITH HIGH ADHERENCE	Loic Ysebaert	Received

2503-PS	SEXUAL HEALTH IN ADOLESCENTS AND YOUNG ADULTS AFTER HEMATOPOIETIC STEM CELL TRANSPLANT – AN OVERLOOKED DIMENSION OF SURVIVORSHIP	Brittany Kimball	Received

2504-PS	LONGITUDINAL PATIENT-REPORTED OUTCOMES HIGHLIGHT IMPROVED QUALITY OF LIFE FOR R-CHOP-INELIGIBLE PATIENTS WITH AGGRESSIVE B-CELL LYMPHOMAS TREATED WITHIN THE FRONTLINE PHASE II R-POLA-GLO TRIAL	Rebecca Wurm-Kuczera	Received

2506-PS	RISK FACTOR ANALYSIS FOR MELPHALAN-RELATED ORAL MUCOSITIS IN ADULT HEMATOPOIETIC STEM CELL TRANSPLANT PATIENTS	Liya Ren	Received

2510-PS	GLOBAL TRENDS OVER TWO DECADES IN CLINICAL TRIALS OF HEMATOLOGICAL MALIGNANCIES	Tarec El-Galaly	Received

2514-PS	COST-EFFECTIVENESS OF AXICABTAGENE CILOLEUCEL FOR TREATING TAIWANESE PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA AND HIGH-GRADE B-CELL LYMPHOMA AFTER FIRST-LINE TREATMENT	Bor-Sheng Ko	Received

2517-PS	COMPARISON OF THE COST OF MANAGING ADVERSE EVENTS WITH FIXED DURATION COMBINATION TARGETED THERAPY REGIMENS IN THE FIRST-LINE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKAEMIA IN BRAZIL	Ian Keary	Received

2518-PS	INCIDENCE AND SURVIVAL OF HEMATOLOGICAL NEOPLASIAS IN THE COMMUNITY OF MADRID (SPAIN) FROM 2014 TO 2024: BURDEN, TEMPORAL IMPROVEMENT, AND CARE HOMOGENEITY	José-Angel Hernández-Rivas	Received

2524-PS	FHIR-FORMER: MATCHING LSTM PERFORMANCE IN PLATELET TRANSFUSION PREDICTION USING A LANGUAGE MODEL WITH ONE-TENTH THE TRAINING DATA	Merlin Engelke	Received

2526-PS	LYMPHKEY: AN INTEGRATIVE SOLUTION FOR THE MOLECULAR CHARACTERIZATION OF B- AND T-CELL MALIGNANCIES	Aleix Real	Received

2529-PS	CLINICAL VALIDATION OF AN AI PLATFORM FOR BONE MARROW ASPIRATE DIFFERENTIAL COUNT: DIAGNOSTIC ACCURACY AND IMPACT OF EXPERT REVIEW.	Irene Zamanillo	Received

2530-PS	HIGH-SENSITIVITY PERIPHERAL BLOOD MEASURABLE RESIDUAL DISEASE DETECTION IN ACUTE MYELOID LEUKEMIA USING A MICROFLUIDIC RARE-CELL IMAGING IMMUNOPHENOTYPING PLATFORM	Ju-Yu Tseng	Received

2532-PS	REFINING THE INTERPRETATION AND REPORTING OF OPTICAL GENOME MAPPING DATA: RESULTS FROM TWO ROUNDS OF A SPANISH MULTICENTER INTERLABORATORY COMPARISON STUDY	Anna Puiggros	Received

EHA2026

11-14 June 2026 Stockholm, Sweden

Help Line

Homepage

Personal Area

Search and consult posters online
in an exclusive section
for each poster

ACTIVE FROM 11/06/2030 TO 11/06/2030

Poster
Gallery

Upload
Poster

Featured Poster

Vote poster

Poster Discussion
Forum



		Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress.

About us

Terms and Conditions